Page last updated: 2024-11-04

fexofenadine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Fexofenadine is a non-sedating antihistamine used to treat allergies. It is a second-generation antihistamine, meaning it is less likely to cause drowsiness than older antihistamines. Fexofenadine is a selective antagonist of the H1 receptor, which means it blocks the action of histamine at this receptor. Histamine is a chemical that is released by the body in response to allergens. When histamine binds to the H1 receptor, it causes a variety of allergic symptoms, such as sneezing, runny nose, itchy eyes, and hives. Fexofenadine blocks histamine from binding to the H1 receptor, which prevents these symptoms from occurring. Fexofenadine is available in both prescription and over-the-counter formulations. It is typically taken once or twice a day. Fexofenadine is generally well-tolerated, but it can cause side effects such as headache, drowsiness, and nausea. Fexofenadine was synthesized by scientists at Hoechst AG in the early 1990s. It was approved for use in the United States in 1996. Fexofenadine is a popular antihistamine because it is effective in treating allergies and is relatively safe for most people. It is studied to better understand its effects on the human body and to develop new and improved antihistamines.'

fexofenadine: a second generation antihistamine; metabolite of the antihistaminic drug terfenadine; structure in first source; RN refers to HCl [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

fexofenadine : A piperidine-based anti-histamine compound. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3348
CHEMBL ID914
CHEBI ID5050
SCHEMBL ID4900
MeSH IDM0245918

Synonyms (131)

Synonym
AKOS005557315
BRD-A73368467-003-02-8
allegra
telfast
2-(4-{1-hydroxy-4-[4-(hydroxydiphenylmethyl)piperidin-1-yl]butyl}phenyl)-2-methylpropanoic acid
2-[4-(1-hydroxy-4-{4-[hydroxy(diphenyl)methyl]piperidin-1-yl}butyl)phenyl]-2-methylpropanoic acid
chembl914 ,
bdbm22874
EU-0100488
SPECTRUM_001914
hsdb 7486
fexofenadine [inn:ban]
mdl 16455
benzeneacetic acid, 4-(1-hydroxy-4-(4-(hydroxydiphenylmethyl)-1-piperidinyl)butyl)-alpha,alpha-dimethyl-
LOPAC0_000488
fexofenadine
4-(1-hydroxy-4-(4-(hydroxydiphenylmethyl)-1-piperidinyl)butyl)-alpha,alpha-dimethylbenzeneacetic acid
83799-24-0
C06999
terfenadine-cooh
DB00950
terfenadine acid metabolite
carboxyterfenadine
terfenadine carboxylate
alpha-(4-(1-carboxy-1-methylethyl)phenyl)-4-hydroxydiphenylmethyl-1-piperidinebutanol
mdl-16455
KBIO3_002742
KBIO2_002449
KBIO2_007585
KBIOSS_002456
KBIOGR_000807
KBIO2_005017
SPECTRUM3_001921
SPECTRUM4_000204
SPBIO_001197
SPECTRUM2_001179
BSPBIO_003521
SPECTRUM5_001474
NCGC00092389-02
NCGC00092389-03
NCGC00015453-03
terfenidine carboxylate, mdl 16455
F 9427 ,
NCGC00015453-06
CHEBI:5050 ,
L000869
fexofenadine (inn)
telfast (tn)
D07958
FT-0668529
FT-0668526
FT-0668527
2-[4-[1-hydroxy-4-[4-[hydroxy(diphenyl)methyl]piperidin-1-yl]butyl]phenyl]-2-methylpropanoic acid
STK624102
138452-21-8
2-[4-[(1s)-1-hydroxy-4-[4-[hydroxy(diphenyl)methyl]-1-piperidyl]butyl]phenyl]-2-methyl-propanoic acid;fexofenadine
A840654
NCGC00092389-04
HMS3261B17
CCG-204579
NCGC00015453-05
NCGC00015453-04
ec 801-893-7
e6582loh6v ,
unii-e6582loh6v
(+/-)-4-(1-hydroxy-4-(4-(hydroxydiphenyl-methyl)-1- piperidinyl)butyl)-alpha-dimethylbenzeneacetic acid
BCP9000683
fexofendine
2-(4-(1-hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid
FT-0626423
LP00488
HMS3370C16
gtpl4819
BBL029080
SCHEMBL4900
2-[4-[1-hydroxy-4-[4-[hydroxy(diphenyl)methyl]-1-piperidyl]butyl]phenyl]-2-methyl-propanoic acid
NCGC00261173-01
tox21_500488
4-[4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-1-hydroxybutyl] -alpha,alpha-dimethylbenzeneacetic acid
4-[4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-1-hydroxybutyl]-alpha,alpha-dimethylphenylacetic acid
4-[4-(4-(hydroxydiphenylmethyl)-1-piperidinyl]-1-hydroxybutyl]-alpha, alpha-dimethylbenzeneacetic acid
racemic 4-[4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-1-hydroxybutyl]-alpha,alpha-dimethylbenzeneacetic acid
4-[4[4-(hydroxydiphenylmethyl)-1-piperidinyl]-1-hydroxybutyl]-alpha,alpha-dimethylbenzeneacetic acid
4-[4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-1-hydroxybutyl]-alpha,alpha-dimethylbenzeneacetic acid
(+)-4-[4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-1-hydroxybutyl]-alpha,alpha-dimethylbenzeneacetic-acid
s-fexofenadine
Q-201113
AB00876239_07
AB00876239_06
sr-01000075889
SR-01000075889-1
SBI-0050472.P002
2-[4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidyl]butyl]phenyl]-2-methyl-propanoic acid
NCGC00015453-10
DTXSID00861411 ,
Q415122
2-(4-(1-hydroxy-4-(4-(hydroxydiphenylmethyl)-piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid
mfcd00871892
AS-35188
butyl)phenyl)-2-methylpropanoic
2-(4-(1-hydroxy-4-(4-(hydroxydiphenylmethyl)
piperidin-1-yl)
1319714-86-7
BCP11806
mdl-16455; terfenadine carboxylate
BRD-A73368467-003-07-7
SDCCGSBI-0050472.P003
NCGC00015453-19
benzeneacetic acid,4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-a,a-dimethyl-
83799-24-0 (free base)
4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-alpha,alpha-dimethyl-benzene-acetic acid
EN300-58439
fexofenadine [inn]
fexofenadine [vandf]
fexofenadine [hsdb]
(+/-)-p-(1-hydroxy-4-(4-(hydroxydiphenylmethyl)piperidino)butyl)-.alpha.-methylhydratropic acid
fexofenadine [who-dd]
fexofenadine [mi]
benzeneacetic acid, 4-(1-hydroxy-4-(4-(hydroxydiphenylmethyl)-1-piperidinyl)butyl)-.alpha.,.alpha.-dimethyl-, (+/-)-
fexofenadine [usp-rs]
CS-0012429
HY-B0801
dtxcid50197277
fexofenadine (usp-rs)
alpha,alpha-dimethyl-4-(1-hydroxy-4-(4-(hydroxydiphenylmethyl)-1-piperidinyl)butyl)-benzeneacetic acid
fexofenadina
(+/-)-p-(1-hydroxy-4-(4-(hydroxydiphenylmethyl)piperidino)butyl)-alpha-methylhydratropic acid
r06ax26
fexofenadinum
benzeneacetic acid, 4-(1-hydroxy-4-(4-(hydroxydiphenylmethyl)-1-piperidinyl)butyl)-alpha,alpha-dimethyl-, (+/-)-
(+/-)-4-(1-hydroxy-4-(4-(hydroxydiphenyl-methyl)-1-piperidinyl)butyl)-alpha-dimethylbenzeneacetic acid

Research Excerpts

Overview

Fexofenadine hydrochloride is an antihistamine agent used for the treatment of allergic disorders like rhinitis. It is a recommended in vivo probe drug for phenotyping P-glycoprotein (P-gp) and organic anion transporting polypeptide (OATP) 1B1/3 transporter activities.

ExcerptReferenceRelevance
"Fexofenadine was confirmed to be a substrate of OATP1A2, and EGCG (100 and 1,000 μM) and GTE (0.1 and 1 mg/mL) inhibited OATP1A2-mediated uptake of fexofenadine."( Exposure of Fexofenadine, but Not Pseudoephedrine, Is Markedly Decreased by Green Tea Extract in Healthy Volunteers.
Fromm, MF; Hoier, E; König, J; Misaka, S; Ogata, H; Ono, T; Ono, Y; Shimomura, K; Taudte, RV; Watanabe, H, 2022
)
1.82
"Fexofenadine is a recommended in vivo probe drug for phenotyping P-glycoprotein (P-gp) and organic anion transporting polypeptide (OATP) 1B1/3 transporter activities. "( Fexofenadine Plasma Concentrations to Estimate Systemic Exposure in Healthy Adults Using a Limited Sampling Strategy with a Population Pharmacokinetic Approach.
Blaquera, CL; Capparelli, EV; Ma, JD; Nikanjam, M; Nolin, TD; Paine, MF; Penzak, SR; Piscitelli, J, 2023
)
3.8
"Fexofenadine hydrochloride is an antihistamine agent used for the treatment of allergic disorders like rhinitis. "( A Review of Different Analytical Techniques for Fexofenadine Hydrochloride and Montelukast Sodium in Different Matrices.
Kumar, V; Nalini, CN, 2021
)
2.32
"Fexofenadine hydrochloride is a frequently used drug for treatment of allergic conditions during pregnancy, but the fetal safety of fexofenadine use has not been well studied."( Association Between Fexofenadine Use During Pregnancy and Fetal Outcomes.
Andersen, JT; Andersson, NW; Torp-Pedersen, C, 2020
)
2.32
"Fexofenadine is a well-identified in vivo probe substrate of P-glycoprotein (P-gp) and/or organic anion transporting polypeptide (OATP). "( Chiral Transplacental Pharmacokinetics of Fexofenadine: Impact of P-Glycoprotein Inhibitor Fluoxetine Using the Human Placental Perfusion Model.
Bapat, P; Berger, H; de Carvalho Cavalli, R; de Lima Moreira, F; Koren, G; Lanchote, VL; Lubetsky, A; Pinto, L, 2021
)
2.33
"Fexofenadine (FXF) is a third-generation antihistamine drug and osthole is assumed as a natural antihistamine alternative. "( Changes in gene expression induced by histamine, fexofenadine and osthole: Expression of histamine H
Cieślińska, A; Fiedorowicz, E; Kordulewska, NK; Kostyra, E; Matysiewicz, M; Sienkiewicz-Szłapka, E, 2017
)
2.15
"Fexofenadine is a second-generation histamine receptor blocker well known for its potent interaction with this inflammatory process."( Effects of fexofenadine on inflammatory mediators in nasal lavage fluid in intermittent allergic rhinitis.
Ewert, R; Gläser, S; Gustavus, B; Hanf, G; Koch, B; Kunkel, G; Noga, O; Schäper, C, 2009
)
1.46
"Fexofenadine is a P-glycoprotein substrate of low bioavailability. "( Microdose study of a P-glycoprotein substrate, fexofenadine, using a non-radioisotope-labelled drug and LC/MS/MS.
Fujita, T; Kumagai, Y; Maeda, M; Sugiyama, Y; Tozuka, Z; Yamane, N; Yamazaki, A; Yokota, S, 2010
)
2.06
"Fexofenadine is a substrate of these transporters and it was previously shown that its clearance is reduced in the rat isolated perfused liver following treatment with E.coli lipopolysaccharide (LPS)."( Pharmacokinetics of fexofenadine following LPS administration to rats.
Davey, AK; Gerber, JP; Jaisue, S, 2010
)
1.41
"Fexofenadine (FXF) is a new non-sedating antihistamine used in the treatment of seasonal allergic rhinitis and chronic idiopathic urticaria. "( Evaluation of the genotoxicity and cytotoxicity of fexofenadine in cultured human peripheral blood lymphocytes.
Kasurka, CB; Sekeroğlu, V; Sekeroğlu, ZA, 2011
)
2.06
"Fexofenadine is a nonsedative antihistamine that exhibits good oral bioavailability despite its zwitterionic chemical structure and efflux by P-gp. "( Vectorial transport of fexofenadine across Caco-2 cells: involvement of apical uptake and basolateral efflux transporters.
Knight, BM; Ming, X; Thakker, DR, 2011
)
2.12
"S-fexofenadine is a more potent human histamine H1 receptor antagonist than R-fexofenadine."( Effect of coadministration of single and multiple doses of rifampicin on the pharmacokinetics of fexofenadine enantiomers in healthy subjects.
Akamine, Y; Fukizawa, S; Ikejiri, K; Kanamitsu, K; Kusuhara, H; Miura, M; Sugiyama, Y; Uno, T; Yasui-Furukori, N; Yokochi, M; Yoshida, K, 2013
)
1.17
"Fexofenadine is an effective H1 antihistamine, but in contrast to its parent compound, terfenadine, it does not affect the release of the mast cell mediators histamine and tryptase."( Effects of fexofenadine on the early response to nasal allergen challenge.
Allocco, FT; Baroody, FM; deTineo, M; Naclerio, RM; Votypka, V, 2002
)
2.15
"Fexofenadine is an intrinsically non-impairing antihistamine in Japanese subjects."( The effects of acute doses of fexofenadine, promethazine, and placebo on cognitive and psychomotor function in healthy Japanese volunteers.
Hindmarch, I; Ridout, F, 2003
)
1.33
"Fexofenadine is a nonsedating, long-acting antihistamine with highly selective H(1)-receptor antagonist activity and a particularly favorable safety profile."( Effects of fexofenadine and other antihistamines on components of the allergic response: adhesion molecules.
Canonica, GW; Ciprandi, G; Cosentino, C; Passalacqua, G; Riccio, AM; Tosca, MA, 2003
)
1.43
"Fexofenadine is a P-glycoprotein (P-gp) substrate and P-gp is certainly involved both in the poor brain penetration by the compound and, at least partially, in a number of observed drug interactions."( Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans.
Benedetti, MS; Diquet, B; Molimard, M, 2004
)
1.28
"Fexofenadine hydrochloride is a non-sedating antihistamine that is used in the treatment of symptoms associated with seasonal allergic rhinitis and chronic idiopathic urticaria. "( The utility of mixed-effects covariate analysis in rapid selection of doses in pediatric subjects: a case study with fexofenadine hydrochloride.
Jensen, BK; Kittner, B; Krishna, R; Krishnaswami, S; Sankoh, AJ, 2004
)
1.98
"Fexofenadine is a P-gp probe but not a CYP3A substrate."( Evaluation of first-pass cytochrome P4503A (CYP3A) and P-glycoprotein activities using alfentanil and fexofenadine in combination.
Hoffer, C; Kharasch, ED; Sheffels, P; Walker, A, 2005
)
1.27
"Fexofenadine is a substrate of P-glycoprotein and organic anion transporting polypeptides. "( Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics.
Sugawara, K; Tateishi, T; Uno, T; Yasui-Furukori, N, 2005
)
1.99
"Fexofenadine is a selective, nonsedating H(1)-receptor antagonist approved for symptoms of allergic conditions, which is mainly excreted into feces via biliary excretion. "( P-glycoprotein plays a major role in the efflux of fexofenadine in the small intestine and blood-brain barrier, but only a limited role in its biliary excretion.
Fuse, E; Kusuhara, H; Sugiyama, Y; Tahara, H, 2005
)
2.02
"Fexofenadine is a potent suppressor of the histamine-induced wheal and flare response in healthy Japanese volunteers. "( Suppression of the histamine-induced wheal and flare response by fexofenadine HCl 60 mg twice daily, loratadine 10 mg once daily and placebo in healthy Japanese volunteers.
Boyle, J; Hindmarch, I; Johnsen, S; Meadows, R; Ridout, F, 2005
)
2.01
"Fexofenadine is a substrate of several drug transporters including P-glycoprotein. "( Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein.
Shimizu, M; Sugawara, K; Tateishi, T; Uno, T, 2006
)
2.01
"Fexofenadine is a substrate for Pgp, Oatp1, Oatp2, and Oatp3."( Altered oral bioavailability and pharmacokinetics of P-glycoprotein substrates by coadministration of biochanin A.
Cousineau, M; Danser, E; Dewire, R; Floden, J; Peng, SX; Ritchie, DM, 2006
)
1.06
"Fexofenadine HCl is a new, nonsedating H1-receptor antagonist approved for treatment of seasonal allergic rhinitis (SAR). "( Effectiveness and safety of fexofenadine, a new nonsedating H1-receptor antagonist, in the treatment of fall allergies.
Ahlbrandt, R; Bronsky, EA; Falliers, CJ; Kaiser, HB; Mason, JM,
)
1.87
"Fexofenadine is a selective, nonsedating H1-receptor antagonist that relieves symptoms of allergic conditions."( Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers.
Russell, T; Stoltz, M; Weir, S, 1998
)
1.97
"Fexofenadine HCl is a nonsedating, long-acting H1 receptor antagonist that provides fast and effective relief from SAR."( The efficacy and safety of fexofenadine HCl and pseudoephedrine, alone and in combination, in seasonal allergic rhinitis.
Compton, D; Mason, J; Ricard, N; Stewart, J; Sussman, GL, 1999
)
1.32
"Fexofenadine is a highly specific, H1-receptor antagonist with a safety profile similar to placebo. "( The systemic safety of fexofenadine HCl.
Mason, J; Rao, N; Reynolds, R, 1999
)
2.06
"Fexofenadine is a nonsedating antihistamine approved for treatment of seasonal allergic rhinitis."( Fexofenadine HCl is safe and effective for treatment of chronic idiopathic urticaria.
Mason, J; Nelson, HS; Reynolds, R, 2000
)
3.19
"Fexofenadine is a non-sedating antihistamine indicated for relieving symptoms from allergic conditions with a rapid onset of action without cardiotoxic risks. "( Multicenter study of the efficacy and safety of fexofenadine 60 mg. twice daily in 108 Thai patients with chronic idiopathic urticaria.
Aunhachoke, K; Charuwichitratana, S; Gherunpong, N; Gritiyarangsan, P; Janjumratsang, P; Jiamton, S; Korkij, W; Krisadapong, J; Kullavanijaya, P; Kulthanan, K; Kuntiranont, M; Sitakalin, C, 2001
)
2.01
"Fexofenadine 180 mg is a new antihistamine that is effective in the treatment of chronic urticaria and that has a profile of side effects similar to placebo."( [Chronic idiopathic urticaria: effectiveness of fexofenadine. A double-blind, placebo controlled study with 21 patients].
Bircher, A; Degonda, M; Helbling, A; Pichler, WJ, 2002
)
1.29

Effects

Fexofenadine has a positive antihistamine effect, which is probably no worse than the second-generation antihistamines. It is also well tolerated in subjects with renal or hepatic impairment, in children and the elderly.

Fexofenadine (FEX) has a positive antihistamine effect, which is probably no worse than the second-generation antihistamines. It has been used for its efficacy and safety in the treatment of allergic rhinitis (AR) for many years although no meta-analyses supporting its use currently exist. FexofENadine has also been shown to have a favorable effect on nasal congestion.

ExcerptReferenceRelevance
"Fexofenadine has a positive antihistamine effect, which is probably no worse than the second-generation antihistamines. "( Antihistamine effects and safety of fexofenadine: a systematic review and Meta-analysis of randomized controlled trials.
Huang, CZ; Jiang, ZH; Luo, Y; Peng, H; Wang, J, 2019
)
2.23
"Fexofenadine has a high margin of safety and is also well tolerated in subjects with renal or hepatic impairment, in children and the elderly."( The systemic safety of fexofenadine HCl.
Mason, J; Rao, N; Reynolds, R, 1999
)
1.34
"Fexofenadine has a positive antihistamine effect, which is probably no worse than the second-generation antihistamines. "( Antihistamine effects and safety of fexofenadine: a systematic review and Meta-analysis of randomized controlled trials.
Huang, CZ; Jiang, ZH; Luo, Y; Peng, H; Wang, J, 2019
)
2.23
"Fexofenadine (FEX) has high solubility and low permeability (BCS, Class III). "( Improvement of effect of water-in-oil microemulsion as an oral delivery system for fexofenadine: in vitro and in vivo studies.
Alvarez, IG; Gundogdu, E; Karasulu, E, 2011
)
2.04
"Fexofenadine has been used for its efficacy and safety in the treatment of allergic rhinitis (AR) for many years although no meta-analyses supporting its use currently exist."( Systematic review on the efficacy of fexofenadine in seasonal allergic rhinitis: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials.
Badellino, H; Baena-Cagnani, CE; Baena-Cagnani, R; Braido, F; Canonica, GW; Compalati, E; Gómez, RM; Penagos, M, 2011
)
1.36
"Fexofenadine (FEX) has been extensively used for therapeutic benefits after the market withdrawal of terfenadine. "( Quantification of fexofenadine in biological matrices: a review of bioanalytical methods.
Srinivas, NR; Yao, M, 2012
)
2.16
"Fexofenadine has also been shown to have a favorable effect on nasal congestion."( Efficacy and safety profile of fexofenadine HCl: a unique therapeutic option in H1-receptor antagonist treatment.
Appajosyula, S; Meeves, SG, 2003
)
1.33
"Fexofenadine has been identified as a substrate for both the efflux transporter, P-glycoprotein (P-gp), as well as the influx transporter, organic anion transporting polypeptide (OATP). "( Effect of fruit juices on the oral bioavailability of fexofenadine in rats.
Chong, S; Kamath, AV; Yao, M; Zhang, Y, 2005
)
2.02
"Fexofenadine HCl (FEX) has previously been shown to have anti-inflammatory properties in relieving nasal congestion in allergic rhinitis. "( New evidence of H1-receptor independent COX-2 inhibition by fexofenadine HCl in vitro.
Darlath, W; Gillissen, A; Juergens, UR; Racké, K; Stöber, M; Uen, S; Vetter, H, 2006
)
2.02
"Fexofenadine has a high margin of safety and is also well tolerated in subjects with renal or hepatic impairment, in children and the elderly."( The systemic safety of fexofenadine HCl.
Mason, J; Rao, N; Reynolds, R, 1999
)
1.34
"Fexofenadine HCl has been investigated more extensively for possible electrophysiological effects than any other antihistamine. "( Cardiovascular safety of fexofenadine HCl.
Ahlbrandt, R; Brown, AM; Mason, J; Pratt, C; Rampe, D; Reynolds, R; Russell, T, 1999
)
2.05

Actions

ExcerptReferenceRelevance
"Fexofenadine does not inhibit cardiac K+ channels and is not associated with prolongation of the corrected QT interval."( Fexofenadine: a review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria.
Jarvis, B; Simpson, K, 2000
)
2.47

Treatment

Fexofenadine treatment of sensitized mice prevented the development of airway hyperresponsiveness in both the primary sensitization and challenge. Treatment resulted in inhibition of allergen-induced symptoms and increased vascular permeability, but not the release of histamine and tryptase.

ExcerptReferenceRelevance
"Fexofenadine treatment of sensitized mice prevented the development of airway hyperresponsiveness in both the primary sensitization and challenge, as well as in the adoptive transfer experiments. "( Fexofenadine modulates T-cell function, preventing allergen-induced airway inflammation and hyperresponsiveness.
Cui, ZH; Gelfand, EW; Joetham, A; Kanehiro, A; Takeda, K, 2002
)
3.2
"Treatment with fexofenadine resulted in inhibition of allergen-induced symptoms and increased vascular permeability, but not the release of histamine and tryptase."( Effects of fexofenadine on the early response to nasal allergen challenge.
Allocco, FT; Baroody, FM; deTineo, M; Naclerio, RM; Votypka, V, 2002
)
1.04
"Pretreatment with fexofenadine 2 hours before immunotherapy significantly reduced the occurrence of severe SRs (P = .03), significantly increased the proportion of patients receiving cedar pollen immunotherapy who achieved the target maintenance dose (TMD) (P = .03), and significantly reduced the length of time to attain the TMD (P = .047 and P = .003 for patients receiving cedar pollen and dust mite immunotherapy, respectively)."( Effect of pretreatment with fexofenadine on the safety of immunotherapy in patients with allergic rhinitis.
Murata, K; Nakai, Y; Ohashi, Y, 2006
)
0.96
"Pretreatment with fexofenadine during venom immunotherapy reduces local allergic reactions and generalized symptoms of the urticaria and angioedema type."( Reduction of side-effects from ultrarush immunotherapy with honeybee venom by pretreatment with fexofenadine: a double-blind, placebo-controlled trial.
Hari, Y; Müller, U; Reimers, A, 2000
)
0.86

Toxicity

Fexofenadine is safe and efficacious at single doses of 60 mg and 120 mg. In placebo-controlled trials of seasonal allergic rhinitis (SAR) and chronic idiopathic urticaria (CIU), the type and incidence of adverse evasions were lower.

ExcerptReferenceRelevance
" The frequency of adverse events was similar among fexofenadine HCl and placebo groups, with no dose-related trends."( Efficacy and safety of fexofenadine hydrochloride for treatment of seasonal allergic rhinitis.
Ahlbrandt, R; Bernstein, DI; Mason, J; Nathan, RA; Schoenwetter, WF; Storms, W, 1997
)
0.86
"Fexofenadine HCl is both effective and safe for the treatment of ragweed seasonal allergic rhinitis."( Efficacy and safety of fexofenadine hydrochloride for treatment of seasonal allergic rhinitis.
Ahlbrandt, R; Bernstein, DI; Mason, J; Nathan, RA; Schoenwetter, WF; Storms, W, 1997
)
2.05
"Fexofenadine is safe and efficacious at single doses of 60 mg and 120 mg."( Onset of action, efficacy, and safety of a single dose of fexofenadine hydrochloride for ragweed allergy using an environmental exposure unit.
Briscoe, MP; Clark, A; Day, JH; Ellis, AK; Mason, J; Smith, JN; Welsh, A, 1997
)
1.98
" In conclusion, fexofenadine HCl is safe and effective in the treatment of fall SAR, with 60 mg bid being the optimal therapeutic dosage."( Effectiveness and safety of fexofenadine, a new nonsedating H1-receptor antagonist, in the treatment of fall allergies.
Ahlbrandt, R; Bronsky, EA; Falliers, CJ; Kaiser, HB; Mason, JM,
)
0.77
" Incidence of adverse events was similar between fexofenadine and placebo groups (30."( Safety and efficacy of once-daily fexofenadine HCl in the treatment of autumn seasonal allergic rhinitis.
Andrade, C; Casale, TB; Qu, R,
)
0.66
" No serious adverse events were reported in any of the treatment groups."( The efficacy and safety of fexofenadine HCl and pseudoephedrine, alone and in combination, in seasonal allergic rhinitis.
Compton, D; Mason, J; Ricard, N; Stewart, J; Sussman, GL, 1999
)
0.6
" In placebo-controlled trials of seasonal allergic rhinitis (SAR) and chronic idiopathic urticaria (CIU), the type and incidence of adverse events were comparable in fexofenadine and placebo recipients."( The systemic safety of fexofenadine HCl.
Mason, J; Rao, N; Reynolds, R, 1999
)
0.81
" These three antihistamines have also been shown safe in special populations, including pediatric and elderly patients."( Safety of second generation antihistamines.
Philpot, EE,
)
0.13
" Adverse events occurred with similar incidence in all treatment groups, with no dose-related increases in any event."( Fexofenadine HCl is safe and effective for treatment of chronic idiopathic urticaria.
Mason, J; Nelson, HS; Reynolds, R, 2000
)
1.75
" Adverse events were recorded."( Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120 mg, loratadine 10 mg and placebo administered once daily for the treatment of seasonal allergic rhinitis.
Juniper, EF; Van Cauwenberge, P, 2000
)
0.54
" The incidence of adverse events was low and similar across all treatment groups."( Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120 mg, loratadine 10 mg and placebo administered once daily for the treatment of seasonal allergic rhinitis.
Juniper, EF; Van Cauwenberge, P, 2000
)
0.54
" Adverse events and onset of symptom relief were also recorded by every patient."( A non-comparative trial of the efficacy and safety of fexofenadine for treatment of perennial allergic rhinitis.
Bunnag, C; Chochaipanichnon, L; Jareoncharsri, P; Kongpatanakul, S; Limprasertsiri, S; Pumhirun, P; Supiyaphun, P; Tunsuriyawong, P, 2000
)
0.56
" The most common adverse event for all regimens was headache, reported in 20 (22%) subjects."( Pharmacokinetic and safety profile of desloratadine and fexofenadine when coadministered with azithromycin: a randomized, placebo-controlled, parallel-group study.
Affrime, M; Banfield, C; Batra, V; Clement, R; Gupta, S; Kantesaria, B; Marino, M, 2001
)
0.56
" Adverse events occurred in 20 cases (18."( Multicenter study of the efficacy and safety of fexofenadine 60 mg. twice daily in 108 Thai patients with chronic idiopathic urticaria.
Aunhachoke, K; Charuwichitratana, S; Gherunpong, N; Gritiyarangsan, P; Janjumratsang, P; Jiamton, S; Korkij, W; Krisadapong, J; Kullavanijaya, P; Kulthanan, K; Kuntiranont, M; Sitakalin, C, 2001
)
0.57
" No serious adverse events were reported."( Controlled comparison of the efficacy and safety of cetirizine 10 mg o.d. and fexofenadine 120 mg o.d. in reducing symptoms of seasonal allergic rhinitis.
Burtin, B; De Vos, C; Donnelly, F; Horak, F; Kavina, A; Stübner, P; Zieglmayer, R, 2001
)
0.54
" Safety was evaluated through adverse event reporting, electrocardiograms, and pre- and posttreatment laboratory panels and physical examinations."( Safety of fexofenadine in children treated for seasonal allergic rhinitis.
Bernstein, DI; Goldsobel, A; Graft, DF; Long, J; Meltzer, EO; Portnoy, J, 2001
)
0.71
" Ten patients (5 on placebo, 5 on fexofenadine) discontinued because of an adverse event; no event that resulted in discontinuation was judged to be caused by study medication."( Safety of fexofenadine in children treated for seasonal allergic rhinitis.
Bernstein, DI; Goldsobel, A; Graft, DF; Long, J; Meltzer, EO; Portnoy, J, 2001
)
0.99
"Fexofenadine, 15, 30, and 60 mg twice daily, was safe and well tolerated in this large pediatric patient population."( Safety of fexofenadine in children treated for seasonal allergic rhinitis.
Bernstein, DI; Goldsobel, A; Graft, DF; Long, J; Meltzer, EO; Portnoy, J, 2001
)
2.16
" There were 40 reports of adverse drug reactions in 27 patients."( Evaluation of the safety of fexofenadine from experience gained in general practice use in England in 1997.
Acharya, NV; Craig-McFeely, PM; Shakir, SA, 2001
)
0.6
"Within the limitations for an observational cohort study, fexofenadine was found to be well tolerated and safe in 16,638 users in general practice in England."( Evaluation of the safety of fexofenadine from experience gained in general practice use in England in 1997.
Acharya, NV; Craig-McFeely, PM; Shakir, SA, 2001
)
0.85
"Fexofenadine-pseudoephedrine was safe and effective in treating a broad range of allergy symptoms, with a rapid onset of action at 45 minutes."( Onset of action, efficacy, and safety of fexofenadine 60 mg/pseudoephedrine 120 mg versus placebo in the Atlanta allergen exposure unit.
Berkowitz, RB; Lutz, C; Meeves, S; Moss, M; Weiler, J; Weiler, K; Woodworth, GG, 2002
)
2.02
" There was no significant difference in adverse events between fexofenadine and placebo, either overall or by causality."( Fexofenadine is efficacious and safe in children (aged 6-11 years) with seasonal allergic rhinitis.
Bachert, C; Baena-Cagnani, C; Decosta, P; Finn, AF; Hedlin, G; Kowalski, ML; Meltzer, EO; Potter, P; Rosado Pinto, JE; Ruuth, E; Scheinmann, P; Simons, FE; Wahn, U, 2003
)
2
" Patients (and investigators) reported any adverse events during the trial."( Safety and efficacy of oral fexofenadine in children with seasonal allergic rhinitis--a pooled analysis of three studies.
Bachert, C; Finn, AF; Hedlin, G; Meltzer, EO; Rosado Pinto, JE; Ruuth, E; Scheinmann, P; Wahn, U, 2004
)
0.62
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" and adverse events were recorded in diary cards by the patients in form of scores as well as by the investigator at each visit."( The efficacy and safety of 30 mg fexofenadine HCl bid in pediatric patients with allergic rhinitis.
Direkwattanachai, C; Ngamphaiboon, J; Tiensuwan, M; Vangveeravong, M; Visitsunthorn, N, 2005
)
0.61
" Before the amendment, assessments included physical examination, vital signs reporting (oral temperature, heart rate, and respiratory rate), and adverse event (AE) reporting."( Safety and tolerability of fexofenadine for the treatment of allergic rhinitis in children 2 to 5 years old.
Hampel, FC; Kittner, B; Lanier, R; Milgrom, H, 2007
)
0.64
"In the combined population, the incidence of treatment-emergent adverse events (TEAEs) was comparable between groups (placebo, 48."( Safety and tolerability of fexofenadine hydrochloride, 15 and 30 mg, twice daily in children aged 6 months to 2 years with allergic rhinitis.
Hampel, FC; Kittner, B; van Bavel, JH, 2007
)
0.64
" Adverse events (AEs); electrocardiograms (ECGs); vital signs; and clinical laboratory tests for hematology, blood chemistry, and urinalysis were analyzed to evaluate safety and tolerability."( Pharmacokinetics, safety and tolerability of an oral suspension of fexofenadine for children with allergic rhinitis.
Grubbe, RE; Kittner, B; Levy, AL; Maloney, MJ; Nayak, AS; Quesada, JT; Segall, N,
)
0.37
" Second-generation antihistamines have become increasingly popular because of their comparable efficacy and lower incidence of adverse effects relative to their first-generation counterparts, and the safety and efficacy of this drug class are established in the adult population."( Treatment of allergic rhinitis in infants and children: efficacy and safety of second-generation antihistamines and the leukotriene receptor antagonist montelukast.
Moeller, ML; Nahata, MC; Phan, H, 2009
)
0.35
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
" When compared with the first-generation antihistamines, fexofenadine produced significantly lower adverse events frequency (OR = 0."( Antihistamine effects and safety of fexofenadine: a systematic review and Meta-analysis of randomized controlled trials.
Huang, CZ; Jiang, ZH; Luo, Y; Peng, H; Wang, J, 2019
)
1.03

Pharmacokinetics

Paroxetine extended the elimination half-life of fexofenadine by 45%. There were no differences in peak concentration, time to peak concentration and area under the time concentration curve up to 8 hr.

ExcerptReferenceRelevance
" Pharmacokinetic investigations have shown the drug to be highly bound to blood proteins, mainly serum albumin, and to have a low brain uptake, explaining its lack of sedative effects."( Molecular properties and pharmacokinetic behavior of cetirizine, a zwitterionic H1-receptor antagonist.
Carrupt, PA; Jolliet, P; Morin, C; Morin, D; Pagliara, A; Rihoux, JP; Testa, B; Tillement, JP; Urien, S, 1998
)
0.3
" This paper reviews the pharmacokinetic properties of these second-generation agents and is intended to provide comparisons that help explain differences in dosing profiles and drug interactions for members of this class of drugs."( Pharmacokinetic overview of oral second-generation H1 antihistamines.
Estes, KS; González, MA, 1998
)
0.3
" For terfenadine, atorvastatin coadministration produced an 8% decrease in maximum concentration (Cmax), a 35% increase in area under the concentration-time curve extrapolated to infinity (AUC0-infinity), and a 2% decrease in elimination half-life (t1/2)."( Atorvastatin does not produce a clinically significant effect on the pharmacokinetics of terfenadine.
Olson, SC; Smithers, JA; Stern, RH, 1998
)
0.3
"This study was undertaken to assess the effects of coadministration of desloratadine or fexofenadine with azithromycin on pharmacokinetic parameters, tolerability, and electrocardiographic (ECG) findings."( Pharmacokinetic and safety profile of desloratadine and fexofenadine when coadministered with azithromycin: a randomized, placebo-controlled, parallel-group study.
Affrime, M; Banfield, C; Batra, V; Clement, R; Gupta, S; Kantesaria, B; Marino, M, 2001
)
0.78
"The results of the pharmacokinetic analysis revealed little change in mean maximum concentration (Cmax) and area under the concentration-time curve (AUC) values for desloratadine with concomitant administration of azithromycin: Cmax ratio, 115% (90% CI, 92-144); AUC, ratio 105% (90% CI, 82-134)."( Pharmacokinetic and safety profile of desloratadine and fexofenadine when coadministered with azithromycin: a randomized, placebo-controlled, parallel-group study.
Affrime, M; Banfield, C; Batra, V; Clement, R; Gupta, S; Kantesaria, B; Marino, M, 2001
)
0.56
"05) decreased the oral clearance by 20%, with no change in half-life or renal clearance."( Effect of St John's wort on the pharmacokinetics of fexofenadine.
Hall, SD; Hamman, MA; Huang, SM; Lesko, LJ; Wang, Z, 2002
)
0.57
" Comparison of the pharmacokinetic parameters of omeprazole before and after fexofenadine revealed that there were no differences in peak concentration, time to peak concentration, area under the time concentration curve up to 8 hr, and elimination half-life."( Fexofenadine does not affect omeprazole pharmacokinetics: both are putative P-glycoprotein substrates.
Sugawara, K; Takahata, T; Tateishi, T; Uno, T; Yasui-Furukori, N; Yoshiya, G, 2004
)
2
" No changes in any plasma pharmacokinetic parameters of fexofenadine were found during cimetidine treatment."( Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics.
Sugawara, K; Tateishi, T; Uno, T; Yasui-Furukori, N, 2005
)
0.79
"In the placebo phase, pharmacokinetic parameters of fexofenadine showed no statistically significant difference between 2 MDR1 haplotypes; the area under the curve from time 0 to infinity (AUC(0-infinity)) of fexofenadine in the T/T and G/C groups was 5194."( Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism.
Cha, IJ; Choi, YG; Hong, WS; Lee, SS; Nguyen, PM; Shin, JG; Shon, JH; Yoon, YR, 2005
)
0.81
" It is concluded that estimating in vivo receptor occupancy, which takes into account both the affinity of the drug for the receptor and its free plasma concentration, is a far better predictor for human pharmacodynamics and hence antihistamine potency, than considering in vitro affinity and plasmatic half-life only."( Histamine H1 receptor occupancy and pharmacodynamics of second generation H1-antihistamines.
Baltes, E; Benedetti, MS; Chatelain, P; Gillard, M, 2005
)
0.33
" Elimination half-life and renal clearance in the itraconazole phase were not altered significantly compared with those in the control phase."( Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein.
Shimizu, M; Sugawara, K; Tateishi, T; Uno, T, 2006
)
0.57
" The current studies used sandwich-cultured (SC) rat hepatocytes combined with a comprehensive pharmacokinetic modeling approach to investigate the hepatobiliary disposition of terfenadine and fexofenadine, a model drug/metabolite pair."( Hepatobiliary disposition of a drug/metabolite pair: Comprehensive pharmacokinetic modeling in sandwich-cultured rat hepatocytes.
Brouwer, KL; Hoffmaster, KA; Kalvass, JC; Pollack, GM; Turncliff, RZ, 2006
)
0.52
" No significant changes in mean residence time and terminal half-life were observed for all drugs, suggesting a negligible effect of BA on their hepatic/renal elimination."( Altered oral bioavailability and pharmacokinetics of P-glycoprotein substrates by coadministration of biochanin A.
Cousineau, M; Danser, E; Dewire, R; Floden, J; Peng, SX; Ritchie, DM, 2006
)
0.33
" Although the elimination half-life and the renal clearance of fexofenadine remained relatively constant, a single administration of itraconazole with fexofenadine significantly increased mean area under the plasma concentration-time curve (AUC(0-infinity)) of fexofenadine (1701/3554, 4308, and 4107 ng h/ml for control; 50 mg, 100 mg, and 200 mg of itraconazole, respectively)."( Lack of dose-dependent effects of itraconazole on the pharmacokinetic interaction with fexofenadine.
Shimizu, M; Sugawara, K; Tateishi, T; Uno, T, 2006
)
0.8
" Eight cystic fibrosis patients and 8 healthy volunteers were recruited into a crossover pharmacokinetic study in which participants received 180 mg fexofenadine with or without 1 g probenecid twice a day."( Probenecid, but not cystic fibrosis, alters the total and renal clearance of fexofenadine.
Beringer, PM; Burckart, GJ; Hidayat, L; Liu, S; Louie, S; Rao, AP; Shapiro, B, 2008
)
0.77
" The purpose of this study was to assess the pharmacokinetic behavior, safety, and tolerability of a single dose of fexofenadine HCl oral suspension administered to children aged 2-5 years with allergic rhinitis."( Pharmacokinetics, safety and tolerability of an oral suspension of fexofenadine for children with allergic rhinitis.
Grubbe, RE; Kittner, B; Levy, AL; Maloney, MJ; Nayak, AS; Quesada, JT; Segall, N,
)
0.58
" Plasma and urinary fexofenadine concentrations were measured, and pharmacokinetic differences between placebo and quercetin phases were assessed."( Short-term effect of quercetin on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein, in healthy volunteers.
Kim, KA; Park, JY; Park, PW, 2009
)
0.92
" The area under the time versus concentration curve (AUC) of plasma fexofenadine was increased by 55% by quercetin (2,005."( Short-term effect of quercetin on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein, in healthy volunteers.
Kim, KA; Park, JY; Park, PW, 2009
)
0.83
"The suitability of fexofenadine as a probe substrate to assess hepatobiliary transport function in humans was evaluated by pharmacokinetic modeling/simulation and in vitro/in situ studies using chemical modulators."( Integration of preclinical and clinical data with pharmacokinetic modeling and simulation to evaluate fexofenadine as a probe for hepatobiliary transport function.
Brouwer, KL; Swift, B; Tian, X, 2009
)
0.9
"Simulations based on a pharmacokinetic model developed to describe fexofenadine disposition in humans were conducted to examine the impact of altered hepatobiliary transport on fexofenadine disposition."( Integration of preclinical and clinical data with pharmacokinetic modeling and simulation to evaluate fexofenadine as a probe for hepatobiliary transport function.
Brouwer, KL; Swift, B; Tian, X, 2009
)
0.8
" The validated method was applied to a pharmacokinetic study in human volunteers following oral administration of 60 or 120 mg fexofenadine formulations, successfully."( Measurement of fexofenadine concentration in micro-sample human plasma by a rapid and sensitive LC-MS/MS employing protein precipitation: application to a clinical pharmacokinetic study.
Fan, H; Guo, D; Lou, S; Qin, Q; Zhu, Y; Zou, J, 2010
)
0.92
"ESRD can affect the pharmacokinetic disposition of drugs subject to nonrenal clearance."( ESRD impairs nonrenal clearance of fexofenadine but not midazolam.
Frye, RF; Himmelfarb, J; Le, P; Leblond, FA; Naud, J; Nolin, TD; Pichette, V; Sadr, H, 2009
)
0.63
" This article reviews the pharmacokinetic differences between fexofenadine enantiomers in humans and summarizes the previous reports that co-administration of P-glycoprotein inhibitors has altered the stereoselective pharmacokinetics of fexofenadine enantiomers."( Clinical pharmacokinetics of fexofenadine enantiomers.
Miura, M; Uno, T, 2010
)
0.89
" The area under the time versus concentration curve of fexofenadine in the metronidazole phase (2075."( Effect of metronidazole on the pharmacokinetics of fexofenadine, a P-glycoprotein substrate, in healthy male volunteers.
Kim, KA; Park, JY, 2010
)
0.86
"A human pharmacokinetic study was performed to assess the ability of a microdose to predict the pharmacokinetics of a therapeutic dose of fexofenadine and to determine its absolute oral bioavailability."( Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability.
Bjerrum, OJ; Garner, C; Gesson, C; Houston, B; Jochemsen, R; Lappin, G; Oosterhuis, B; Rowland, M; Shishikura, Y; Weaver, RJ, 2010
)
0.89
" The pharmacokinetic properties of S-fexofenadine are affected by a single polymorphism of SLCO2B1 in combination with several polymorphisms of ABCB1 C1236T, C3435T, and ABCC2 C-24T."( Influence of drug-transporter polymorphisms on the pharmacokinetics of fexofenadine enantiomers.
Akamine, Y; Kagaya, H; Miura, M; Sunagawa, S; Uno, T; Yasui-Furukori, N, 2010
)
0.87
" Oral or intravenous (IV) fexofenadine (10 mg/kg) was administered 24 h later and plasma and urine samples collected for pharmacokinetic analysis."( Pharmacokinetics of fexofenadine following LPS administration to rats.
Davey, AK; Gerber, JP; Jaisue, S, 2010
)
0.98
" Neither the genotype nor the apple juice showed significant effects on the pharmacokinetics of midazolam except for a marginally significant decrease in Cmax after administration with apple juice."( The effects of the SLCO2B1 c.1457C > T polymorphism and apple juice on the pharmacokinetics of fexofenadine and midazolam in humans.
Imai, H; Imanaga, J; Kotegawa, T; Ohashi, K; Ohyama, T; Shirasaka, Y; Tamai, I; Tateishi, T; Tsutsumi, K; Yoshizato, T, 2011
)
0.59
"The authors evaluated the contribution of the SLCO2B1 polymorphism to the pharmacokinetics of celiprolol at a microdose (MD) and therapeutic dose (TD) and compared pharmacokinetic proportionality between the 2 dose forms in 30 SLCO2B1 genotype-matched healthy volunteers."( Microdosing clinical study: pharmacokinetic, pharmacogenomic (SLCO2B1), and interaction (grapefruit juice) profiles of celiprolol following the oral microdose and therapeutic dose.
Chiyoda, T; Doi, Y; Hirota, T; Ieiri, I; Irie, S; Iwasaki, K; Kimura, M; Maeda, K; Miyagawa, M; Sasaki, T; Sugiyama, Y, 2012
)
0.38
" In this study, fexofenadine, verapamil, risperidone, ondansetron, and imipramine were used as model compounds to investigate the effectiveness of MIM in pharmacokinetic studies."( Development of a novel high-throughput analytical methodology, multiple injection method, for quantitative analysis in drug metabolism and pharmacokinetic studies using liquid chromatography with tandem mass spectrometry.
Ohkawa, T; Tanaka, Y; Yasui, H, 2011
)
0.72
" The P-gp inducer showed a greater effect on the pharmacokinetic parameters of (S)-fexofenadine."( Carbamazepine differentially affects the pharmacokinetics of fexofenadine enantiomers.
Akamine, Y; Kojima, M; Miura, M; Uno, T; Yasui-Furukori, N, 2012
)
0.85
" Safety and pharmacokinetic analyses were performed."( Intestinal OATP1A2 inhibition as a potential mechanism for the effect of grapefruit juice on aliskiren pharmacokinetics in healthy subjects.
Alexander, N; Dahlke, M; Hanna, I; Hariry, S; Jarugula, V; Rebello, S; Vapurcuyan, A; Zhao, S, 2012
)
0.38
" In addition, a physiologically based pharmacokinetic (PBPK) model consisting of 11 compartments (6 tissues +5 sample sites) was applied for mechanistic elucidation and estimation of individual PK parameters."( Effects of verapamil on the pharmacokinetics and hepatobiliary disposition of fexofenadine in pigs.
Bondesson, U; Hedeland, M; Lennernäs, H; Sjögren, E, 2014
)
0.63
" The pharmacokinetic studies proved F23 ability to increase extent of FXD absorption and reduce T(max)."( Phenylalanine-free taste-masked orodispersible tablets of fexofenadine hydrochloride: development, in vitro evaluation and in vivo estimation of the drug pharmacokinetics in healthy human volunteers.
El-Ridi, MS; El-Sherif, NG; Tadros, MI; Yehia, SA, 2015
)
0.66
"A population pharmacokinetic analysis was conducted to characterize the pharmacokinetics of fexofenadine in Japanese pediatric patients (6 months through 16 years) with perennial allergic rhinitis or atopic dermatitis."( Population pharmacokinetic analysis of fexofenadine in Japanese pediatric patients.
Fabre, D; Khier, S; Martinez, JM; Morita, S; Rauch, C, 2014
)
0.89
"The aim of presented study was to assess pharmacokinetic properties of fexofenadine in Taiwanese volunteers."( Pharmacokinetics of fexofenadine in healthy Taiwanese volunteers.
Chen, YA; Hsu, KY, 2014
)
0.96
"In pharmacokinetic evaluation of mice, using serial sampling methods rather than a terminal blood sampling method could reduce the number of animals needed and lead to more reliable data by excluding individual differences."( Using improved serial blood sampling method of mice to study pharmacokinetics and drug-drug interaction.
Nezasa, K; Ogawa, K; Shimizu, R; Takai, N; Tanaka, Y; Watanabe, A; Watari, R; Yamaguchi, Y, 2015
)
0.42
" These results were confirmed by an in vivo pharmacokinetic study of oral administered fexofenadine (10mg/kg) in rats."( Effect of diosmin on the intestinal absorption and pharmacokinetics of fexofenadine in rats.
Bedada, SK; Neerati, P, 2015
)
0.87
" This method was successfully applied for therapeutic drug monitoring in patients treated with clinical doses of fexofenadine and for pharmacokinetic studies."( HPLC Determination of Fexofenadine in Human Plasma For Therapeutic Drug Monitoring and Pharmacokinetic Studies.
El Bedaiwy, HM; Helmy, SA, 2016
)
0.96
" These results were confirmed by an in vivo pharmacokinetic study of oral administered FEX (10mg/kg) in rats."( Effect of resveratrol on the pharmacokinetics of fexofenadine in rats: Involvement of P-glycoprotein inhibition.
Bedada, SK; Neerati, P; Yellu, NR, 2016
)
0.69
" In comparison with FEX alone, RSV pretreatment significantly increased maximum plasma concentration (Cmax) and area under the concentration-time curve (AUC), while there was no significant change was observed in T1/2 and Tmax of FEX."( Effect of resveratrol on the pharmacokinetics of fexofenadine in rats: Involvement of P-glycoprotein inhibition.
Bedada, SK; Neerati, P; Yellu, NR, 2016
)
0.69
"RSV significantly enhanced the exposure of FEX in rats likely by the inhibition of P-glycoprotein (P-gp) mediated efflux during the intestinal absorption, suggesting that there is a potential pharmacokinetic interaction between RSV and FEX."( Effect of resveratrol on the pharmacokinetics of fexofenadine in rats: Involvement of P-glycoprotein inhibition.
Bedada, SK; Neerati, P; Yellu, NR, 2016
)
0.69
"Whether the combined use of probe drugs for CYP3A4 and P-glycoprotein can clarify the relative contribution of these proteins to pharmacokinetic variability of a dual substrate like tacrolimus has never been assessed."( Fexofenadine, a Putative In Vivo P-glycoprotein Probe, Fails to Predict Clearance of the Substrate Tacrolimus in Renal Recipients.
Annaert, P; Bouillon, T; de Loor, H; Kuypers, D; Vanhove, T, 2017
)
1.9
"In order to better understand the variability of pharmacodynamic and pharmacokinetic profiles of terfenadine between the previous studies as well as to qualitatively and quantitatively examine the proarrhythmic potential of its major active metabolite fexofenadine in comparison with that of terfenadine, we directly compared their electropharmacological effects with halothane-anesthetized dogs (n = 3)."( Comparison of electropharmacological effects between terfenadine and its active derivative fexofenadine using a cross-over study in halothane-anesthetized dogs to analyze variability of pharmacodynamic and pharmacokinetic profiles of terfenadine and torsa
Ando, K; Chiba, K; Goto, A; Hagiwara-Nagasawa, M; Harada, H; Inamura, N; Izumi-Nakaseko, H; Lubna, NJ; Miyamoto, H; Naito, AT; Nakamura, Y; Sugiyama, A; Takagi, K, 2018
)
0.88
" Values for total clearance of compounds from plasma should be one of the most important pharmacokinetic parameters for predictions."( Predicted values for human total clearance of a variety of typical compounds with differently humanized-liver mouse plasma data.
Ito, S; Iwamoto, K; Kamimura, H; Mizunaga, M; Nakayama, K; Negoro, T; Nishiwaki, M; Nomura, Y; Suemizu, H; Yamazaki, H; Yoneda, N, 2020
)
0.56
" This study evaluated a limited sampling strategy using a population pharmacokinetic approach to estimate plasma fexofenadine exposure as an index of P-gp and OATP activities."( Fexofenadine Plasma Concentrations to Estimate Systemic Exposure in Healthy Adults Using a Limited Sampling Strategy with a Population Pharmacokinetic Approach.
Blaquera, CL; Capparelli, EV; Ma, JD; Nikanjam, M; Nolin, TD; Paine, MF; Penzak, SR; Piscitelli, J, 2023
)
2.56
" A population pharmacokinetic model was developed using nonlinear mixed-effects modeling."( Fexofenadine Plasma Concentrations to Estimate Systemic Exposure in Healthy Adults Using a Limited Sampling Strategy with a Population Pharmacokinetic Approach.
Blaquera, CL; Capparelli, EV; Ma, JD; Nikanjam, M; Nolin, TD; Paine, MF; Penzak, SR; Piscitelli, J, 2023
)
2.35

Compound-Compound Interactions

Fexofenadine is expected to interact with GFJ on OATP2B1 at therapeutic concentrations, in accordance with the clinical observations. A substantial increase was observed in mean Cmax and AUC values when administered with azithromycin.

ExcerptReferenceRelevance
" A substantial increase was observed in mean Cmax and AUC values for fexofenadine when administered with azithromycin: Cmax, ratio, 169% (90% CI, 120-237); AUC ratio, 167% (90% CI, 122-229)."( Pharmacokinetic and safety profile of desloratadine and fexofenadine when coadministered with azithromycin: a randomized, placebo-controlled, parallel-group study.
Affrime, M; Banfield, C; Batra, V; Clement, R; Gupta, S; Kantesaria, B; Marino, M, 2001
)
0.79
" The purpose of the present study is to investigate the possibility that the drug-drug interaction between fexofenadine and probenecid involves the renal basolateral uptake process."( Inhibition of oat3-mediated renal uptake as a mechanism for drug-drug interaction between fexofenadine and probenecid.
Fuse, E; Koepsell, H; Kusuhara, H; Maeda, K; Sugiyama, Y; Tahara, H, 2006
)
0.77
"Cimetidine is known to cause drug-drug interactions (DDIs) with organic cations in the kidney, and a previous clinical study showed that coadministration of cimetidine or probenecid with fexofenadine (FEX) decreased its renal clearance."( The inhibition of human multidrug and toxin extrusion 1 is involved in the drug-drug interaction caused by cimetidine.
Horita, S; Inoue, K; Kondo, T; Kusuhara, H; Maeda, K; Matsushima, S; Nakayama, H; Ohta, KY; Sugiyama, Y; Yuasa, H, 2009
)
0.54
" Given that both fluvastatin and fexofenadine can interact with organic anion-transporting polypeptides (OATPs) expressed in intestine and liver, the present results suggest the potential drug interaction between fluvastatin and fexofenadine via the competition for the OATP-mediated cellular transport pathway during intestinal absorption and/or hepatic uptake of drugs."( Pharmacokinetic drug interaction between fexofenadine and fluvastatin mediated by organic anion-transporting polypeptides in rats.
Han, HK; Lee, BJ; Lee, W; Qiang, F, 2009
)
0.9
" Inhibition or induction of P-gp can cause drug-drug interactions and thus influence the effects of P-gp substrate drugs."( 20(S)-ginsenoside Rh2 noncompetitively inhibits P-glycoprotein in vitro and in vivo: a case for herb-drug interactions.
Ai, H; Gu, Y; Hao, G; Li, Y; Peng, Y; Sun, J; Wang, G; Wu, X; Zhang, J; Zhang, X; Zheng, Y; Zhou, F, 2010
)
0.36
"The hepatic organic anion transporting polypeptides (OATPs) influence the pharmacokinetics of several drug classes and are involved in many clinical drug-drug interactions."( Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR, 2012
)
0.38
" These findings indicate that only fexofenadine is expected to interact with GFJ on OATP2B1 at therapeutic concentrations, in accordance with the clinical observations."( Substrate- and dose-dependent drug interactions with grapefruit juice caused by multiple binding sites on OATP2B1.
Mori, T; Murata, Y; Nakanishi, T; Shirasaka, Y; Tamai, I, 2014
)
0.68
" In addition, using serial sampling methods can be valuable for evaluation of the drug-drug interaction (DDI) potential of drug candidates."( Using improved serial blood sampling method of mice to study pharmacokinetics and drug-drug interaction.
Nezasa, K; Ogawa, K; Shimizu, R; Takai, N; Tanaka, Y; Watanabe, A; Watari, R; Yamaguchi, Y, 2015
)
0.42
" To further validate this cocktail, in this study, we have verified whether probe drugs contained in the latter cause mutual drug-drug interactions."( Evaluation of Mutual Drug-Drug Interaction within Geneva Cocktail for Cytochrome P450 Phenotyping using Innovative Dried Blood Sampling Method.
Bosilkovska, M; Daali, Y; Déglon, J; Desmeules, J; Samer, C; Thomas, A; Walder, B, 2016
)
0.43

Bioavailability

Grapefruit and orange juices inhibited human enteric organic anion-transporting polypeptide (OATP)1A2 in vitro. LPS treatment increased the bioavailability of fexofenadine but did not affect other pharmacokinetic parameters.

ExcerptReferenceRelevance
"Grapefruit juice (GJ) is known to increase the oral bioavailability of many CYP3A-substrates by inhibiting intestinal phase-I metabolism."( Grapefruit juice activates P-glycoprotein-mediated drug transport.
Benet, LZ; Christians, U; Silverman, JA; Soldner, A; Susanto, M; Wacher, VJ, 1999
)
0.3
" We conclude that the cause of the increased oral clearance of fexofenadine is a reduced bioavailability caused by induction of intestinal P-glycoprotein."( The effect of rifampin administration on the disposition of fexofenadine.
Bruce, MA; Haehner-Daniels, BD; Hall, SD; Hamman, MA, 2001
)
0.79
"Certain foods, such as grapefruit juice, are known to substantially alter the bioavailability of some drugs."( Grapefruit juice reduces the oral bioavailability of fexofenadine but not desloratadine.
Affrime, M; Banfield, C; Gupta, S; Lim, J; Marino, M, 2002
)
0.56
"To assess the effect of consumption of grapefruit juice on the oral bioavailability of two nonsedating antihistamines, fexofenadine and desloratadine."( Grapefruit juice reduces the oral bioavailability of fexofenadine but not desloratadine.
Affrime, M; Banfield, C; Gupta, S; Lim, J; Marino, M, 2002
)
0.77
" In contrast, the bioavailability of desloratadine was unaffected by grapefruit juice."( Grapefruit juice reduces the oral bioavailability of fexofenadine but not desloratadine.
Affrime, M; Banfield, C; Gupta, S; Lim, J; Marino, M, 2002
)
0.56
"The bioavailability of drugs that do not undergo significant intestinal or hepatic metabolism, such as fexofenadine, may be altered when administered with agents that influence drug transport mechanisms."( Grapefruit juice reduces the oral bioavailability of fexofenadine but not desloratadine.
Affrime, M; Banfield, C; Gupta, S; Lim, J; Marino, M, 2002
)
0.78
"Our objective was to investigate the main in vivo transport mechanisms of fexofenadine involved in the intestinal absorption and bioavailability of the drug in humans."( Multiple transport mechanisms involved in the intestinal absorption and first-pass extraction of fexofenadine.
Bondesson, U; Hedeland, M; Knutson, L; Lennernäs, H; Petri, N; Tannergren, C, 2003
)
0.77
"In this in vivo perfusion study verapamil increased the bioavailability of fexofenadine."( Multiple transport mechanisms involved in the intestinal absorption and first-pass extraction of fexofenadine.
Bondesson, U; Hedeland, M; Knutson, L; Lennernäs, H; Petri, N; Tannergren, C, 2003
)
0.77
" The absolute bioavailability is 50-65% for mizolastine; it is high for levocetirizine as the percentage of the drug eliminated unchanged in the 48 h urine is 77% of the oral dose; the estimation for fexofenadine is at least 33%; no estimation was found for desloratadine."( Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans.
Benedetti, MS; Diquet, B; Molimard, M, 2004
)
0.75
" Clinical studies in humans showed that fruit juices reduced the oral bioavailability of fexofenadine by preferentially inhibiting OATP over P-gp."( Effect of fruit juices on the oral bioavailability of fexofenadine in rats.
Chong, S; Kamath, AV; Yao, M; Zhang, Y, 2005
)
0.8
"This study suggests that verapamil increases fexofenadine exposure probably because of an increase in bioavailability through P-glycoprotein inhibition and that probenecid slightly increases the area under the plasma concentration-time curve of fexofenadine as a result of a pronounced reduction in renal clearance."( Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics.
Sugawara, K; Tateishi, T; Uno, T; Yasui-Furukori, N, 2005
)
0.81
"The purpose of this study was to elucidate the potential clinical relevance and mechanism(s) of action of 2 different volumes of grapefruit juice on the reduction of bioavailability of fexofenadine, a substrate of organic anion transporting polypeptides."( Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: possible role of organic anion transporting polypeptides.
Bailey, DG; Dresser, GK; Kim, RB, 2005
)
0.77
"Grapefruit juice at a commonly consumed volume diminished the oral bioavailability of fexofenadine sufficiently to be pertinent clinically, likely by direct inhibition of uptake by intestinal organic anion transporting polypeptide A (OATP-A; new nomenclature, OATP1A2)."( Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: possible role of organic anion transporting polypeptides.
Bailey, DG; Dresser, GK; Kim, RB, 2005
)
0.8
" Comparing the pharmacokinetics after intravenous and oral administration indicated that the bioavailability of fexofenadine was at most 2% in mice."( P-glycoprotein plays a major role in the efflux of fexofenadine in the small intestine and blood-brain barrier, but only a limited role in its biliary excretion.
Fuse, E; Kusuhara, H; Sugiyama, Y; Tahara, H, 2005
)
0.79
" Consistent with this finding, in vivo studies showed that ketoconazole did not affect the Fa Fg for fexofenadine, a pharmacokinetic parameter that reflects absorption and bioavailability in the small intestine."( The advantages of the Ussing chamber in drug absorption studies.
Gotoh, Y; Kamada, N; Momose, D, 2005
)
0.54
" The apparent absorption rate constant (ka) of [(14)C]bepotastine in the small intestine was greatly increased by cyclosporin A and verapamil, especially in the distal portion, and the site-specific absorption of [(14)C]bepotastine disappeared."( Effect of P-glycoprotein on intestinal absorption and brain penetration of antiallergic agent bepotastine besilate.
Fukuda, H; Kamikozawa, Y; Ohashi, R; Sugiura, M; Tamai, I; Yabuuchi, H, 2006
)
0.33
" The fexofenadine AUC(infinity) was increased by lopinavir/ritonavir, likely due to increased bioavailability secondary to P-glycoprotein inhibition."( Time-dependent interaction between lopinavir/ritonavir and fexofenadine.
Bourbeau, M; Cameron, DW; Campbell, P; Chauhan, BM; Foster, BC; Seguin, I; van Heeswijk, RP, 2006
)
1.09
"To support the pharmacokinetic and bioavailability study of a once-daily fexofenadine/pseudoephedrine combination, a high-performance liquid chromatography/positive ion electrospray tandem mass spectrometry (HPLC/ESI-MS/MS) method for the simultaneous quantification of fexofenadine and pseudoephedrine was developed and validated with 500 microL human plasma using mosapride as an internal standard (IS)."( Simultaneous quantification of fexofenadine and pseudoephedrine in human plasma by liquid chromatography/tandem mass spectrometry with electrospray ionization: method development, validation and application to a clinical study.
Kandikere, VN; Komarneni, P; Maurya, S; Mudigonda, K; Nirogi, RV; Shukla, M, 2006
)
0.85
" The validated method has been successfully used to analyze human plasma samples for application in pharmacokinetic, bioavailability or bioequivalence studies."( Quantification of fexofenadine in human plasma by liquid chromatography coupled to electrospray tandem mass spectrometry using mosapride as internal standard.
Kandikere, VN; Komarneni, P; Maurya, S; Mudigonda, K; Nirogi, RV; Shukla, M, 2007
)
0.67
"We showed previously that grapefruit and orange juices inhibited human enteric organic anion-transporting polypeptide (OATP)1A2 in vitro and lowered oral fexofenadine bioavailability clinically."( Naringin is a major and selective clinical inhibitor of organic anion-transporting polypeptide 1A2 (OATP1A2) in grapefruit juice.
Bailey, DG; Dresser, GK; Kim, RB; Leake, BF, 2007
)
0.54
" The absolute oral bioavailability of fexofenadine in humans is not known because of a lack of studies of intravenous administration of this agent."( Some pharmacokinetic aspects of the lipophilic terfenadine and zwitterionic fexofenadine in humans.
Chen, C, 2007
)
0.84
" Although itraconazole co-administration is known to increase the bioavailability of a racemic mixture of fexofenadine, little is known about the stereoselective inhibition of P-gp activity by itraconazole."( The different effects of itraconazole on the pharmacokinetics of fexofenadine enantiomers.
Miura, M; Suzuki, T; Tateishi, T; Uno, T, 2008
)
0.8
" No major cytochrome P450 inhibition has been reported with desloratadine, fexofenadine and levocetirizine, and the bioavailability of desloratadine is minimally affected by drugs interfering with transporter molecules."( Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review.
Devillier, P; Faisy, C; Roche, N, 2008
)
0.81
" bioavailability in preclinical species and humans."( Involvement of intestinal uptake transporters in the absorption of azithromycin and clarithromycin in the rat.
Davis, CB; Dawson, PA; Garver, E; Han, C; Hugger, ED; Rao, A; Shearn, SP, 2008
)
0.35
"51 to 0); and increased bioavailability (from 37 to 95%)."( Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities.
Bedynek, PS; Hoffer, C; Kharasch, ED; Walker, A; Whittington, D, 2008
)
0.35
" Whole-body MALDI-IMS data showed that the poor oral bioavailability of terfenadine was largely due to high first-pass metabolism in the intestines and the liver before the compound reached systemic circulation."( Visualization of first-pass drug metabolism of terfenadine by MALDI-imaging mass spectrometry.
Chen, J; Crossman, L; Hsieh, Y; Knemeyer, I; Korfmacher, WA, 2008
)
0.35
" Selected compounds were further evaluated for their oral anti-histaminic activity in mice and bioavailability in rats."( Synthesis and structure-activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H(1) antagonists.
Isobe, Y; Kubota, K; Kurebayashi, H; Miyachi, H; Onishi, M; Tobe, M, 2009
)
0.35
" Consequently, the bioavailability of oral fluvastatin was significantly lower (p<0."( Pharmacokinetic drug interaction between fexofenadine and fluvastatin mediated by organic anion-transporting polypeptides in rats.
Han, HK; Lee, BJ; Lee, W; Qiang, F, 2009
)
0.62
" The mean bioavailability (F(ev)) of fexofenadine was decreased by 16."( Long-term effects of Panax ginseng on disposition of fexofenadine in rats in vivo.
Cao, Z; Jie, J; Li, W; Zhang, R; Zhou, Y, 2009
)
0.88
" Since the quality of final drug product is affected by the source of ingredients, type and amount of excipients and manufacturing process, bioequivalence studies are used to determine the bioavailability and characterize the pharmacokinetics of the new formulation relative to a reference formulation."( Bioequivalence of fexofenadine tablet formulations assessed in healthy Iranian volunteers.
Barghi, L; Islambulchilar, Z; Jalilian, H; Valizadeh, H; Zakeri-Milani, P, 2009
)
0.69
" These "in combo" PAMPA data were used to predict the human absolute bioavailability of the ampholytes."( The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
Avdeef, A; Sun, N; Tam, KY; Tsinman, O, 2010
)
0.36
" Moreover, the bioavailability of fexofenadine x HCl after nasal administration of the microsphere formulation to rabbits was increased up to about 48% while that of the control solution was only about 3%."( Preparation and evaluation of spray-dried hyaluronic acid microspheres for intranasal delivery of fexofenadine hydrochloride.
Cho, HJ; Choi, MK; Chung, SJ; Huh, Y; Kim, DD; Kim, JS; Oh, E; Shim, CK; Yoon, IS, 2010
)
0.86
" The bioavailability of fexofenadine was increased by approximately 2-folds via the concomitant use of piperine."( Effect of piperine, a major component of black pepper, on the intestinal absorption of fexofenadine and its implication on food-drug interaction.
Han, HK; Jin, MJ, 2010
)
0.89
"To enhance the solubility and bioavailability of poorly absorbable fexofenadine, microemulsion system composed of oil, surfactant and co-surfactant was developed for intranasal delivery."( Preparation and evaluation of fexofenadine microemulsions for intranasal delivery.
Balakrishnan, P; Cho, HJ; Chung, SJ; Kim, DD; Kim, H; Kim, YS; Piao, HM; Shim, CK, 2010
)
0.89
"P-Glycoprotein accounts for multidrug resistance in chemotherapy patients and contributes to reduced oral bioavailability and distribution of drugs in the brain."( A quantitative structure-activity relationship for the modulation effects of flavonoids on p-glycoprotein-mediated transport.
Ho, HO; Kao, YH; Lin, YK; Liou, YB; Sheu, MT, 2010
)
0.36
" In conclusion, LPS treatment increased the bioavailability of fexofenadine but did not affect other pharmacokinetic parameters."( Pharmacokinetics of fexofenadine following LPS administration to rats.
Davey, AK; Gerber, JP; Jaisue, S, 2010
)
0.92
" Although the relative bioavailability of colonic administration of diclofenac, metformin and cevimeline compared to oral administration was similar regardless of the drug doses in the colon, colonic absorption of diltiazem varied according to the doses."( The relationship between the drug concentration profiles in plasma and the drug doses in the colon.
Hosoi, Y; Kanamaru, T; Konno, T; Nakagami, H; Tajiri, S; Yada, S; Yoshida, K, 2010
)
0.36
"A new type of interaction in which fruit juices diminish oral drug bioavailability through inhibition of uptake transport is the focus of this review."( Fruit juice inhibition of uptake transport: a new type of food-drug interaction.
Bailey, DG, 2010
)
0.36
" Selected compounds were further evaluated for their oral anti-histaminic activity in mice, bioavailability in rats, and their anti-inflammatory activity in mice OVA-induced biphasic cutaneous reaction model."( Synthesis and structure-activity relationship of tricyclic carboxylic acids as novel anti-histamines.
Isobe, Y; Kubota, K; Kurebayashi, H; Miyachi, H; Onishi, M; Tobe, M, 2011
)
0.37
"Fexofenadine is a nonsedative antihistamine that exhibits good oral bioavailability despite its zwitterionic chemical structure and efflux by P-gp."( Vectorial transport of fexofenadine across Caco-2 cells: involvement of apical uptake and basolateral efflux transporters.
Knight, BM; Ming, X; Thakker, DR, 2011
)
2.12
" In this work, novel FEX loaded water in oil microemulsion (w/o) was designed to improve bioavailability and compared with Fexofen(®) syrup in in vitro and in vivo studies."( Improvement of effect of water-in-oil microemulsion as an oral delivery system for fexofenadine: in vitro and in vivo studies.
Alvarez, IG; Gundogdu, E; Karasulu, E, 2011
)
0.59
" In conclusion, intranasal administration of chitosan coated liposome appeared to be effective to enhance the bioavailability as well as prolonged exposure of fexofenadine in rats."( Enhanced systemic exposure of fexofenadine via the intranasal administration of chitosan-coated liposome.
Han, HK; Lee, BJ; Qiang, F; Shin, HJ, 2012
)
0.86
" When FEX was administered at 3 h after the administration of CsA, the hepatic availability (F(h)) and the fraction absorbed in the intestine as an unchanged form (F(a)·F(g)) of FEX were increased, resulting in increased bioavailability (=F(a)·F(g)·F(h))."( Long-lasting inhibition of the intestinal absorption of fexofenadine by cyclosporin A in rats.
Fukuda, K; Horie, T; Shitara, Y; Suzuki, K, 2012
)
0.63
"The contribution of intestinal first-pass hydrolysis to oral bioavailability was evaluated in rats using a model prodrug of fexofenadine (FXD), which has poor oral bioavailability."( Effect of intestinal first-pass hydrolysis on the oral bioavailability of an ester prodrug of fexofenadine.
Adachi, Y; Imai, T; Ninomiya, S; Nogata, R; Ohura, K; Soejima, T, 2012
)
0.8
"  Ritonavir dramatically increases the bioavailability of a variety of concurrently administered drugs by inhibition of metabolic enzymes and drug transporters."( Analysis of the pharmacokinetic boosting effects of ritonavir on oral bioavailability of drugs in mice.
Banba, H; Takayama, K; Takeda-Morishita, M; Tomaru, A, 2013
)
0.39
" This experimental system is useful for clarifying the cause of low bioavailability of various drugs."( In vivo assessment of the impact of efflux transporter on oral drug absorption using portal vein-cannulated rats.
Hashimoto, T; Konno, Y; Matsuda, Y; Nagai, M; Satsukawa, M; Taguchi, T; Yamashita, S, 2013
)
0.39
"Fexofenadine hydrochloride (FXD) is a slightly soluble, bitter-tasting, drug having an oral bioavailability of 35%."( Phenylalanine-free taste-masked orodispersible tablets of fexofenadine hydrochloride: development, in vitro evaluation and in vivo estimation of the drug pharmacokinetics in healthy human volunteers.
El-Ridi, MS; El-Sherif, NG; Tadros, MI; Yehia, SA, 2015
)
2.1
"OATP2B1-mediated grapefruit juice (GFJ)-drug interactions are substrate-dependent; for example, GFJ ingestion significantly reduces bioavailability of fexofenadine, but not pravastatin."( Substrate- and dose-dependent drug interactions with grapefruit juice caused by multiple binding sites on OATP2B1.
Mori, T; Murata, Y; Nakanishi, T; Shirasaka, Y; Tamai, I, 2014
)
0.6
"Diosmin is a natural flavone glycoside, a potent P-glycoprotein (P-gp) inhibitor in cultured cells and have the potential to alter the bioavailability of P-gp substrate drugs."( Effect of diosmin on the intestinal absorption and pharmacokinetics of fexofenadine in rats.
Bedada, SK; Neerati, P, 2015
)
0.65
"Diosmin significantly enhanced the oral bioavailability of fexofenadine by the inhibition of P-gp mediated drug efflux during the intestinal absorption."( Effect of diosmin on the intestinal absorption and pharmacokinetics of fexofenadine in rats.
Bedada, SK; Neerati, P, 2015
)
0.89
"5 mg/kg dose) showed that the relative bioavailability of drug from P407/C934P gel was 11."( Carbopol-incorporated thermoreversible gel for intranasal drug delivery.
Balakrishnan, P; Cho, HJ; Hahn, TW; Ko, HJ; Park, EK; Song, CK; Song, KW, 2015
)
0.42
" The intestinal absorption rate for each drug was acquired by deconvolution, using historical intravenous data as reference, and used with the intestinal surface area and the dose remaining in the lumen to estimate the Peff."( Human in vivo regional intestinal permeability: quantitation using site-specific drug absorption data.
Dahlgren, D; Lennernäs, H; Roos, C; Sjögren, E, 2015
)
0.42
" FXD contains a carboxyl group and is poorly absorbed because of low membrane permeability and efflux by P-glycoprotein (P-gp)."( Design of Fexofenadine Prodrugs Based on Tissue-Specific Esterase Activity and Their Dissimilar Recognition by P-Glycoprotein.
Imai, T; Kotani, S; Nakada, Y; Ohura, K, 2015
)
0.82
"Attempts to formulate acyclovir to improve its bioavailability and reduce the frequency of dosing from the present q4h have not materialized."( The Interesting Case of Acyclovir Delivered Using Chitosan in Humans: Is it a Drug Issue or Formulation Issue?
Srinivas, NR, 2016
)
0.43
" Similarly absorption rate constant (Ka), fraction absorbed (Fab) and effective permeability (Peff) of FEX were increased significantly in ileum of RSV and VER pretreated groups when compared to FEX alone group."( Effect of resveratrol on the pharmacokinetics of fexofenadine in rats: Involvement of P-glycoprotein inhibition.
Bedada, SK; Neerati, P; Yellu, NR, 2016
)
0.69
"The results suggest that altered pharmacokinetics and enhanced bioavailability of FEX might be attributed to PIP-mediated inhibition of P-gp drug efflux."( The influence of piperine on the pharmacokinetics of fexofenadine, a P-glycoprotein substrate, in healthy volunteers.
Bedada, SK; Boga, PK, 2017
)
0.7
"Capsaicin is the main pungent principle present in chili peppers has been found to possess P-glycoprotein (P-gp) inhibition activity in vitro, which may have the potential to modulate bioavailability of P-gp substrates."( Capsaicin pretreatment enhanced the bioavailability of fexofenadine in rats by P-glycoprotein modulation: in vitro, in situ and in vivo evaluation.
Appani, R; Bedada, SK; Boga, PK, 2017
)
0.7
"Capsaicin pretreatment significantly enhanced the intestinal absorption and bioavailability of fexofenadine in rats likely by inhibition of P-gp mediated cellular efflux, suggesting that the combined use of capsaicin with P-gp substrates may require close monitoring for potential drug interactions."( Capsaicin pretreatment enhanced the bioavailability of fexofenadine in rats by P-glycoprotein modulation: in vitro, in situ and in vivo evaluation.
Appani, R; Bedada, SK; Boga, PK, 2017
)
0.92
" Oral area under the plasma concentration-time curve (AUC) and bioavailability of well known BCRP (sulfasalazine and rosuvastatin), P-glycoprotein (fexofenadine, aliskiren, and talinolol), and CYP3A (midazolam) substrates were investigated in the presence and absence of inhibitors."( Curcumin as an In Vivo Selective Intestinal Breast Cancer Resistance Protein Inhibitor in Cynomolgus Monkeys.
Abe, K; Ando, O; Imaoka, T; Karibe, T, 2018
)
0.68
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
"Alogliptin (ALG), an inhibitor of dipeptidylpeptidase-4, is used in the management of type 2 diabetes mellitus, and has a high absorption rate (>60-71%), despite its low lipophilicity (logP=-1."( Intestinal Absorption of Alogliptin Is Mediated by a Fruit-Juice-Sensitive Transporter.
Abe, M; Ishii, M; Kikuchi, T; Morimoto, K; Ogihara, T; Oikawa, E; Sasaki, M; Tomita, M, 2021
)
0.62
"The aim of this work was to probe cubosomes for enhanced intestinal absorption and oral bioavailability of poorly absorbable fexofenadine HCl (FEX-HCl)."( Cubosomes for Enhancing Intestinal Absorption of Fexofenadine Hydrochloride: In situ and in vivo Investigation.
Ashmawy, SM; El Maghraby, GM; El Nashar, NF; Sultan, AA, 2022
)
1.18

Dosage Studied

Fexofenadine HCl (Allegra, Telfast) is approved in the US for twice-daily dosing for treatment of seasonal allergic rhinitis. Although widely used in the treatment of allergic diseases, fexofen adine is not listed in any pharmacopeia. There are few methods in the literature for its quantitation in pharmaceutical dosage forms.

ExcerptRelevanceReference
"To investigate the clinical efficacy and safety of fexofenadine HCl in the treatment of ragweed seasonal allergic rhinitis and to characterize the dose-response relationship of fexofenadine HCl at dosages of 60, 120, and 240 mg bid."( Efficacy and safety of fexofenadine hydrochloride for treatment of seasonal allergic rhinitis.
Ahlbrandt, R; Bernstein, DI; Mason, J; Nathan, RA; Schoenwetter, WF; Storms, W, 1997
)
0.86
" Patients were randomized to receive fexofenadine HCl (60, 120, or 240 mg bid) or placebo at 12-hour dosing intervals (7:00 AM and 7:00 PM)."( Efficacy and safety of fexofenadine hydrochloride for treatment of seasonal allergic rhinitis.
Ahlbrandt, R; Bernstein, DI; Mason, J; Nathan, RA; Schoenwetter, WF; Storms, W, 1997
)
0.88
" Fexofenadine HCl at each dosage provided significant improvement in total symptom score (P < or = ."( Efficacy and safety of fexofenadine hydrochloride for treatment of seasonal allergic rhinitis.
Ahlbrandt, R; Bernstein, DI; Mason, J; Nathan, RA; Schoenwetter, WF; Storms, W, 1997
)
1.52
" Because there was no additional efficacy at higher dosages, 60 mg bid appears to be the optimal therapeutic dosage for these patients."( Efficacy and safety of fexofenadine hydrochloride for treatment of seasonal allergic rhinitis.
Ahlbrandt, R; Bernstein, DI; Mason, J; Nathan, RA; Schoenwetter, WF; Storms, W, 1997
)
0.61
"It was concluded that fexofenadine has no effect on performance after being taken in the recommended dosage of 60 mg twice daily."( Fexofenadine's effects, alone and with alcohol, on actual driving and psychomotor performance.
O'Hanlon, JF; Vermeeren, A, 1998
)
2.06
" Their longer duration of action also enables a more patient-friendly dosing regimen which increases patient compliance."( Pharmacokinetic overview of oral second-generation H1 antihistamines.
Estes, KS; González, MA, 1998
)
0.3
" In addition, fexofenadine hydrochloride showed significant antihistaminic activity and dose-proportional pharmacokinetics over a wide dosing range."( Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers.
Russell, T; Stoltz, M; Weir, S, 1998
)
0.89
" Twelve-lead electrocardiographic data were collected once before and after dosing or serially throughout these studies."( Cardiovascular safety of fexofenadine HCl.
Ahlbrandt, R; Mason, J; Pratt, CM; Reynolds, R; Russell, T, 1999
)
0.61
"Fexofenadine HCl (Allegra, Telfast) is approved in the US for twice-daily dosing in the treatment of seasonal allergic rhinitis (SAR)."( Safety and efficacy of once-daily fexofenadine HCl in the treatment of autumn seasonal allergic rhinitis.
Andrade, C; Casale, TB; Qu, R,
)
1.85
") after dosing to steady-state (6."( Cardiovascular safety of fexofenadine HCl.
Ahlbrandt, R; Brown, AM; Mason, J; Pratt, C; Rampe, D; Reynolds, R; Russell, T, 1999
)
0.61
"Fexofenadine HCl (Allegra, Telfast) is approved in the US for twice-daily dosing for treatment of seasonal allergic rhinitis."( Once-daily fexofenadine HCl improves quality of life and reduces work and activity impairment in patients with seasonal allergic rhinitis.
Casale, TB; Meltzer, EO; Nathan, RA; Thompson, AK, 1999
)
2.14
" In addition, assessment was made immediately before dosing in the morning for the previous 30 minutes."( Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal allergic rhinitis.
Bousquet, J; Howarth, PH; Reynolds, R; Roi, L; Stern, MA, 1999
)
0.53
" Efficacy was maintained for the entire dosing interval (ie, for 24 hours)."( Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal allergic rhinitis.
Bousquet, J; Howarth, PH; Reynolds, R; Roi, L; Stern, MA, 1999
)
0.53
" Fexofenadine given in the conventional dosage can prevent recurrences and represents a successful treatment measure when dealing with this peculiar form of solar urticaria."( Fixed solar urticaria to visible light successfully treated with fexofenadine.
Bazex, J; Journé, F; Loche, E; Marguery, MC; Schwarze, HP, 2001
)
1.46
"Subjects evaluated at a referral medical center were placed on traditional dosing of fexofenadine at 60 mg, twice daily, or placebo in a double-blind, crossover fashion for 1 week before the nasal challenge."( Evaluation of cytokines in nasal secretions after nasal antigen challenge: lack of influence of antihistamines.
Bensch, GW; Borish, LC; Nelson, HS, 2002
)
0.54
" Before dosing and at 1, 3, 6, 9, and 24 hours after the first antihistamine dose as well as at 168, 192, and 216 hours after the first dose (ie, 12, 36, and 60 hours after the seventh and last consecutive daily H(1)-antihistamine dose), we measured fexofenadine, loratadine, or chlorpheniramine concentrations in plasma and in skin tissue samples obtained through use of punch biopsies, along with suppression of histamine-induced skin wheals and flares."( Clinical pharmacology of H1-antihistamines in the skin.
Gu, X; Silver, NA; Simons, FE; Simons, KJ, 2002
)
0.5
" In conclusion, this study shows that, at the end of the conventional dosing interval, ebastine 10 mg and cetirizine 10 mg once daily in repeated doses suppressed the histamine wheal more effectively than did loratadine 10 mg once daily or fexofenadine 60 mg twice daily."( Inhibition of the histamine wheal by ebastine compared with cetirizine, fexofenadine and loratadine at steady state.
Boyce, M; Carey, W; Luria, X; Warrington, S, 2002
)
0.73
") to be more effective overall than the regimen containing the highest fexo-fenadine dosage (with nedocromil as rescue only)."( Supplementation of fexofenadine therapy with nedocromil sodium 2% ophthalmic solution to treat ocular symptoms of seasonal allergic conjunctivitis.
Alexander, M; Allegro, S; Hicks, A; Patel, P, 2003
)
0.65
"Supplementation of oral fexofenadine therapy with nedocromil sodium 2% ophthalmic solution relieves ocular symptoms of seasonal allergic rhinoconjunctivitis, allowing control of rhinal symptoms with half the recommended dosage of fexofenadine."( Supplementation of fexofenadine therapy with nedocromil sodium 2% ophthalmic solution to treat ocular symptoms of seasonal allergic conjunctivitis.
Alexander, M; Allegro, S; Hicks, A; Patel, P, 2003
)
0.95
" Onset of flare suppression occurred 2 hours after dosing with fexofenadine and 4 hours after dosing with loratadine."( Relative potency of fexofenadine HCl 180 mg, loratadine 10 mg, and placebo using a skin test model of wheal-and-flare suppression.
Christian, CD; Crisalida, T; Economides, A; Georges, GC; Hale, M; Kaliner, MA; Liao, Y; Meeves, SG; White, MV; Woodworth, TH, 2003
)
0.88
"The anti-inflammatory effects of repeated dosing with mediator antagonists as add-on therapy to that with inhaled corticosteroids (ICSs) in patients with asthma remain to be fully established."( Repeated dosing effects of mediator antagonists in inhaled corticosteroid-treated atopic asthmatic patients.
Haggart, K; Jackson, CM; Lee, DK; Lipworth, BJ, 2004
)
0.32
"We elected to evaluate the effects of repeated dosing with fexofenadine (FEX) and montelukast (ML) at clinically recommended doses in ICS-treated asthmatic patients using adenosine monophosphate (AMP) bronchial challenge as the primary outcome."( Repeated dosing effects of mediator antagonists in inhaled corticosteroid-treated atopic asthmatic patients.
Haggart, K; Jackson, CM; Lee, DK; Lipworth, BJ, 2004
)
0.57
"Repeated dosing with FEX and ML as add-on therapy improved AMP PC(20) and other surrogate inflammatory markers along with asthma diary outcomes in ICS-treated atopic asthmatic patients."( Repeated dosing effects of mediator antagonists in inhaled corticosteroid-treated atopic asthmatic patients.
Haggart, K; Jackson, CM; Lee, DK; Lipworth, BJ, 2004
)
0.32
" Although widely used in the treatment of allergic diseases, fexofenadine is not listed in any pharmacopeia, and there are few methods in the literature for its quantitation in pharmaceutical dosage forms."( Development and validation of a liquid chromatographic method for fexofenadine hydrochloride in capsules.
Breier, AR; Menegola, J; Paim, CS; Schapoval, EE; Steppe, M,
)
0.61
" The trials were designed as crossover studies in 18 subjects comprising various potential dosing regimens with and without weight stratification."( The utility of mixed-effects covariate analysis in rapid selection of doses in pediatric subjects: a case study with fexofenadine hydrochloride.
Jensen, BK; Kittner, B; Krishna, R; Krishnaswami, S; Sankoh, AJ, 2004
)
0.53
" A dosing regimen was identified in which fexofenadine disposition was not affected by alfentanil."( Evaluation of first-pass cytochrome P4503A (CYP3A) and P-glycoprotein activities using alfentanil and fexofenadine in combination.
Hoffer, C; Kharasch, ED; Sheffels, P; Walker, A, 2005
)
0.81
"Pharmacokinetic parameters AUC0-infinity1 and Cmax1 following a single-dose (Day 1, dose 1), Cmax7, AUC0-24(7) at steady-state and Cmin7 measured at the end of the dosing interval (Day 9, dose 7) revealed bioequivalence between FEX 180 mg/PSE 240 mg combination tablet and the individual components taken concurrently."( Single-dose and steady-state bioequivalence of fexofenadine and pseudoephedrine combination tablets compared with individual formulations in healthy adults.
Agrawala, P; Haribhakti, R; Howard, DR; Kittner, B, 2005
)
0.59
"To evaluate the efficacy and safety of once-daily dosing of fexofenadine hydrochloride, 180 mg, on CIU."( Once-daily fexofenadine treatment for chronic idiopathic urticaria: a multicenter, randomized, double-blind, placebo-controlled study.
Georges, G; Kaplan, AP; Liao, Y; Meeves, S; Spector, SL; Varghese, ST, 2005
)
0.96
" The best dissolution conditions tested, for the products in each respective pharmaceutical dosage form were applied to evaluate the dissolution profiles."( Development and validation of dissolution tests for fexofenadine hydrochloride capsules and coated tablets.
Breier, AR; Paim, CS; Schapoval, EE; Steppe, M, 2005
)
0.58
"A single dose of fexofenadine hydrochloride (60 mg as solution) was applied under fasting conditions, either alone or directly after a solution of erythromycin lactobionate (corresponding to a dose of 250 mg erythromycin), to the jejunum, ileum and colon in 6 healthy volunteers (3 male and 3 female) using a regional intubation dosing technology (Bioperm AB, Lund, Sweden)."( Effect of erythromycin on the absorption of fexofenadine in the jejunum, ileum and colon determined using local intubation in healthy volunteers.
Bondesson, U; Borga, O; Hedeland, M; Lennernas, H; Nyberg, L; Petri, N, 2006
)
0.93
"00105) and 10-day dosing (102 +/- 40 L/h, P = ."( The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates.
Gorski, JC; Hall, SD; Hamman, MA; Lemma, GL; Wang, Z; Zaheer, NA, 2006
)
0.33
" In addition, small tablet size and once-daily dosing may provide patients with increased convenience and improve adherence."( Once-daily immediate-release fexofenadine and sustained-release pseudoephedrine combination: a new treatment option for allergic rhinitis.
Mansfield, LE, 2006
)
0.63
" She subsequently received maintenance dosing in the outpatient clinic weekly for 4 weeks and bimonthly for 8 weeks, and she continues monthly maintenance VIT."( Ultrarush venom desensitization after systemic reactions during conventional venom immunotherapy.
Chegini, S; Hamilos, DL; Oren, E, 2006
)
0.33
"A simple RP-HPLC method using a PDA detector was developed and validated for the analysis and dissolution studies of fexofenadine hydrochloride (FEX) in dosage forms."( Simple and reliable HPLC analysis of fexofenadine hydrochloride in tablets and its application to dissolution studies.
Oliveira, DC; Rolim, CM; Weigch, A, 2007
)
0.82
"The objective of the current study was to develop a simple, accurate, precise and rapid reversed-phase HPLC method and subsequent validation using ICH suggested approach for the determination of antihistaminic-decongestant pharmaceutical dosage forms containing binary mixtures of pseudoephedrine hydrochloride (PSE) with fexofenadine hydrochloride (FEX) or cetirizine dihydrochloride (CET)."( Development and validation of a rapid RP-HPLC method for the determination of cetirizine or fexofenadine with pseudoephedrine in binary pharmaceutical dosage forms.
Karakuş, S; Küçükgüzel, I; Küçükgüzel, SG, 2008
)
0.74
" No significant change in latency for REM sleep or percentage REM sleep after dosing with fexofenadine was observed."( The effects of fexofenadine at steady-state on sleep architecture: a study using polysomnography in healthy Korean volunteers.
Ahn, JH; Kim, JE; Kim, MJ; Kim, SD; Lee, HW; Moon, SO; Park, DJ; Yoon, YR, 2008
)
0.92
" In a randomized, two-phase, crossover design, verapamil was dosed 80 mg three times daily (with total daily doses of 240 mg) for 6 days, and on day 6, a single 120-mg dose of fexofenadine was administered along with an 80-mg dose of verapamil."( Enantioselective disposition of fexofenadine with the P-glycoprotein inhibitor verapamil.
Hokama, N; Miura, M; Sakugawa, T; Suzuki, T; Tateishi, T; Uno, T, 2009
)
0.83
" In the treatment phase, carbamazepine was dosed 100 mg three times daily (for a total daily dose of 300 mg) for 7 days, and on Day 7, a single 60-mg dose of fexofenadine was coadministered with a 100-mg dose of carbamazepine."( Effects of the P-glycoprotein inducer carbamazepine on fexofenadine pharmacokinetics.
Akamine, Y; Kaneko, S; Uno, T; Yamada, S; Yasui-Furukori, N, 2009
)
0.8
" Alternative dosage forms such as liquids or oral disintegrating tablets are available for most agents, allowing ease of administration to most young children and infants; however, limited data are available regarding use in infants for most agents, except desloratadine, cetirizine and montelukast."( Treatment of allergic rhinitis in infants and children: efficacy and safety of second-generation antihistamines and the leukotriene receptor antagonist montelukast.
Moeller, ML; Nahata, MC; Phan, H, 2009
)
0.35
" Thus, the proposed method is suitable for the simultaneous analysis of active ingredients in tablet dosage forms and human serum."( Simultaneous determination of gliquidone, fexofenadine, buclizine, and levocetirizine in dosage formulation and human serum by RP-HPLC.
Arayne, MS; Mirza, AZ; Siddiqui, FA; Sultana, N,
)
0.4
" These results suggested the feasibility that thermosensitive gels could be used as an effective dosage form to enhance the nasal absorption of FXD HCl."( Poloxamer/cyclodextrin/chitosan-based thermoreversible gel for intranasal delivery of fexofenadine hydrochloride.
Balakrishnan, P; Cho, HJ; Chung, SJ; Hong, SS; Jang, TY; Kim, DD; Kim, KS; Park, EK; Shim, CK; Song, KW, 2011
)
0.59
"After the dosing of an extended-release (ER) formulation, compounds may exist in solutions at various concentrations in the colon because the drugs are released at various speeds from the ER dosage form."( The relationship between the drug concentration profiles in plasma and the drug doses in the colon.
Hosoi, Y; Kanamaru, T; Konno, T; Nakagami, H; Tajiri, S; Yada, S; Yoshida, K, 2010
)
0.36
" Three drugs (celiprolol, fexofenadine, and atenolol) were orally administered as a cassette dosing following the MD (totally 97."( Microdosing clinical study: pharmacokinetic, pharmacogenomic (SLCO2B1), and interaction (grapefruit juice) profiles of celiprolol following the oral microdose and therapeutic dose.
Chiyoda, T; Doi, Y; Hirota, T; Ieiri, I; Irie, S; Iwasaki, K; Kimura, M; Maeda, K; Miyagawa, M; Sasaki, T; Sugiyama, Y, 2012
)
0.68
" Micro/small dosing is useful for examining the mechanism of drug interactions without safety concern."( Mechanisms of pharmacokinetic enhancement between ritonavir and saquinavir; micro/small dosing tests using midazolam (CYP3A4), fexofenadine (p-glycoprotein), and pravastatin (OATP1B1) as probe drugs.
Ando, Y; Deguchi, M; Hirota, T; Ieiri, I; Irie, S; Izumi, N; Kanda, E; Kimura, M; Kotani, N; Kusuhara, H; Maeda, K; Matsuguma, K; Matsuki, S; Morishita, M; Okuzono, T; Sugiyama, Y; Tsunemitsu, S; Yamane, N, 2013
)
0.6
" A rapid, simple, selective and precise densitometric method was developed and validated for simultaneous estimation of six synthetic binary mixtures and their pharmaceutical dosage forms."( Thin layer chromatography-densitometric determination of some non-sedating antihistamines in combination with pseudoephedrine or acetaminophen in synthetic mixtures and in pharmaceutical formulations.
Atia, NN; El-Gizawy, SM; El-Kommos, ME; Hosny, NM, 2014
)
0.4
" Co-administration of diosmin with fexofenadine can reduce the dosage and results in reduced side effects of fexofenadine."( Effect of diosmin on the intestinal absorption and pharmacokinetics of fexofenadine in rats.
Bedada, SK; Neerati, P, 2015
)
0.93
" These findings suggested that developed thermoreversible gels could be used as promising dosage forms to improve intranasal drug absorption."( Carbopol-incorporated thermoreversible gel for intranasal drug delivery.
Balakrishnan, P; Cho, HJ; Hahn, TW; Ko, HJ; Park, EK; Song, CK; Song, KW, 2015
)
0.42
"Attempts to formulate acyclovir to improve its bioavailability and reduce the frequency of dosing from the present q4h have not materialized."( The Interesting Case of Acyclovir Delivered Using Chitosan in Humans: Is it a Drug Issue or Formulation Issue?
Srinivas, NR, 2016
)
0.43
" If one examines the pharmacokinetic disposition of acyclovir, it is clear that renal elimination is so rapid necessitating frequent dosing of acyclovir."( The Interesting Case of Acyclovir Delivered Using Chitosan in Humans: Is it a Drug Issue or Formulation Issue?
Srinivas, NR, 2016
)
0.43
" Male rats were dosed orally with garlic (120 mg/kg), ginkgo (17 mg/kg), St."( Effect of Garlic, Gingko, and St. John's Wort Extracts on the Pharmacokinetics of Fexofenadine: A Mechanistic Study.
Gerber, JP; Milne, RW; Turkanovic, J; Ward, MB, 2017
)
0.68
" In cases of failure, treatment was switched to omalizumab at doses of < 300 mg/month with incremental dosage increases as necessary (monthly dose range, 150-600 mg/month)."( Real-life experience in the treatment of solar urticaria: retrospective cohort study.
Enk, CD; Hodak, E; Lapidoth, M; Levi, A; Mazor, S; Snast, I; Uvaidov, V, 2019
)
0.51
" This article exemplifies the reported analytical methods like electrometric methods, ultraviolet spectroscopy, mass spectroscopy, thin layer chromatography, high performance liquid chromatography, high performance thin layer chromatography and tandem spectroscopy for determination of fexofenadine HCl and montelukast sodium in dosage form and in biological matrices."( A Review of Different Analytical Techniques for Fexofenadine Hydrochloride and Montelukast Sodium in Different Matrices.
Kumar, V; Nalini, CN, 2021
)
1.05
"Drug dosing is challenging in patients with end-stage renal disease."( Chronic Inhibition of CYP3A is Temporarily Reduced by Each Hemodialysis Session in Patients With End-Stage Renal Disease.
Åsberg, A; Christensen, H; Egeland, EJ; Robertsen, I; Witczak, BJ; Zaré, HK, 2020
)
0.56
"Drug combinations are commonly used in pain management, which can produce potent analgesic effects with reduced dosage and adverse effects."( Flupirtine and antihistamines exert synergistic anti-nociceptive effects in mice.
Bao, Y; Chen, Y; Huang, C; Qin, H; Xiao, X; Zhang, G; Zhou, H; Zhu, J; Zhuang, T, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
H1-receptor antagonistH1-receptor antagonists are the drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine.
anti-allergic agentA drug used to treat allergic reactions.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
piperidines
tertiary amineA compound formally derived from ammonia by replacing three hydrogen atoms by hydrocarbyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Fexofenadine H1-Antihistamine Action87

Protein Targets (17)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency19.99420.003245.467312,589.2998AID1705; AID2517
arylsulfatase AHomo sapiens (human)Potency2.68551.069113.955137.9330AID720538
Bloom syndrome protein isoform 1Homo sapiens (human)Potency0.00890.540617.639296.1227AID2364; AID2528
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency4.77550.425612.059128.1838AID504536
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency39.81070.251215.843239.8107AID504327
lamin isoform A-delta10Homo sapiens (human)Potency0.15850.891312.067628.1838AID1487
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency33.80780.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
DNA gyrase subunit BStaphylococcus aureusIC50 (µMol)500.00000.00401.50207.7000AID1164962
Cytochrome P450 2C9 Homo sapiens (human)IC50 (µMol)50.00000.00002.800510.0000AID1210069
DNA gyrase subunit AStaphylococcus aureusIC50 (µMol)500.00000.00401.98397.7000AID1164962
Histamine H1 receptorHomo sapiens (human)IC50 (µMol)0.06230.00000.44365.1768AID1202708; AID426615; AID426616; AID595800
Histamine H1 receptorHomo sapiens (human)Ki0.02700.00000.511010.0000AID448777
Cytochrome P450 2J2Homo sapiens (human)IC50 (µMol)50.00000.01202.53129.4700AID1210069
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)IC50 (µMol)32.13380.00091.901410.0000AID161283; AID243188; AID276169; AID393560; AID420668; AID448775; AID448776; AID576612; AID661410; AID82355
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)Ki23.00000.00211.840710.0000AID1202709
Histamine H4 receptorHomo sapiens (human)Ki10.00000.00060.478710.0000AID1798265
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier organic anion transporter family member 1A4Rattus norvegicus (Norway rat)Km6.00000.24003.28416.5300AID681826
Solute carrier organic anion transporter family member 1A1Rattus norvegicus (Norway rat)Km32.00000.01503.49967.0000AID680243
Solute carrier organic anion transporter family member 1A2Homo sapiens (human)Km6.40006.40007.42009.6000AID679886
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (63)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processCytochrome P450 2C9 Homo sapiens (human)
steroid metabolic processCytochrome P450 2C9 Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2C9 Homo sapiens (human)
estrogen metabolic processCytochrome P450 2C9 Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C9 Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
urea metabolic processCytochrome P450 2C9 Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 2C9 Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C9 Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
amide metabolic processCytochrome P450 2C9 Homo sapiens (human)
icosanoid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
oxidative demethylationCytochrome P450 2C9 Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
inflammatory responseHistamine H1 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayHistamine H1 receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayHistamine H1 receptorHomo sapiens (human)
memoryHistamine H1 receptorHomo sapiens (human)
visual learningHistamine H1 receptorHomo sapiens (human)
regulation of vascular permeabilityHistamine H1 receptorHomo sapiens (human)
positive regulation of vasoconstrictionHistamine H1 receptorHomo sapiens (human)
regulation of synaptic plasticityHistamine H1 receptorHomo sapiens (human)
cellular response to histamineHistamine H1 receptorHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayHistamine H1 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerHistamine H1 receptorHomo sapiens (human)
chemical synaptic transmissionHistamine H1 receptorHomo sapiens (human)
xenobiotic metabolic processSolute carrier organic anion transporter family member 1A2Homo sapiens (human)
monoatomic ion transportSolute carrier organic anion transporter family member 1A2Homo sapiens (human)
organic cation transportSolute carrier organic anion transporter family member 1A2Homo sapiens (human)
organic anion transportSolute carrier organic anion transporter family member 1A2Homo sapiens (human)
bile acid and bile salt transportSolute carrier organic anion transporter family member 1A2Homo sapiens (human)
sodium-independent organic anion transportSolute carrier organic anion transporter family member 1A2Homo sapiens (human)
transmembrane transportSolute carrier organic anion transporter family member 1A2Homo sapiens (human)
fatty acid metabolic processCytochrome P450 2J2Homo sapiens (human)
icosanoid metabolic processCytochrome P450 2J2Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2J2Homo sapiens (human)
regulation of heart contractionCytochrome P450 2J2Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2J2Homo sapiens (human)
linoleic acid metabolic processCytochrome P450 2J2Homo sapiens (human)
organic acid metabolic processCytochrome P450 2J2Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by hormonePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion homeostasisPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cardiac muscle contractionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cellular response to xenobiotic stimulusPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane depolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion import across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inflammatory responseHistamine H4 receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationHistamine H4 receptorHomo sapiens (human)
biological_processHistamine H4 receptorHomo sapiens (human)
regulation of MAPK cascadeHistamine H4 receptorHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayHistamine H4 receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayHistamine H4 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerHistamine H4 receptorHomo sapiens (human)
chemical synaptic transmissionHistamine H4 receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (39)

Processvia Protein(s)Taxonomy
monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
iron ion bindingCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
caffeine oxidase activityCytochrome P450 2C9 Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
aromatase activityCytochrome P450 2C9 Homo sapiens (human)
heme bindingCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C9 Homo sapiens (human)
histamine receptor activityHistamine H1 receptorHomo sapiens (human)
G protein-coupled serotonin receptor activityHistamine H1 receptorHomo sapiens (human)
neurotransmitter receptor activityHistamine H1 receptorHomo sapiens (human)
organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 1A2Homo sapiens (human)
organic cation transmembrane transporter activitySolute carrier organic anion transporter family member 1A2Homo sapiens (human)
bile acid transmembrane transporter activitySolute carrier organic anion transporter family member 1A2Homo sapiens (human)
transmembrane transporter activitySolute carrier organic anion transporter family member 1A2Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 1A2Homo sapiens (human)
monooxygenase activityCytochrome P450 2J2Homo sapiens (human)
iron ion bindingCytochrome P450 2J2Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
isomerase activityCytochrome P450 2J2Homo sapiens (human)
linoleic acid epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
hydroperoxy icosatetraenoate isomerase activityCytochrome P450 2J2Homo sapiens (human)
arachidonic acid 5,6-epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
heme bindingCytochrome P450 2J2Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2J2Homo sapiens (human)
transcription cis-regulatory region bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ubiquitin protein ligase bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
identical protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein homodimerization activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
C3HC4-type RING finger domain bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
scaffold protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
histamine receptor activityHistamine H4 receptorHomo sapiens (human)
G protein-coupled serotonin receptor activityHistamine H4 receptorHomo sapiens (human)
G protein-coupled acetylcholine receptor activityHistamine H4 receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (15)

Processvia Protein(s)Taxonomy
endoplasmic reticulum membraneCytochrome P450 2C9 Homo sapiens (human)
plasma membraneCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
cytoplasmCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
cytosolHistamine H1 receptorHomo sapiens (human)
plasma membraneHistamine H1 receptorHomo sapiens (human)
synapseHistamine H1 receptorHomo sapiens (human)
dendriteHistamine H1 receptorHomo sapiens (human)
plasma membraneHistamine H1 receptorHomo sapiens (human)
plasma membraneSolute carrier organic anion transporter family member 1A2Homo sapiens (human)
basal plasma membraneSolute carrier organic anion transporter family member 1A2Homo sapiens (human)
apical plasma membraneSolute carrier organic anion transporter family member 1A2Homo sapiens (human)
basolateral plasma membraneSolute carrier organic anion transporter family member 1A2Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2J2Homo sapiens (human)
extracellular exosomeCytochrome P450 2J2Homo sapiens (human)
cytoplasmCytochrome P450 2J2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2J2Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
perinuclear region of cytoplasmPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
plasma membraneHistamine H4 receptorHomo sapiens (human)
plasma membraneHistamine H4 receptorHomo sapiens (human)
dendriteHistamine H4 receptorHomo sapiens (human)
synapseHistamine H4 receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (184)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1211874Total biliary clearance in rat at 10 mg/kg, iv2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
AID420669Lipophilicity, log D at pH 7.02009European journal of medicinal chemistry, May, Volume: 44, Issue:5
GRIND-based 3D-QSAR and CoMFA to investigate topics dominated by hydrophobic interactions: the case of hERG K+ channel blockers.
AID16029Pharmacokinetic parameter :drug bound to plasma was reported1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
Molecular properties and pharmacokinetic behavior of cetirizine, a zwitterionic H1-receptor antagonist.
AID701301Efflux ratio of permeability in MDCK cells expressing human MDR12012Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
Structural modifications that alter the P-glycoprotein efflux properties of compounds.
AID426618In vivo antihistaminic activity at histamine H1 receptor in ddY mouse assessed as inhibition of histamine-induced skin vascular permeability at 3 mg/kg, po administered 1 hr before histamine challenge measured after 30 mins by Evan's blue staining2009Bioorganic & medicinal chemistry letters, May-15, Volume: 19, Issue:10
Synthesis and structure-activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H(1) antagonists.
AID1210299Apparent intrinsic clearance in Sprague-Dawley rat hepatocytes assessed per 10'6 cells at 0.1 to 10 uM up to 90 mins by conventional assay2012Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8
Utility of drug depletion-time profiles in isolated hepatocytes for accessing hepatic uptake clearance: identifying rate-limiting steps and role of passive processes.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1616997Antiallergic activity in rat RBL2H3 cells assessed as inhibition of DNP-HSA-mediated degranulation by measuring decrease in beta-hexosaminidase activity preincubated for 30 mins followed by DNP-HSA stimulation and measured after 30 mins by 4-nitrophenyl 22019Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21
Structure-Activity Relationships of Fish Oil Derivatives with Antiallergic Activity in Vitro and in Vivo.
AID679107TP_TRANSPORTER: transepithelial transport in MDR1-expressing LLC-PK1 cells1999Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 27, Issue:8
OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID699540Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID426624Antiinflammatory activity in BALB/c mouse model assessed as inhibition of ovalbumin-induced ear swelling at 10 mg/kg, po administered 60 mins before ovalbumin challenge measured 24 hrs after elicitation by late type reaction assay2009Bioorganic & medicinal chemistry letters, May-15, Volume: 19, Issue:10
Synthesis and structure-activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H(1) antagonists.
AID24562Pharmacokinetic parameter :half life in humans was reported1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
Molecular properties and pharmacokinetic behavior of cetirizine, a zwitterionic H1-receptor antagonist.
AID1221960Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY3359792011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID448777Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHO cell by Betaplate scintillation counting2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
Structural determinants for histamine H(1) affinity, hERG affinity and QTc prolongation in a series of terfenadine analogs.
AID448778Antihistamine activity in iv dosed Hartley guinea pig assessed as inhibition of histamine-induced bronchoconstriction pretreated before histamine challenge2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
Structural determinants for histamine H(1) affinity, hERG affinity and QTc prolongation in a series of terfenadine analogs.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID701299Ratio of drug level in brain to plasma in mdr1a expressing CF-1 mouse at 872 ug, sc2012Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
Structural modifications that alter the P-glycoprotein efflux properties of compounds.
AID1698016Dissociation constant, basic pKa of compound measured up to 18 mins by capillary electrophoresis
AID420668Inhibition of human ERG in MCF7 cells2009European journal of medicinal chemistry, May, Volume: 44, Issue:5
GRIND-based 3D-QSAR and CoMFA to investigate topics dominated by hydrophobic interactions: the case of hERG K+ channel blockers.
AID453203Lipophilicity, log D of the compound2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
Development of an in silico model for human skin permeation based on a Franz cell skin permeability assay.
AID448780Cardiovascular toxicity in Hartley guinea pig assessed as QTc prolongation at 100 mg/kg, iv after 30 mins by ECG2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
Structural determinants for histamine H(1) affinity, hERG affinity and QTc prolongation in a series of terfenadine analogs.
AID595887In vivo antihistaminic activity at histamine H1 receptor in ddY mouse assessed as inhibition of histamine-induced skin vascular permeability po administered 1 hr before histamine challenge by Evan's blue staining2011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Synthesis and structure-activity relationship of tricyclic carboxylic acids as novel anti-histamines.
AID481446Effective permeability across human jejunum2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID678766TP_TRANSPORTER: increase in liver concentration in mdr1a(-/-) mouse1999Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 27, Issue:8
OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine.
AID1211825Drug excretion in human assessed as compound excreted into bile at 60 mg, po after 12 hrs by fecal extraction method2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
AID1221957Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID679348TP_TRANSPORTER: transepithelial transport (basal to apical) in MDR1-expressing MDCK cells1999Pharmaceutical research, Apr, Volume: 16, Issue:4
Grapefruit juice activates P-glycoprotein-mediated drug transport.
AID679602TP_TRANSPORTER: inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 5 uM, Fexofenadine: 100 uM) in Caco-2 cells1999Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 27, Issue:8
OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine.
AID661410Inhibition of human Erg expressed in HEK293 cells assessed as rubidium efflux after 4 hrs by atomic absorbance spectrometric analysis2012Bioorganic & medicinal chemistry letters, Jun-01, Volume: 22, Issue:11
Discovery of a novel melanin concentrating hormone receptor 1 (MCHR1) antagonist with reduced hERG inhibition.
AID595805Antiinflammatory activity in ovalbumin-sensitized BALB/c mouse biphasic allergic model assessed as late type reaction at 10 mg/kg, po administered 1 hr before ovalbumin challenge measured 24 hrs after elicitation by ear swelling assay2011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Synthesis and structure-activity relationship of tricyclic carboxylic acids as novel anti-histamines.
AID1202709Inhibition of human ERG channel2015Journal of medicinal chemistry, Mar-26, Volume: 58, Issue:6
CNS drug design: balancing physicochemical properties for optimal brain exposure.
AID393560Inhibition of human ERG expressed in HEK293 cells by whole cell patch clamp method2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Docking model of drug binding to the human ether-à-go-go potassium channel guided by tandem dimer mutant patch-clamp data: a synergic approach.
AID701300Apparent permeability across MDCK cells expressing human MDR12012Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
Structural modifications that alter the P-glycoprotein efflux properties of compounds.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1698000Apparent permeability in dog MDCKII-LE cells at pH 7.4
AID1164961Antimicrobial activity against Staphylococcus aureus UAMS1 incubated for 16 hrs by CLSI based method2014Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20
Repurposing the antihistamine terfenadine for antimicrobial activity against Staphylococcus aureus.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID699539Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID448776Inhibition of human ERG in L929 cells at 10 uM by whole cell patch-clamp assay2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
Structural determinants for histamine H(1) affinity, hERG affinity and QTc prolongation in a series of terfenadine analogs.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1210300Drug metabolism in Sprague-Dawley rat hepatocytes assessed per 10'6 cells at 0.1 to 10 uM up to 90 mins by conventional assay2012Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8
Utility of drug depletion-time profiles in isolated hepatocytes for accessing hepatic uptake clearance: identifying rate-limiting steps and role of passive processes.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID448779Cardiovascular toxicity in iv dosed Hartley guinea pig QTc prolongation after 30 mins by ECG2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
Structural determinants for histamine H(1) affinity, hERG affinity and QTc prolongation in a series of terfenadine analogs.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID678779TP_TRANSPORTER: increase in brain concentration in mdr1a(-/-) mouse1999Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 27, Issue:8
OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine.
AID655741Antipruritic activity in ICR mouse assessed as inhibition of compound 48/80-induced scratching at 30 mg/kg, po measured after 30 mins2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Discovery of S-777469: an orally available CB2 agonist as an antipruritic agent.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID699541Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1221966Ratio of plasma AUC in po dosed mdr1 knock out mouse to plasma AUC in po dosed wild type mouse2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1221961Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY3359792011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID701297Ratio of brain to plasma ratio in mdr1a deficient CF-1 mouse to brain to plasma ratio in mdr1a expressing CF-1 mouse at 872 ug, sc2012Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
Structural modifications that alter the P-glycoprotein efflux properties of compounds.
AID679423TP_TRANSPORTER: uptake (pH 7.4) of Fexofenadine at a concentration of 10 u M in OATP-B-expressing HEK293 cells2004The Journal of pharmacology and experimental therapeutics, Feb, Volume: 308, Issue:2
Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human.
AID404304Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
AID576612Inhibition of human ERG2011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
AID1202708Inhibition of histamine H1 receptor (unknown origin)2015Journal of medicinal chemistry, Mar-26, Volume: 58, Issue:6
CNS drug design: balancing physicochemical properties for optimal brain exposure.
AID453204Permeability in human skin after 48 hrs by Franz cell permeability assay2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
Development of an in silico model for human skin permeation based on a Franz cell skin permeability assay.
AID1221958Efflux ratio of permeability from apical to basolateral side over basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID481442Transcellular permeability at pH 6.5 calculated from in vitro P app values in Caco-2 and/or MDCK cells2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID701298Ratio of drug level in brain to plasma in mdr1a deficient CF-1 mouse at 872 ug, sc2012Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
Structural modifications that alter the P-glycoprotein efflux properties of compounds.
AID678756TP_TRANSPORTER: increase in small intestine concentration in mdr1a(-/-) mouse1999Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 27, Issue:8
OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1164962Inhibition of Staphylococcus aureus DNA gyrase assessed as reduction in enzyme-catalyzed supercoiling of relaxed circular pBR322 DNA by agarose gel electrophoresis2014Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20
Repurposing the antihistamine terfenadine for antimicrobial activity against Staphylococcus aureus.
AID588967Substrates of transporters of clinical importance in the absorption and disposition of drugs, OATP1A22010Nature reviews. Drug discovery, Mar, Volume: 9, Issue:3
Membrane transporters in drug development.
AID1698006Ratio of drug level in cynomolgus monkey blood to plasma administered through iv dosing by LC-MS/MS analysis
AID426615Inhibition of histamine H1 receptor2009Bioorganic & medicinal chemistry letters, May-15, Volume: 19, Issue:10
Synthesis and structure-activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H(1) antagonists.
AID1221962Efflux ratio of permeability from apical to basolateral side over basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY3359792011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID161283Inhibition of K+ channel activity in CHO cells expressing HERG Kv11.12003Bioorganic & medicinal chemistry letters, May-19, Volume: 13, Issue:10
Characterization of HERG potassium channel inhibition using CoMSiA 3D QSAR and homology modeling approaches.
AID22246Pharmacokinetic parameter :volume apparent of distribution was reported1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
Molecular properties and pharmacokinetic behavior of cetirizine, a zwitterionic H1-receptor antagonist.
AID1211845Total biliary clearance in human at 60 mg, po after 12 hrs by fecal extraction method2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
AID1210069Inhibition of human recombinant CYP2J2 assessed as reduction in astemizole O-demethylation by LC-MS/MS method2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID678753TP_TRANSPORTER: increase in spleen concentration in mdr1a(-/-) mouse1999Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 27, Issue:8
OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine.
AID481439Absolute bioavailability in human2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID1698001Lipophilicity, log D of the compound at pH 7.4 by by shake flask method
AID426616Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHOK1 cells by scintillation counting2009Bioorganic & medicinal chemistry letters, May-15, Volume: 19, Issue:10
Synthesis and structure-activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H(1) antagonists.
AID82355K+ channel blocking activity in human embryonic kidney cells expressing HERG Kv11.12002Journal of medicinal chemistry, Aug-29, Volume: 45, Issue:18
Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1616999Substrate activity at human FAAH expressed in baculovirus infected Sf9 cells assessed as docosahexaenoic acid formation incubated for 60 mins by HPLC analysis2019Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21
Structure-Activity Relationships of Fish Oil Derivatives with Antiallergic Activity in Vitro and in Vivo.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID678771TP_TRANSPORTER: increase in heart concentration in mdr1a(-/-) mouse1999Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 27, Issue:8
OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine.
AID1210301Apparent intrinsic clearance in Sprague-Dawley rat hepatocytes assessed per 10'6 cells at 0.1 to 10 uM up to 90 mins by media-loss method2012Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8
Utility of drug depletion-time profiles in isolated hepatocytes for accessing hepatic uptake clearance: identifying rate-limiting steps and role of passive processes.
AID485979Inhibition of CETP in rabbit serum at 10 uM after 1 hr by fluorescent cholesteryl esters transfer assay2010European journal of medicinal chemistry, Apr, Volume: 45, Issue:4
Discovery of new cholesteryl ester transfer protein inhibitors via ligand-based pharmacophore modeling and QSAR analysis followed by synthetic exploration.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID678760TP_TRANSPORTER: increase in plasma concentration in mdr1a(-/-) mouse1999Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 27, Issue:8
OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine.
AID1221964Transporter substrate index ratio of permeability from basolateral to apical side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY3359792011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID481440Dissociation constant, pKa of the compound2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1698004Fraction unbound in cynomolgus monkey plasma
AID1698007Ratio of drug level in human blood to plasma administered through iv dosing by LC-MS/MS analysis
AID481441Aqueous diffusivity at 37C2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID679886TP_TRANSPORTER: uptake in OATP-A-expressing HeLa cells1999Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 27, Issue:8
OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine.
AID1698011Fraction unbound in human plasma
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID448775Inhibition of human ERG in L929 cells by whole cell patch-clamp assay2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
Structural determinants for histamine H(1) affinity, hERG affinity and QTc prolongation in a series of terfenadine analogs.
AID680243TP_TRANSPORTER: uptake in Oatp1-expressing HeLa cells1999Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 27, Issue:8
OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine.
AID243188Inhibition of human voltage-gated potassium channel subunit Kv11.1 (ERG K+ channel) in open state2005Bioorganic & medicinal chemistry letters, Mar-15, Volume: 15, Issue:6
A two-state homology model of the hERG K+ channel: application to ligand binding.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID588968Substrates of transporters of clinical importance in the absorption and disposition of drugs, OATP2B12010Nature reviews. Drug discovery, Mar, Volume: 9, Issue:3
Membrane transporters in drug development.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1129361Unbound fraction in HEK293 cell homogenate at 0.1 uM by equilibrium dialysis based UPLC-MS/MS analysis2014Journal of medicinal chemistry, Apr-10, Volume: 57, Issue:7
A high-throughput cell-based method to predict the unbound drug fraction in the brain.
AID426617Apparent permeability from apical to basolateral side of human Caco-2 cells after 120 mins2009Bioorganic & medicinal chemistry letters, May-15, Volume: 19, Issue:10
Synthesis and structure-activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H(1) antagonists.
AID1617002Antiallergic activity in BALB/c mouse assessed as reduction in anti-DNP-IgE-mediated passive cutaneous anaphylaxis at 50 mg/kg, po administered once daily for 5 days followed by anti-DNP-IgE stimulation on day 4 and subsequent DNP-HSA challenge on day 5 p2019Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21
Structure-Activity Relationships of Fish Oil Derivatives with Antiallergic Activity in Vitro and in Vivo.
AID1164963Inhibition of Staphylococcus aureus topoisomerase 4 assessed as reduction in decatenation of kDNA at 100 to 500 uM by gel electrophoresis method2014Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20
Repurposing the antihistamine terfenadine for antimicrobial activity against Staphylococcus aureus.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID595888Ex vivo receptor occupancy of histamine H1 receptor in mouse brain at ED70 after 30 mins by scintillation counting2011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Synthesis and structure-activity relationship of tricyclic carboxylic acids as novel anti-histamines.
AID445445Permeability at pH 6.5 by PAMPA method2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
AID1221956Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID678770TP_TRANSPORTER: increase in kidney concentration in mdr1a(-/-) mouse1999Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 27, Issue:8
OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine.
AID1616996Inhibition of human FAAH expressed in baculovirus infected Sf9 cells using N-(6-methoxypyridin-3-yl)octanamide as substrate measured for 15 mins by fluorescence based assay2019Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21
Structure-Activity Relationships of Fish Oil Derivatives with Antiallergic Activity in Vitro and in Vivo.
AID276169Inhibition of human ERG potassium channel in HEK293 cells by patch clamp assay2006Bioorganic & medicinal chemistry letters, Nov-01, Volume: 16, Issue:21
Inhibitory effect of carboxylic acid group on hERG binding.
AID445446Oral bioavailability in human2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID595804Antiinflammatory activity in ovalbumin-sensitized BALB/c mouse biphasic allergic model assessed as immediate type reaction at 10 mg/kg, po administered 1 hr before ovalbumin challenge measured 1 hr after elicitation by ear swelling assay2011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Synthesis and structure-activity relationship of tricyclic carboxylic acids as novel anti-histamines.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1211803Drug excretion in iv dosed Wistar rat assessed as compound excreted into bile2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
AID1221963Transporter substrate index ratio of permeability from apical to basolateral side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY3359792011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID481444Octanol-water partition coefficient, log P of the compound2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID1697999Dissociation constant, acidic pKa of compound measured up to 18 mins by capillary electrophoresis
AID592681Apparent permeability across human Caco2 cell membrane after 2 hrs by LC-MS/MS analysis2011Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8
QSAR-based permeability model for drug-like compounds.
AID1698009Hepatic clearance in cynomolgus monkey at < 1 mg/kg, iv administered as cassette dosing
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1698010Hepatic clearance in human administered through iv dosing
AID588974Substrates of transporters of clinical importance in the absorption and disposition of drugs, MDR12010Nature reviews. Drug discovery, Mar, Volume: 9, Issue:3
Membrane transporters in drug development.
AID679111TP_TRANSPORTER: transepithelial transport in Caco-2 cells2004Pharmaceutical research, Aug, Volume: 21, Issue:8
Transport characteristics of fexofenadine in the Caco-2 cell model.
AID1211864Unbound biliary clearance in human at 60 mg, po after 24 hrs by fecal extraction method2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
AID681826TP_TRANSPORTER: uptake in Oatp2-expressing HeLa cells1999Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 27, Issue:8
OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID595800Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting2011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Synthesis and structure-activity relationship of tricyclic carboxylic acids as novel anti-histamines.
AID426622Antiinflammatory activity in BALB/c mouse model assessed as inhibition of ovalbumin-induced ear swelling at 10 mg/kg, po administered 60 mins before ovalbumin challenge measured 1 hr after elicitation by immediate type reaction assay2009Bioorganic & medicinal chemistry letters, May-15, Volume: 19, Issue:10
Synthesis and structure-activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H(1) antagonists.
AID679433TP_TRANSPORTER: uptake (pH 5.0) of Fexofenadine at a concentration of 10 u M in OATP-B-expressing HEK293 cells2004The Journal of pharmacology and experimental therapeutics, Feb, Volume: 308, Issue:2
Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human.
AID1202710Apparent permeability of the compound2015Journal of medicinal chemistry, Mar-26, Volume: 58, Issue:6
CNS drug design: balancing physicochemical properties for optimal brain exposure.
AID588963Substrates of transporters of clinical importance in the absorption and disposition of drugs, OATP1B32010Nature reviews. Drug discovery, Mar, Volume: 9, Issue:3
Membrane transporters in drug development.
AID1221965Transporter substrate index of efflux ratio in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY3359792011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1211883Unbound biliary clearance in rat at 10 mg/kg, iv2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID588978Substrates of transporters of clinical importance in the absorption and disposition of drugs, MPR32010Nature reviews. Drug discovery, Mar, Volume: 9, Issue:3
Membrane transporters in drug development.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1798265H4R Radioligand Binding Assay from Article 10.1124/jpet.105.087965: \\Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of 4-methylhistamine as the first potent and selective H4 receptor agonist.\\2005The Journal of pharmacology and experimental therapeutics, Sep, Volume: 314, Issue:3
Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of 4-methylhistamine as the first potent and selective H4 receptor agonist.
AID1346037Human H1 receptor (Histamine receptors)2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
Structural determinants for histamine H(1) affinity, hERG affinity and QTc prolongation in a series of terfenadine analogs.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (659)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's46 (6.98)18.2507
2000's322 (48.86)29.6817
2010's234 (35.51)24.3611
2020's57 (8.65)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 87.84

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index87.84 (24.57)
Research Supply Index6.83 (2.92)
Research Growth Index4.98 (4.65)
Search Engine Demand Index233.84 (26.88)
Search Engine Supply Index2.95 (0.95)

This Compound (87.84)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials226 (32.29%)5.53%
Reviews50 (7.14%)6.00%
Case Studies42 (6.00%)4.05%
Observational2 (0.29%)0.25%
Other380 (54.29%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (80)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase 1 Double-blind (3rd Party Open), Randomized, Placebo-controlled Study To Investigate The Safety And Toleration Of Multiple Oral Doses Of Pf-03654764 In Combination With Fexofenadine In Healthy Subjects [NCT01298505]Phase 136 participants (Actual)Interventional2010-06-04Terminated(stopped due to This study was stopped due to lack of evidence for clinical efficacy.)
A Three-Part Phase 1 Study to Determine the Potential Drug Interaction Between ACH-0144471 and Midazolam, Fexofenadine and Mycophenolate Mofetil in Healthy Subjects [NCT03108274]Phase 135 participants (Actual)Interventional2017-04-18Completed
[NCT02391688]Phase 130 participants (Actual)Interventional2014-11-30Completed
A Two-part Study to Determine the Relative Bioavailability of Dabigatran Etexilate 150 mg Bid (Capsules) With and Without 600 mg Quinidine Sulfate Tablets (Part 1) and to Measure the Effect of Quinidine as a Probe Inhibitor of P-glycoprotein on the Absorp [NCT02171546]Phase 142 participants (Actual)Interventional2007-11-30Terminated
Single-Dose Fasting In Vivo Bioequivalence Study of Fexofenadine Tablets (180 mg; Mylan) and Allegra® Tablets (180 mg; Aventis) in Healthy Adult Volunteers [NCT00649376]Phase 168 participants (Actual)Interventional2003-10-31Completed
A Phase 1 Open-label Study to Assess the Effect of BMS-986419 on the Single Dose Pharmacokinetics of Probe Substrates (Caffeine, Bupropion, Flurbiprofen, Omeprazole, Midazolam, and Fexofenadine) in Healthy Participants [NCT05932277]Phase 122 participants (Actual)Interventional2023-06-29Completed
Investigation of the Safety and Performance of the NVT ALLEGRA THV System With a New Delivery System in Patients With Severe Calcified Aortic Stenosis or Failed Surgical Aortic Bioprosthesis [NCT05478161]107 participants (Anticipated)Interventional2022-01-24Recruiting
Cocktail Phenotypic Approach to Explore Antidepressant Pharmacokinetic Variability: a Pilot Study [NCT02438072]100 participants (Anticipated)Interventional2014-12-31Recruiting
A Relative Bioavailability Study of 180 mg Fexofenadine Hydrochloride Tablets Under Fed Conditions. [NCT00835640]Phase 124 participants (Actual)Interventional2002-01-31Completed
Preference Evaluation of Clarinex Tablets vs. Allegra Tablets in Subjects With Symptomatic Seasonal Allergic Rhinitis [NCT00794248]Phase 4122 participants (Actual)Interventional2002-11-30Completed
A Phase 1, Open-label, Single-center, 2-period, Single Sequence Drug-drug Interaction Study to Evaluate the Effects of Multiple-dose Telotristat Etiprate on the Pharmacokinetics of Single-dose Fexofenadine, a Sensitive P Glycoprotein Substrate, in Healthy [NCT02157558]Phase 124 participants (Actual)Interventional2014-07-31Completed
Clinical Trials on Evaluate the Red Ginseng and Fermented-Red Ginseng Affect to Drug Metabolizing Enzyme and Transporter in Healthy Volunteers; Open-label, Parallel Group [NCT02056743]Phase 130 participants (Actual)Interventional2013-09-30Completed
Randomized Clinical Study for Efficacy Assessment Between Cloratadd-D, Loratadine + Pseudoephedrine (Coated Pill), Produced by EMS S/A Laboratories and Allegra-D , Produced by Sanofi-Aventis for Patients With Perennial Allergic Rhinitis. [NCT01228630]Phase 3156 participants (Actual)Interventional2011-08-31Completed
An Open Label, Balanced, Randomized, Two-way, Single Dose, Crossover Bioequivalence Study of Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tabs of Dr. Reddy's and Allegra-D 24 hr ER Tabs of Aventis, in Healthy Subjects Under Fasting Conditions [NCT01133470]Phase 154 participants (Actual)Interventional2007-02-28Completed
A Relative Bioavailability Study of 180 mg Fexofenadine Hydrochloride Tablets Under Fasting Conditions. [NCT00835276]Phase 160 participants (Actual)Interventional2002-03-31Completed
An Open Label, Single-Dose, Single-Treatment, Single-Period Safety and Bioavailability Study of Fexofenadine Hydrochloride Topical Lotion 1% in Healthy, Adult, Male Human Subjects [NCT05461456]Phase 112 participants (Actual)Interventional2022-04-01Completed
An Open Label, Balanced, Randomized, Two-way, Single Dose, Crossover Bioequivalence Study of Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tabs of Dr. Reddy's and Allegra-D 24 hr ER Tabs of Aventis, in Healthy Subjects Under Fed Conditions [NCT01133483]Phase 138 participants (Actual)Interventional2007-04-30Completed
A Randomized, Double Blind, Parallel Group Study for Assessing the Efficacy and Safety of a Twice-daily Fexofenadine HCl 60 mg - Pseudoephedrine HCl 60 mg Combination or Fexofenadine HCl 60 mg - Pseudoephedrine HCl 120 mg Combination Versus Allegra® 60 mg [NCT01306721]Phase 3520 participants (Actual)Interventional2011-02-28Completed
Single-Dose Food In Vivo Bioequivalence Study of Fexofenadine Tablets (180 mg; Mylan) and Allegra® Tablets (180 mg; Aventis) in Healthy Adult Volunteers [NCT00647985]Phase 128 participants (Actual)Interventional2003-11-30Completed
A Placebo Controlled Study of the Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. in the Treatment of Subjects With Symptomatic Seasonal Allergic Rhinitis (SAR) [NCT00783146]Phase 4728 participants (Actual)Interventional2004-08-01Completed
A Comparison of Fexofenadine HCl 180 mg, Montelukast Sodium 10 mg and Placebo in Suppression of Wheal and Flare Induced by Seasonal Allergen [NCT00638118]Phase 448 participants (Actual)Interventional2003-02-28Completed
Evaluation of Efficacy of Dellegra® Combination Tablet (Fexofenadine Hydrochloride 30mg /Pseudoephedrine Hydrochloride 60mg) in Allergic Rhinitis After Japanese Cedar Antigen Exposure in Japanese Population. Open Label Study [NCT02175485]Phase 424 participants (Actual)Interventional2014-06-30Completed
Preference Evaluation of Clarinex Tablets vs. Allegra Tablets in Subjects With Symptomatic Seasonal Allergic Rhinitis [NCT00794768]Phase 4118 participants (Actual)Interventional2002-11-30Completed
Fexofenadine as Adjunct to Standard Rheumatoid Therapy in Patients With Active Rheumatoid [NCT05264025]Phase 1/Phase 280 participants (Anticipated)Interventional2022-06-01Recruiting
A Double-Blind, Placebo-Controlled, 4-Way Crossover Study to Evaluate the Pharmacokinetics and Pharmacodynamics at Two Dose Levels of JMI-001 in Comparison With Fexofenadine and Naproxen Administered in Conjunction With Alcohol. [NCT03183297]Phase 148 participants (Anticipated)Interventional2017-08-31Not yet recruiting
A Randomized, Double Blind, Placebo Controlled, Four Way Crossover Study To Determine The Effects Of PF-03654764 +/- Allegra (Fexofenadine) On Symptoms Of Allergic Rhinitis In Subjects Exposed To Ragweed Pollen In An Environmental Exposure Unit. [NCT01033396]Phase 264 participants (Actual)Interventional2010-01-31Completed
A Comparison of Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine in the Treatment of Seasonal Allergic Rhinitis [NCT00435461]Phase 41,000 participants (Actual)Interventional2006-12-20Completed
A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Study Designed to Evaluate the Efficacy of Fexofenadine HCl 180 mg for Preventing and Controlling Cat Allergy Symptoms [NCT00637884]Phase 470 participants (Actual)Interventional2003-11-30Completed
A Randomized, Double-blind, Repeat-dose, Crossover Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Desloratadine (Clarinex®) Compared to Fexofenadine (Allegra®) in Healthy Adults Who Have Been Identified as Slow Metabolizers for Deslor [NCT00636870]Phase 4220 participants (Actual)Interventional2003-02-28Completed
A Monitored Release Study On The Efficacy And Safety of Fexofenadine (Telfast®) 30mg Pediatric Tablets On Filipino Children Aged 6 To 11 for The Relief of Perennial And Intermittent Allergic Rhinitis. [NCT00741897]Phase 4264 participants (Actual)Interventional2002-03-31Completed
An Open-label, Uncontrolled 4-week Study to Assess the Safety, Efficacy and Pharmacokinetics of Allegra® (Dry Syrup Formulation) 15 mg or 30 mg Twice Daily in Pediatric Patients With Perennial Allergic Rhinitis [NCT01244217]Phase 2/Phase 3100 participants (Actual)Interventional2010-10-31Completed
Clinical Trial of the Results of Allegra vs Sapien Transcatheter Aortic Valves in Valve-In-Valve Indication [NCT06049654]104 participants (Anticipated)Interventional2023-12-15Not yet recruiting
Phase 3, Single-center, Sequential and Parallel-group, Double-blind, Randomized Study Evaluating the Efficacy and Safety of Fexofenadine Hydrochloride 180 mg (Allegra®/Telfast®) Versus Placebo in Subjects Suffering From Seasonal Allergic Rhinitis With Sym [NCT03664882]Phase 3240 participants (Actual)Interventional2018-09-17Completed
A Randomized, Double Blind, Double Dummy, Placebo Controlled, Four Way Crossover Study To Determine The Effects Of An H3 Receptor Antagonist (PF-03654746) On Congestion Following A Nasal Allergen Challenge In Subjects With Seasonal Allergic Rhinitis. [NCT00562120]Phase 221 participants (Actual)Interventional2007-12-31Completed
InvEstigation of the Safety and Performance of the NVT ALLEGRA Plus THV SysteM in Patients With Severe aortIc Stenosis or Failed suRgical Aortic bioprosthEsis [NCT05804903]177 participants (Anticipated)Interventional2023-09-01Not yet recruiting
Comparison of Efficacy, Safety and Cost Effectiveness of Montelukast and Levocetirizine Versus Montelukast and Fexofenadine in Patients of Allergic Rhinitis: a Randomized, Double-blind Clinical Trial [NCT02551536]Phase 470 participants (Actual)Interventional2014-04-30Completed
[NCT00547768]Phase 436 participants (Actual)Interventional2002-11-30Completed
Randomized, 2-Way Crossover, Bioequivalence Study of Fexofenadine Hydrochloride 180 mg Tablets and Allegra® 180 mg Tablets Administered as 1 x 180 mg Tablet in Healthy Subjects Under Fed Conditions [NCT01066767]Phase 130 participants (Actual)Interventional2002-04-30Completed
The Role of Histamine in Muscle Protein Synthesis Following Chronic Resistance Training [NCT06152497]50 participants (Anticipated)Interventional2023-09-01Recruiting
A Comparison of Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine in the Treatment of Seasonal Allergic Rhinitis [NCT00502775]Phase 4680 participants (Actual)Interventional2007-08-31Completed
Randomized, 2-Way Crossover, Bioequivalence Study of Fexofenadine Hydrochloride 180 mg Tablets and Allegra® 180 mg Tablets Administered as 1 x 180 mg Tablet in Healthy Subjects Under Fasting Conditions [NCT01066754]Phase 144 participants (Actual)Interventional2002-04-30Completed
Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single Dose, Crossover, Oral Bioequivalence Study of Fexofenadine Hydrochloride Orally Disintegrating Tablets 30 mg of Dr. Reddy's Laboratories Limited, India Comparing With That o [NCT01888718]Phase 180 participants (Actual)Interventional2011-02-28Completed
Evaluation of the Inhibitory Effect of 5 Anti-Histamines in Urticaria [NCT01940393]Phase 4150 participants (Actual)Interventional2013-08-31Completed
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving KRYSTEXXA® (Pegloticase) (MIRROR Randomized Controlled Trial [RCT]) [NCT03994731]Phase 4152 participants (Actual)Interventional2019-06-13Completed
A Comparison of Fexofenadine HCl 180 mg, Desloratadine 5 mg and Placebo in Suppression of Wheal and Flare Induced by Histamine [NCT00637585]Phase 442 participants (Actual)Interventional2002-12-31Completed
Aprepitant in the Management of Biological Therapies-related Severe Pruritus: a Pilot Study in 45 Cancer Patients [NCT01683552]Phase 245 participants (Actual)Interventional2010-09-30Completed
Master Protocol of Two Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Studies to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Chronic Pruritus of Unknown Origin (CPUO) [NCT05263206]Phase 3208 participants (Anticipated)Interventional2022-02-15Recruiting
Single-Center, Double-Blind, Randomized , Parallel Study Comparing Onset of Action, Efficacy & Safety of a Single-Dose of Fexofenadine HCl 180 mg vs Montelukast Na 10 mg & Placebo in Treating Seasonal Allergic Rhinitis Subjects in an Allergen Exposure Uni [NCT00637611]Phase 41,010 participants (Actual)Interventional2003-02-28Completed
A Placebo Controlled Study of the Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. in the Treatment of Subjects With Symptomatic Seasonal Allergic Rhinitis (SAR) [NCT00783211]Phase 4722 participants (Actual)Interventional2004-08-01Completed
A Multicenter, Double-blind, Randomized, Placebo and Active-controlled Study of Pregabalin for the Treatment of Uremic Pruritus [NCT01852318]Phase 4210 participants (Anticipated)Interventional2014-04-30Not yet recruiting
Vascular Function in Health & Disease: Rehabilitation for Hypertension; Exercise and Skeletal Muscle Afferent Feedback [NCT02966665]Phase 1420 participants (Anticipated)Interventional2008-09-30Recruiting
The Evaluation of Efficacy and Safety of Fexofenadine 180mg Tablets for 7 Days in the Treatment of Pruritic Skin Disease [NCT00261079]Phase 4435 participants (Actual)Interventional2005-04-30Completed
All Women A Multicenter Randomized Clinical Trial Comparing Self-expanding ALLEGRA Valve to Any Other Balloon-expandable Valve in a Women Population [NCT05989074]130 participants (Anticipated)Interventional2023-09-01Not yet recruiting
A Randomized, Double-Blind, 4 Way Cross-over, Placebo Controlled Trial to Evaluate the Onset of Action of Bilastine 20 mg vs. Placebo, Cetirizine 10 mg, and Fexofenadine 120 mg in the Vienna Challenge Chamber [NCT00420082]Phase 275 participants (Actual)Interventional2006-10-31Completed
A Phase IV, Open Label, Clinical Trial to Assess Safety and Efficacy of Fexofenadine HCL + Pseudoephedrine HCL Fixed Dose Combination in Indian Participants With Allergic Rhinitis (AR) Who Are 12 Years and Above (FAST Trial) [NCT05720455]Phase 4203 participants (Anticipated)Interventional2024-07-21Not yet recruiting
An Open-label, Uncontrolled 4-week Study to Assess the Safety, Efficacy and Pharmacokinetics of Allegra® (Dry Syrup Formulation) 15 mg or 30 mg Twice Daily in Pediatric Patients With Atopic Dermatitis [NCT01244230]Phase 2/Phase 3100 participants (Actual)Interventional2010-11-30Completed
Danish Non-inferiority Study of Ocrelizumab and Rituximab in MS (DanNORMS): A Randomized Study Comparing the Efficacy of Ocrelizumab and Rituximab in Active Multiple Sclerosis [NCT04688788]Phase 3594 participants (Anticipated)Interventional2021-04-28Recruiting
Single Center, Randomized,Double-Blind,Crossover Study Comparing the Effects of Single-Dose Fexofenadine HCl 180 mg, Cetirizine 10 mg, and Placebo on Cognitive Performance in Naval Flight Personnel [NCT00637455]Phase 472 participants (Actual)Interventional2003-09-30Completed
A Multicenter, Double-Blind, Randomized, Parallel Groups Placebo-Controlled Study to Assess the Efficacy and Safety of Fexofenadine 120mg BID in Subjects With Mild to Moderate Persistent Asthma [NCT00044824]Phase 31,000 participants (Anticipated)Interventional2002-02-28Completed
A Multicenter, Open-Label, Randomized, Parallel Groups Study to Assess the Long-Term Safety Performance of Fexofenadine Compared to Montelukast in Subjects With Asthma [NCT00045955]Phase 31,200 participants (Anticipated)Interventional2002-02-28Completed
Effect of Antihistamines on Ureteral Stent-Related Symptoms: Randomized Controlled Trial [NCT04726345]Phase 278 participants (Anticipated)Interventional2021-06-29Recruiting
A Multicenter, Double-Blind, Randomized, Parallel Groups Placebo-Controlled Study to Assess the Efficacy and Safety of Fexofenadine 120mg BID in Subjects With Mild to Moderate Persistent Asthma [NCT00044811]Phase 31,000 participants (Anticipated)Interventional2002-03-31Completed
A Phase IIIb, Single-center, Double-blind, Two-arms, Placebo-controlled, Randomized, Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of 2-day Pre-treatment With Fexofenadine in Patients Suffering From Seasonal Allergic Rhinitis [NCT05692154]Phase 394 participants (Actual)Interventional2023-01-23Completed
Role of Histamine H1/H2 Receptors in the Health- and Performance-promoting Adaptations to High-intensity Interval Training [NCT04450134]20 participants (Actual)Interventional2019-10-02Completed
[NCT01731067]Phase 110 participants (Anticipated)Interventional2012-11-30Completed
Dose Proportionality of Fexofenadine [NCT01767272]25 participants (Actual)Interventional2012-12-31Completed
Comparative Study Between Use of Alpha Blocker Versus Alpha Blocker and Antihistaminic in Management of Acute Renal Colic Prevent Pain Recurrence and Increase Expulsion Rate of Ureteric Stone ≤ 1cm [NCT05150899]100 participants (Anticipated)Observational [Patient Registry]2021-11-30Not yet recruiting
A Pilot Randomized Double Blind Study to Assess the Safety and Efficacy of 1% Ibuprofen/ 1%Fexofenadine Topical Cream for the Treatment of Dark Circles Under the Eyes [NCT01172522]Phase 230 participants (Actual)Interventional2010-09-30Completed
A Double-Blind, Parallel, Randomized, Placebo Controlled Trial to Evaluate Onset of Action of Loratadine and Fexofenadine in Subjects With Seasonal Allergic Rhinitis in a Pollen Challenge Chamber [NCT01469234]Phase 4255 participants (Actual)Interventional2011-10-31Completed
A Randomized, Double Blind, Crossover Trial Comparing Fexofenadine to Placebo for the Treatment of Proton Pump Inhibitor Refractory Gastroesophageal Reflux Symptoms [NCT03425097]Phase 211 participants (Actual)Interventional2018-02-07Terminated(stopped due to The study was terminated due to insufficient evidence for Fexofenadine efficacy to treat GERD symptoms after the interim analysis.)
Pharmacokinetics of Sulfasalazine, Paracetamol, Fexofenadine and Valsartan After Oral Administration Using 240 ml Non-caloric Water, a Carbohydrate Enriched Drink and Grapefruit Juice in Correlation to the Intestinal Availability of Water as Quantified by [NCT03012763]Phase 19 participants (Actual)Interventional2016-04-30Completed
Comparison of Efficacy and Consistency of Action of Levocetirizine 5 mg Once Daily With Fexofenadine 60 mg Twice Daily in the Histamine Induced Wheal, Flare and Itch Response [NCT01586091]Phase 418 participants (Actual)Interventional2011-02-28Completed
The Effect Dialysis on the Pharmacokinetics of Fexofenadine [NCT03078777]Phase 430 participants (Anticipated)Interventional2017-11-29Recruiting
Do Furanocoumarins Mediate the Fexofenadine-grapefruit Juice Interaction? [NCT01526213]18 participants (Actual)Interventional2009-09-30Completed
An Open-label, Non-randomised, Phase I Study to Assess the Effect of Single and Multiple Oral Doses of Osimertinib (TAGRISSO™) on the Pharmacokinetics of a P-glycoprotein Probe Drug (Fexofenadine) in Patients With Advanced EGFRm NSCLC That Have Progressed [NCT02908750]Phase 124 participants (Actual)Interventional2017-03-02Completed
The Effect of Sodium Lauryl Sulfate on the Oral Absorption of Fexofenadine in Humans [NCT04534153]Early Phase 112 participants (Anticipated)Interventional2023-01-31Recruiting
Comparison of Maximum Blood Concentrations of Colchicine Between Responders and Non-responders to Colchicine Treatment During Gout Flare [NCT03933007]Phase 488 participants (Anticipated)Interventional2019-09-10Recruiting
Preference Evaluation of Clarinex Tablets vs. Allegra Tablets in Subjects With Symptomatic Seasonal Allergic Rhinitis [NCT00783133]Phase 4131 participants (Actual)Interventional2002-11-01Completed
Role of Fexofenadine in Reducing Albuminurea in Patients With Diabetic Kidney Disease [NCT04224428]Phase 360 participants (Actual)Interventional2020-01-01Completed
A Multicenter, Randomized, Parallel-group, Double-blind, Comparative Trial of the Superiority of Paracetamol 500mg/Fexofenadine 60mg/Phenylephrine 20mg Fixed-dose Combination Versus Placebo in the Symptomatic Treatment of Flu and Cold [NCT05118672]Phase 3478 participants (Anticipated)Interventional2024-08-30Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00435461 (10) [back to overview]Mean Change From Baseline Over the Two-week Treatment Period in 24-hour Reflective Total Nasal Symptom Scores (24-hour rTNSS) and Component Nasal Score
NCT00435461 (10) [back to overview]Mean Change From Baseline Over the Two-week Treatment Period in Daytime Reflective Total Ocular Symptom Scores (D-rTOSS)
NCT00435461 (10) [back to overview]Mean Change From Baseline Over the Two-week Treatment Period in Nighttime Reflective Total Nasal Symptom Scores (N-rTNSS) and Component Nasal Symptoms Score
NCT00435461 (10) [back to overview]Mean Change From Baseline Over the Two-week Treatment Period in Nighttime Reflective Total Ocular Symptom Scores (N-rTOSS)
NCT00435461 (10) [back to overview]Mean Change From Baseline Over the Two-week Treatment Period in Nighttime Symptoms Score (NSS)
NCT00435461 (10) [back to overview]Mean Change From Baseline Over the Two-week Treatment Period in Pre-dose Instantaneous Total Nasal Symptom Score (Pre-dose iTNSS) and Pre-dose Instantaneous Total Ocular Symptom Scores (Pre-dose iTOSS)
NCT00435461 (10) [back to overview]Mean Change From Baseline for Nocturnal Rhinoconjunctivitis Quality of Life Questionnaire (NRQLQ)
NCT00435461 (10) [back to overview]Mean Change From Baseline Over the Two-week Treatment Period in Peak NasalIinspiratory Flow (PNIF)
NCT00435461 (10) [back to overview]Mean Change From Baseline Over the Two-week Treatment Period in 24-hour Reflective Total Ocular Symptom Scores (24-hour rTOSS)
NCT00435461 (10) [back to overview]Mean Change From Baseline Over the Two-week Treatment Period in D-rTNSS
NCT00502775 (12) [back to overview]Mean Change From Baseline in the Nighttime Symptom Score (NSS)
NCT00502775 (12) [back to overview]Mean Change From Baseline at Day 15 for Nocturnal Rhinoconjunctivitis Quality of Life Questionnaire (NRQLQ)
NCT00502775 (12) [back to overview]Mean Change From Baseline in 24 Hour Reflective Total Nasal Symptom Score (24 Hour rTNSS)
NCT00502775 (12) [back to overview]Mean Change From Baseline in 24 Hour Reflective Total Ocular Symptoms Score (rTOSS)
NCT00502775 (12) [back to overview]Mean Change From Baseline in Daytime Reflective Total Nasal Symptom Score (D-rTNSS)
NCT00502775 (12) [back to overview]Mean Change From Baseline in Daytime Reflective Total Ocular Symptom Score (D-rTOSS)
NCT00502775 (12) [back to overview]Mean Change From Baseline in Evening Peak Nasal Inspiratory Flow (PNIF)
NCT00502775 (12) [back to overview]Mean Change From Baseline in Morning Peak Nasal Inspiratory Flow (PNIF)
NCT00502775 (12) [back to overview]Mean Change From Baseline in Nighttime Reflective Total Nasal Symptom Score (N-rTNSS)
NCT00502775 (12) [back to overview]Mean Change From Baseline in Nighttime Reflective Total Ocular Symptom Score (N-rTOSS)
NCT00502775 (12) [back to overview]Mean Change From Baseline in Pre-Dose Instantaneous Total Nasal Symptom Score (iTNSS)
NCT00502775 (12) [back to overview]Mean Change From Baseline in Pre-Dose Instantaneous Total Ocular Symptom Score (iTOSS)
NCT00562120 (7) [back to overview]Minimum Cross-Sectional Area (Amin) Maximum Fall Measured Using Acoustic Rhinometry
NCT00562120 (7) [back to overview]Minimum Cross-Sectional Area (Amin) Proportion Measured Using Acoustic Rhinometry
NCT00562120 (7) [back to overview]Nasal Volume Maximum Fall Measured Using Acoustic Rhinometry
NCT00562120 (7) [back to overview]Nasal Volume Proportion Measured Using Acoustic Rhinometry
NCT00562120 (7) [back to overview]Serum PF-03654746 Concentration
NCT00562120 (7) [back to overview]Nasal Symptom Scores: Nasal Congestion, Nasal Itching, Rhinorrhea
NCT00562120 (7) [back to overview]Nasal Symptom Scores: Sneezing
NCT00835276 (3) [back to overview]AUC0-inf = Area Under the Concentration-time Curve From Time Zero to Infinity.
NCT00835276 (3) [back to overview]AUC0-t = Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration (Per Participant)
NCT00835276 (3) [back to overview]Cmax = Maximum Observed Concentration.
NCT00835640 (3) [back to overview]AUC0-t = Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration (Per Participant)
NCT00835640 (3) [back to overview]Cmax = Maximum Observed Concentration.
NCT00835640 (3) [back to overview]AUC0-inf = Area Under the Concentration-time Curve From Time Zero to Infinity.
NCT01172522 (1) [back to overview]Number of Participants Who Showed Improvement in Under Eye Swelling and Dark Circles Relative to Baseline Per Intervention
NCT01469234 (8) [back to overview]Mean Individual Symptom Score for Itchy Nose by Post-Treatment Evaluation Time Point
NCT01469234 (8) [back to overview]Mean Individual Symptom Score for Runny Nose by Post-Treatment Evaluation Time Point
NCT01469234 (8) [back to overview]Mean Individual Symptom Scores for Itchy Eyes by Post-Treatment Evaluation Time Point
NCT01469234 (8) [back to overview]Mean Individual Symptom Scores for Itchy Mouth/Throat/Ears by Post-Treatment Evaluation Time Point
NCT01469234 (8) [back to overview]Mean Individual Symptom Scores for Nasal Congestion by Post-Treatment Evaluation Time Point
NCT01469234 (8) [back to overview]Mean Individual Symptom Scores for Sneezing by Post-Treatment Evaluation Time Point
NCT01469234 (8) [back to overview]Mean Individual Symptom Scores for Watery Eyes by Post-Treatment Evaluation Time Point
NCT01469234 (8) [back to overview]Mean Major Symptom Complex (MSC) Score by Post-Treatment Evaluation Time Point (From 180 Minutes to 300 Minutes)
NCT01526213 (1) [back to overview]Primary Pharmacokinetic Measure: Area Under the Curve (AUC)
NCT01586091 (3) [back to overview]Flaire Diameter (mm)
NCT01586091 (3) [back to overview]Pruritus as Assessed by the VAS Score
NCT01586091 (3) [back to overview]Wheal Volume (cm3)
NCT03425097 (6) [back to overview]Count of Participants With Side Effects
NCT03425097 (6) [back to overview]Mean GERD-HRQL Questionnaire Score
NCT03425097 (6) [back to overview]Mean Percent of Days With Reflux
NCT03425097 (6) [back to overview]Mean Rescue Medications Per Day
NCT03425097 (6) [back to overview]Mean Symptom Severity Score
NCT03425097 (6) [back to overview]Mean Number of Reflux Episodes Per Day
NCT03994731 (6) [back to overview]Mean Change From Baseline HAQ Pain Score at Week 52
NCT03994731 (6) [back to overview]Mean Change From Baseline in HAQ Health Score at Week 52
NCT03994731 (6) [back to overview]Mean Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 52
NCT03994731 (6) [back to overview]Percentage of Participants With Complete Resolution of ≥ 1 Tophi at Week 52
NCT03994731 (6) [back to overview]Percentage of Serum Uric Acid (sUA) Responders (sUA < 6 mg/dL) During Month 6
NCT03994731 (6) [back to overview]Percentage of sUA (sUA < 6 mg/dL) Responders During Month 12

Mean Change From Baseline Over the Two-week Treatment Period in 24-hour Reflective Total Nasal Symptom Scores (24-hour rTNSS) and Component Nasal Score

Daily 24-hour rTNSS was calculated as the average of the corresponding N-rTNSS and D-rTNSS using a 4-point scale where, 0- 'None' (symptom is not present), 1- 'Mild' (sign/symptom present; easily tolerated), 2- 'Moderate' (sign/symptom bothersome but tolerable), 3- 'Severe' (sign/symptom hard to tolerate; interference with activities of daily living). The total score ranged from 0 (best) to 12 (worst). The 24-hour total symptom score for a Day is the average of the daytime total symptom score for that Day and the nighttime score for (D+1). If either component of a given date's 24-hour total symptom score was missing, then the 24-hour total symptom score itself were to be set to missing. Each participant's average change from Baseline 24-hour total symptom score for Weeks 1-2 was the participants average 24-hour total symptom score over the treatment period minus the participant's Baseline score. (NCT00435461)
Timeframe: Baseline (Day 1) and up to 2 Weeks

,,
InterventionScores on a scale (Mean)
TNSSNasal congestionItchy noseRunny noseSneezing
Fex 180 mg-2.8-0.7-0.8-0.7-0.8
FFNS 110 mcg-3.6-0.9-0.9-0.9-1.0
Placebo-2.5-0.6-0.7-0.6-0.7

[back to top]

Mean Change From Baseline Over the Two-week Treatment Period in Daytime Reflective Total Ocular Symptom Scores (D-rTOSS)

The Daytime reflective assessments were recorded each evening and assessed the 3 nasal symptoms (tearing/watering, itching/burning, and redness) at evening and night using a 4-point scale where, 0- 'None' (symptom is not present), 1- 'Mild' (sign/symptom present; easily tolerated), 2- 'Moderate' (sign/symptom bothersome but tolerable), 3- 'Severe' (sign/symptom hard to tolerate; interference with activities of daily living). The scores of each of the three Daytime symptoms were summed for each participant to create a D-rTOSS for each day. The total score ranged from 0 (best) to 9 (worst). Each participants Baseline total symptom score was the average of the four highest total symptom score calculated for the seven days immediately prior to the day of randomization. Each participant's average change from Baseline Daytime total symptom score for Weeks 1-2 was the participant's average Daytime total symptom score over the treatment period minus the participant's Baseline score. (NCT00435461)
Timeframe: Baseline (Day 1) and up to 2 Weeks

,,
InterventionScores on a scale (Mean)
TOSSEye tearingEye itchingEye redness
Fex 180 mg-2.4-0.8-0.9-0.7
FFNS 110 mcg-2.6-0.9-0.9-0.8
Placebo-2.2-0.8-0.8-0.7

[back to top]

Mean Change From Baseline Over the Two-week Treatment Period in Nighttime Reflective Total Nasal Symptom Scores (N-rTNSS) and Component Nasal Symptoms Score

The nighttime reflective assessments were recorded each morning and assessed 4 nasal symptoms (rhinorrhea, nasal congestion, nasal itching, sneezing) at evening and night using a 4-point scale, 0- 'None' (symptom is not present), 1- 'Mild' (sign/symptom present; easily tolerated), 2- 'Moderate' (sign/symptom bothersome but tolerable), 3- 'Severe' (sign/symptom hard to tolerate; interference with activities of daily living). Scores of each of the 4 symptoms were summed for each participant to create a N-rTNSS for each day. The total score ranged from 0 (best) to 12 (worst). Each participant's Baseline total score was average of nighttime total symptom score on day of randomization and 3 highest scores calculated for 6 days immediately prior to day of randomization. Each participant's average change from Baseline nighttime total symptom score for Weeks 1-2 was the participant's average Nighttime total symptom score over the treatment period minus the participant's Baseline score. (NCT00435461)
Timeframe: Baseline (Day 1) and up to 2 Weeks

,,
InterventionScores on a scale (Mean)
TNSSNasal congestionItchy noseRunny noseSneezing
Fex 180 mg-2.7-0.7-0.7-0.7-0.7
FFNS 110 mcg-3.7-0.9-0.9-0.9-1.0
Placebo-2.5-0.6-0.7-0.6-0.7

[back to top]

Mean Change From Baseline Over the Two-week Treatment Period in Nighttime Reflective Total Ocular Symptom Scores (N-rTOSS)

The nighttime reflective assessments were recorded each morning and assessed 3 ocular symptoms (tearing/watering, itching/burning, and redness) at evening and night using a 4-point scale, 0- 'None' (symptom is not present), 1- 'Mild' (sign/symptom present; easily tolerated), 2- 'Moderate' (sign/symptom bothersome but tolerable), 3- 'Severe' (sign/symptom hard to tolerate; interference with activities of daily living). Scores of each of 3 Nighttime symptoms were summed for each participant to create a N-rTOSS for each day. The total score ranged from 0 (best) to 9 (worst). Each participants Baseline total score was average of nighttime total symptom score on day of randomization and the 3 highest scores calculated for 6 days immediately prior to the day of randomization. Each participant's average change from Baseline nighttime total symptom score for Weeks 1-2 was the participant's average Nighttime total symptom score over treatment period minus the participant's Baseline score. (NCT00435461)
Timeframe: Baseline (Day 1) and up to 2 Weeks

,,
InterventionScores on a scale (Mean)
TOSSEye tearingEye itchingEye redness
Fex 180 mg-2.2-0.8-0.8-0.7
FFNS 110 mcg-2.5-0.9-0.9-0.8
Placebo-2-0.7-0.7-0.6

[back to top]

Mean Change From Baseline Over the Two-week Treatment Period in Nighttime Symptoms Score (NSS)

The NSS is a three-item questionnaire which assesses three aspects of allergic rhinitis symptoms at night which were rated using three 4-point scales, the sum of which comprises NSS. The total score ranged from 0 (best) to 9 (worst). The symptoms were: PM nasal congestion upon awakening (PMNCA) (0- None, 1- Mild, 2- Moderate, 3- Severe), difficulty in going to sleep due to nasal symptoms (DSNS) (0- Not at all, 1- Little, 2- Moderately, 3- Very), and nighttime awakenings due to nasal symptoms (NANS) (0- Not at all, 1- Once, 2- More than once, 3- I felt like I was awake all night). Each participant's Baseline NSS was defined as the average of the NSS calculated for the day of randomization and the three highest NSS scores calculated during the six days immediately prior to the day of randomization. Each participant's average change from Baseline NSS for Weeks 1-2 was the participant's average NSS over the treatment period minus the participant's Baseline NSS. (NCT00435461)
Timeframe: Baseline (Day 1) and up to 2 Weeks

,,
InterventionScores on a scale (Mean)
NSS, Week 1-2PMNCA, Week 1-2NANS, Week 1-2DSNS, Week 1-2
Fex 180 mg-2.0-0.6-0.7-0.8
FFNS 110 mcg-2.9-0.9-1.0-1.1
Placebo-1.9-0.6-0.7-0.7

[back to top]

Mean Change From Baseline Over the Two-week Treatment Period in Pre-dose Instantaneous Total Nasal Symptom Score (Pre-dose iTNSS) and Pre-dose Instantaneous Total Ocular Symptom Scores (Pre-dose iTOSS)

Participants were instructed to score and document their symptoms in an instantaneous manner on a diary card. The instantaneous rating was performed once daily just prior to administering their morning dose. The scores of each of the instantaneous nasal symptoms (nasal congestion, itching, rhinorrhea, and sneezing) and ocular symptoms (tearing/watering, itching/burning, and redness) were summed for each participant to create a iTNSS and iTOSS, respectively using a 4-point scale, 0- 'None' (symptom is not present), 1- 'Mild' (sign/symptom present; easily tolerated), 2- 'Moderate' (sign/symptom bothersome but tolerable), 3- 'Severe' (sign/symptom hard to tolerate; interference with activities of daily living). Total score ranged from 0 (best) to 12 (worst) for iTNSS and 0 (best) to 9 (worst) for iTOSS. Each participant's average change from Baseline iTNSS and iTOSS was participant's average iTNSS and iTOSS total score over the treatment period minus the participant's Baseline score. (NCT00435461)
Timeframe: Baseline (Day 1) and up to 2 Weeks

,,
InterventionScore on a scale (Mean)
TNSSPre-dose iTNSS, Nasal congestionPre-dose iTNSS, Itchy nosePre-dose iTNSS, Runny nosePre-dose iTNSS, SneezingTOSSPre-dose iTOSS, Eye tearingPre-dose iTOSS, Eye itchingPre-dose iTOSS, Eye redness
Fex 180 mg-2.6-0.6-0.7-0.6-0.7-2.2-0.8-0.8-0.7
FFNS 110 mcg-3.6-0.8-1.0-0.9-1.0-2.4-0.9-0.9-0.8
Placebo-2.3-0.6-0.7-0.6-0.7-1.9-0.7-0.7-0.6

[back to top]

Mean Change From Baseline for Nocturnal Rhinoconjunctivitis Quality of Life Questionnaire (NRQLQ)

The NRQLQ is a paper instrument administered on the day of randomization and at Visit 4/Early Withdrawal to assess nocturnal rhinitis-related quality of life. The NRQLQ is a 16-item, self-administered, disease-specific (allergic rhinitis), and quality of life instrument that measures the functional problems most troublesome to patients with nocturnal allergy symptoms over a one-week interval. Each question is scored from 0 to 6 with higher scores indicating more nocturnal impairment. Items are grouped into four domains: Sleep problems, Sleep time problems, Symptoms on waking in the morning and Practical problems. An overall score was calculated from the mean score of all items. Each participant's average change from Baseline NRQLQ score was the participant's average NRQLQ score over the treatment period minus the participant's baseline score. (NCT00435461)
Timeframe: Baseline (Day 1) and Day 15

,,
InterventionScores on a scale (Mean)
Overall scoreSleep problemsSleep time problemsSymptoms on wakingPractical problems
Fex 180 mg-1.5-1.5-1.5-1.5-1.6
FFNS 110 mcg-1.9-1.9-1.9-2-1.9
Placebo-1.3-1.2-1.3-1.4-1.2

[back to top]

Mean Change From Baseline Over the Two-week Treatment Period in Peak NasalIinspiratory Flow (PNIF)

PNIF was measured by participants using an In-Check Nasal portable hand-held inspiratory flow meter and face mask. Participants recorded PNIF twice daily (in the morning prior to taking their study medication and in the evening). Three measurements were taken on each occasion and the highest measurement recorded on the electronic diary. Each participant's average change from Baseline PNIF was the participant's average PNIF over the treatment period minus the participant's baseline PNIF. (NCT00435461)
Timeframe: Baseline (Day 1) and up to 2 Weeks

,,
InterventionLiter(L)/minute (min) (Mean)
Morning PNIFEvening PNIF
Fex 180 mg1.41.3
FFNS 110 mcg9.97.1
Placebo1.70.2

[back to top]

Mean Change From Baseline Over the Two-week Treatment Period in 24-hour Reflective Total Ocular Symptom Scores (24-hour rTOSS)

Daily 24-hour rTOSS was calculated as the average of the corresponding N-rTOSS and D-rTOSS using a 4-point scale, 0- 'None' (symptom is not present), 1- 'Mild' (sign/symptom present; easily tolerated), 2- 'Moderate' (sign/symptom bothersome but tolerable), 3- 'Severe' (sign/symptom hard to tolerate; interference with activities of daily living). The total score ranged from 0 (best) to 9 (worst). The 24-hour total symptom score for a Day is the average of the daytime total symptom score for that Day and the nighttime score for (D+1). If either component of a given date's 24-hour total symptom score was missing, then the 24-hour total symptom score itself was to be set to missing. Each participant's average change from Baseline 24-hour total symptom score for Weeks 1-2 was the participant's average 24-hour total symptom score over the treatment period minus the participant's Baseline score. Baseline is the 4 highest scores calculated for the 7 days prior to Day 1. (NCT00435461)
Timeframe: Baseline (Day 1) and up to 2 Weeks

,,
InterventionScores on a scale (Mean)
TOSSEye tearingEye itchingEye redness
Fex 180 mg-2.2-0.8-0.8-0.7
FFNS 110 mcg-2.5-0.9-0.9-0.8
Placebo-2.0-0.7-0.7-0.7

[back to top]

Mean Change From Baseline Over the Two-week Treatment Period in D-rTNSS

The Daytime reflective assessments were recorded each evening and assessed 4 nasal symptoms (rhinorrhea, nasal congestion, nasal itching, and sneezing) at evening and night using a 4-point scale, 0- 'None' (symptom is not present), 1- 'Mild' (sign/symptom present; easily tolerated), 2- 'Moderate' (sign/symptom bothersome but tolerable), 3- 'Severe' (sign/symptom hard to tolerate; interference with activities of daily living). The scores of each of the four Daytime symptoms were summed for each participant to create a D-rTNSS for each day. The total score ranged from 0 (best) to 12 (worst). Each participant's Baseline total symptom score was the average of the four highest total symptom score calculated for the seven days immediately prior to the day of randomization. Each participant's average change from Baseline Daytime total symptom score for Weeks 1-2 was the participant's average Daytime total symptom score over the treatment period minus the participants Baseline score. (NCT00435461)
Timeframe: Baseline (Day 1) and up to 2 Weeks

,,
InterventionScores on a scale (Mean)
TNSSNasal congestionItchy noseRunny noseSneezing
Fex 180 mg-3.0-0.8-0.8-0.7-0.9
FFNS 110 mcg-3.7-0.9-1.0-0.9-1.1
Placebo-2.6-0.7-0.7-0.6-0.7

[back to top]

Mean Change From Baseline in the Nighttime Symptom Score (NSS)

Questions include: 1. Nasal congestion on awakening (Score: 0=none, 1=mild, 2=moderate, 3=severe); 2. Difficulty going to sleep (Score: 0=not at all, 1=little, 2=moderately, 3=very); 3. Nighttime awakenings (Score: 0=not at all, 1=once, 2=more than once, 3=felt like awake all night). The sum of the ratings for the three items comprises the NSS. (NCT00502775)
Timeframe: Baseline and Weeks 1-2

InterventionScore on a Scale (Mean)
Placebo-2.3
Fluticasone Furoate 110mcg-3.1
Fexofenadine 180 mg-2.2

[back to top]

Mean Change From Baseline at Day 15 for Nocturnal Rhinoconjunctivitis Quality of Life Questionnaire (NRQLQ)

Subjects completed the 16-item Nocturnal Rhinoconjunctivitis Quality of Life Questionnaire (NRQLQ)to assess nocturnal rhinitis-related quality of life. The NRQLQ measures the functional problems most troublesome to patients with nocturnal allergy symptoms. Each question scored from 0-6 with higher scores indicating more nocturnal impairment. (NCT00502775)
Timeframe: Baseline, Day 15 or if Early Withdrawal Day

InterventionScore on a Scale (Mean)
Placebo-1.4
Fluticasone Furoate 110mcg-2.0
Fexofenadine 180 mg-1.4

[back to top]

Mean Change From Baseline in 24 Hour Reflective Total Nasal Symptom Score (24 Hour rTNSS)

Subjects assessed four nasal symptoms (rhinorrhea, nasal congestion, nasal itching, and sneezing). The sum of the four nasal symptoms comprised the total nasal symptom score (TNSS).Reflective rating represented symptoms over preceding 12 hours. Scores: 0=symptoms not present, 1=mild severity, 2=moderate severity, 3=severe. (NCT00502775)
Timeframe: Baseline and Weeks 1-2

InterventionScore on a Scale (Mean)
Placebo-2.8
Fluticasone Furoate 110mcg-4.1
Fexofenadine 180 mg-2.8

[back to top]

Mean Change From Baseline in 24 Hour Reflective Total Ocular Symptoms Score (rTOSS)

Subjects assessed three ocular symptoms (itching/ burning eyes, tearing/watering eyes, and eye redness). The sum of the 3 ocular symptoms comprised the total ocular symptom score (TOSS). Reflective rating represented symptoms over preceding 12 hours. Scores: 0=symptoms not present, 1=mild severity, 2=moderate severity, 3=severe. (NCT00502775)
Timeframe: Baseline and Weeks 1-2

InterventionScore on a Scale (Mean)
Placebo-2.3
Fluticasone Furoate 110mcg-2.7
Fexofenadine 180 mg-2.2

[back to top]

Mean Change From Baseline in Daytime Reflective Total Nasal Symptom Score (D-rTNSS)

Subjects assessed four nasal symptoms (rhinorrhea, nasal congestion, nasal itching, and sneezing). The sum of the four nasal symptoms comprised the total nasal symptom score (TNSS). Reflective rating represented symptoms over preceding 12 hours. Scores: 0=symptoms not present, 1=mild severity, 2=moderate severity, 3=severe. (NCT00502775)
Timeframe: Baseline and Weeks 1-2

InterventionScore on a Scale (Mean)
Placebo-3.0
Fluticasone Furoate 110mcg-4.2
Fexofenadine 180 mg-2.9

[back to top]

Mean Change From Baseline in Daytime Reflective Total Ocular Symptom Score (D-rTOSS)

Subjects assessed three ocular symptoms (itching/ burning eyes, tearing/watering eyes, and eye redness). The sum of the 3 ocular symptoms comprised the total ocular symptom score (TOSS). Reflective rating represented symptoms over preceding 12 hours. Scores: 0=symptoms not present, 1=mild severity, 2=moderate severity, 3=severe. (NCT00502775)
Timeframe: Baseline and Weeks 1-2

InterventionScore on a Scale (Mean)
Placebo-2.5
Fluticasone Furoate 110mcg-2.9
Fexofenadine 180 mg-2.4

[back to top]

Mean Change From Baseline in Evening Peak Nasal Inspiratory Flow (PNIF)

Subjects used a portable hand-held inspiratory flow meter to measure and record PNIF in the evening. Three measurements were taken and the highest measurement was recorded in the electronic diary. A positive change signifies improved nasal air flow. (NCT00502775)
Timeframe: Baseline and Weeks 1-2

InterventionScore on a Scale (Mean)
Placebo2.3
Fluticasone Furoate 110mcg9.7
Fexofenadine 180 mg0.3

[back to top]

Mean Change From Baseline in Morning Peak Nasal Inspiratory Flow (PNIF)

Subjects used a portable hand-held inspiratory flow meter to measure and record PNIF in the morning prior to taking the study medication. Three measurements were taken and the highest measurement was recorded in the electronic diary. A positive change signifies improved nasal air flow. (NCT00502775)
Timeframe: Baseline and Weeks 1-2

InterventionScore on a Scale (Mean)
Placebo4.8
Fluticasone Furoate 110mcg13.0
Fexofenadine 180 mg2.2

[back to top]

Mean Change From Baseline in Nighttime Reflective Total Nasal Symptom Score (N-rTNSS)

Subjects assessed four nasal symptoms (rhinorrhea, nasal congestion, nasal itching, and sneezing). The sum of the four nasal symptoms comprised the total nasal symptom score (TNSS). Reflective rating represented symptoms over preceding 12 hours. Scores: 0=symptoms not present, 1=mild severity, 2=moderate severity, 3=severe. (NCT00502775)
Timeframe: Baseline and Weeks 1-2

InterventionScore on a Scale (Mean)
Placebo-2.9
Fluticasone Furoate 110mcg-4.1
Fexofenadine 180 mg-2.9

[back to top]

Mean Change From Baseline in Nighttime Reflective Total Ocular Symptom Score (N-rTOSS)

Subjects assessed three ocular symptoms (itching/ burning eyes, tearing/watering eyes, and eye redness). The sum of the 3 ocular symptoms comprised the total ocular symptom score (TOSS). Reflective rating represented symptoms over preceding 12 hours. Scores: 0=symptoms not present, 1=mild severity, 2=moderate severity, 3=severe. (NCT00502775)
Timeframe: Baseline and Weeks 1-2

InterventionScore on a Scale (Mean)
Placebo-2.3
Fluticasone Furoate 110mcg-2.7
Fexofenadine 180 mg-2.2

[back to top]

Mean Change From Baseline in Pre-Dose Instantaneous Total Nasal Symptom Score (iTNSS)

Subjects assessed four nasal symptoms (rhinorrhea, nasal congestion, nasal itching, and sneezing). The sum of the four nasal symptoms comprised the total nasal symptom score (TNSS).Instantaneous rating represented symptoms at the time of the assessment. Scores: 0=symptoms not present, 1=mild severity, 2=moderate severity, 3=severe. (NCT00502775)
Timeframe: Baseline and Weeks 1-2

InterventionScore on a Scale (Mean)
Placebo-2.8
Fluticasone Furoate 110mcg-4.1
Fexofenadine 180 mg-2.7

[back to top]

Mean Change From Baseline in Pre-Dose Instantaneous Total Ocular Symptom Score (iTOSS)

Subjects assessed three ocular symptoms (itching/ burning eyes, tearing/watering eyes, and eye redness). The sum of the four ocular symptoms comprised the total nasal symptom score (TOSS).Instantaneous rating represented symptoms at the time of the assessment. Scores: 0=symptoms not present, 1=mild severity, 2=moderate severity, 3=severe. (NCT00502775)
Timeframe: Baseline and Weeks 1-2

InterventionScore on a Scale (Mean)
Placebo-2.2
Fluticasone Furoate 110mcg-2.7
Fexofenadine 180 mg-2.2

[back to top]

Minimum Cross-Sectional Area (Amin) Maximum Fall Measured Using Acoustic Rhinometry

Acoustic rhinometry: a technique intended for assessment of the geometry of the nasal cavity and nasopharynx and for evaluating nasal obstruction. At each time point, there were 2 acoustic rhinometry measurements taken, one for each nostril. The mean of the left and right nostril measurements was taken as the measurement at each time point. Minimum Cross-Sectional Area (Amin) at Baseline was defined as mean of the 3, 'post-diluent, pre-allergen challenge' measures for each intervention period at 2 hrs 10 min, 2 hrs 25 min and 2 hrs 40 min post PF-03654746/placebo dose. Amin 'post-allergen challenge' measures were recorded at 2 hrs 55 min, 3 hrs 10 min and 3 hrs 25 min post PF-03654746/placebo dose for each intervention period. The maximum fall in Amin was calculated as baseline measure minus smallest 'post-allergen challenge' Amin measurement of the 3 measures. (NCT00562120)
Timeframe: 2 hrs 10 min, 2 hrs 25 min, 2 hrs 40 min post dose (Baseline); 2 hrs 55 min, 3 hrs 10 min, 3 hrs 25 min post dose on Day 1 of each intervention period

Interventionsquare centimeter (cm^2) (Mean)
PF-03654746 10 mg0.155
PF-03654746 1 mg0.157
Allegra-D0.204
Placebo0.190

[back to top]

Minimum Cross-Sectional Area (Amin) Proportion Measured Using Acoustic Rhinometry

Acoustic rhinometry: a technique intended for assessment of the geometry of nasal cavity and nasopharynx and for evaluating nasal obstruction. At each time point, there were 2 acoustic rhinometry measurements taken, one for each nostril. Mean of the left and right nostril measurements was taken as measurement at each time point. Minimum Cross-Sectional Area (Amin) at Baseline was defined as mean of 3, 'post-diluent, pre-allergen challenge' measures for each intervention period at 2 hours (hrs) 10 minutes (min), 2 hrs 25 min and 2 hrs 40 min post PF-03654746/placebo dose. Amin 'post-allergen challenge' measures recorded at 2 hrs 55 min, 3 hrs 10 min and 3 hrs 25 min post PF-03654746/placebo dose for each intervention period was averaged to derive single 'post-allergen challenge' value. Amin proportion was defined as ratio of 'post-allergen challenge' value and 'Baseline/pre-allergen challenge value'. Diluent used was saline and allergen was short ragweed extract. (NCT00562120)
Timeframe: 2 hrs 10 min, 2 hrs 25 min, 2 hrs 40 min post dose (Baseline); 2 hrs 55 min, 3 hrs 10 min, 3 hrs 25 min post dose on Day 1 of each intervention period

Interventionratio (Mean)
PF-03654746 10 mg0.760
PF-03654746 1 mg0.742
Allegra-D0.717
Placebo0.795

[back to top]

Nasal Volume Maximum Fall Measured Using Acoustic Rhinometry

Acoustic rhinometry: a technique intended for assessment of the geometry of the nasal cavity and nasopharynx and for evaluating nasal obstruction. At each time point, there were 2 acoustic rhinometry measurements taken, one for each nostril. The mean of the left and right nostril measurements was taken as the measurement at each time point. Nasal volume at Baseline was defined as mean of the 3, 'post-diluent, pre-allergen challenge' measures for each intervention period at 2 hrs 10 min, 2 hrs 25 min and 2 hrs 40 min post PF-03654746/placebo dose. Nasal volume 'post-allergen challenge' measures were recorded at 2 hrs 55 min, 3 hrs 10 min and 3 hrs 25 min post PF-03654746/placebo dose for each intervention period. The maximum fall for nasal volume was calculated as baseline measure minus smallest 'post-allergen challenge' nasal volume measurement among the 3 measures. (NCT00562120)
Timeframe: 2 hrs 10 min, 2 hrs 25 min, 2 hrs 40 min post dose (Baseline); 2 hrs 55 min, 3 hrs 10 min, 3 hrs 25 min post dose on Day 1 of each intervention period

Interventioncubic centimeter (cm^3) (Mean)
PF-03654746 10 mg3.132
PF-03654746 1 mg3.244
Allegra-D4.443
Placebo3.275

[back to top]

Nasal Volume Proportion Measured Using Acoustic Rhinometry

Acoustic rhinometry: a technique intended for assessment of the geometry of nasal cavity and nasopharynx and for evaluating nasal obstruction. At each time point, there were 2 acoustic rhinometry measurements taken, one for each nostril. Mean of the left and right nostril measurements was taken as measurement at each time point. Nasal volume at Baseline was defined as mean of 3, 'post-diluent, pre-allergen challenge' measures for each intervention period at 2 hrs 10 min, 2 hrs 25 min and 2 hrs 40 min post PF-03654746/placebo dose. Nasal volume 'post-allergen challenge' measures recorded at 2 hrs 55 min, 3 hrs 10 min and 3 hrs 25 min post PF-03654746/placebo dose for each intervention period was averaged to derive single 'post-allergen challenge' value. Nasal volume proportion was defined as ratio of 'post-allergen challenge' value and 'Baseline/pre-allergen challenge value'. Diluent used was saline and allergen was short ragweed extract. (NCT00562120)
Timeframe: 2 hrs 10 min, 2 hrs 25 min, 2 hrs 40 min post dose (Baseline); 2 hrs 55 min, 3 hrs 10 min, 3 hrs 25 min post dose on Day 1 of each intervention period

Interventionratio (Mean)
PF-03654746 10 mg0.800
PF-03654746 1 mg0.796
Allegra-D0.744
Placebo0.856

[back to top]

Serum PF-03654746 Concentration

Only participants receiving PF-03654746 were analyzed for this outcome measure. Mean serum concentration of PF-03654746 was calculated of each intervention period. (NCT00562120)
Timeframe: 1 hr 30 min post dose on Day 1 of each intervention period

Interventionnanogram per milliliter (ng/mL) (Mean)
PF-03654746 10 mg34.16
PF-03654746 1 mg2.78

[back to top]

Nasal Symptom Scores: Nasal Congestion, Nasal Itching, Rhinorrhea

Nasal symptoms included; nasal congestion: participants rated sensation of nasal blockage on 0 (no blockage) to 5 (total blockage) scale, nasal itching: participants rated sensation of nasal itch on 0 (no itch) to 5 (very itchy) scale, rhinorrhea: participants rated sensation of runny nose on 0 (no running) to 5 (very runny) scale. Symptom scores were assessed as mean of each intervention period at specified time-points for 'post-diluent, pre-allergen challenge' measure and 'post-challenge' measure. Post-diluent, pre-allergen challenge (for congestion, itching, rhinorrhea) included 2 hrs 10 min, 2 hrs 25 min and 2 hrs 40 min post PF-03654746/placebo dose at each intervention period and post-allergen challenge (for congestion, itching, rhinorrhea) included 2 hrs 55 min, 3 hrs 10 min and 3 hrs 25 min post PF-03654746/placebo dose at each intervention period and (for congestion only) 3 hrs 40 min post PF-03654746/placebo dose (Post-oxymetazoline) at each intervention period. (NCT00562120)
Timeframe: 2 hrs 10 min, 2 hrs 25 min, 2 hrs 40 min post dose (Pre-allergen challenge); 2 hrs 55 min, 3 hrs 10 min, 3 hrs 25 min post dose (Post-allergen challenge); 3 hrs 40 min post dose (Post-oxymetazoline) on Day 1 of each intervention period

,,,
Interventionunits on a scale (Mean)
Nasal congestion: Pre-allergen challengeNasal congestion: Post-allergen challengeNasal congestion: Post-oxymetazolineNasal Itching: Pre-allergen challengeNasal Itching: Post-allergen challengeRhinorrhea: Pre-allergen challengeRhinorrhea: Post-allergen challenge
Allegra-D0.41.90.90.00.90.21.3
PF-03654746 1 mg0.41.80.80.10.80.11.1
PF-03654746 10 mg0.21.50.80.00.40.10.6
Placebo0.42.20.90.11.40.11.9

[back to top]

Nasal Symptom Scores: Sneezing

The absolute number of sneezes was recorded by the participants under supervision of study personnel. Nasal symptom score for sneezing was assessed as the total number of sneezes of each intervention period at specified time-points for the post-diluent and post-challenge and post where 'post-diluent, pre-allergen challenge' included 2 hrs 10 min, 2 hrs 25 min and 2 hrs 40 min post PF-03654746/placebo dose at each intervention period and 'post-allergen challenge' included 2 hrs 55 min, 3 hrs 10 min and 3 hrs 25 min post PF-03654746/placebo dose at each intervention period. (NCT00562120)
Timeframe: 2 hrs 10 min, 2 hrs 25 min, 2 hrs 40 min post dose (Baseline); 2 hrs 55 min, 3 hrs 10 min, 3 hrs 25 min post dose on Day 1 of each intervention period

,,,
Interventionsneezes (Mean)
Sneezing: Pre-allergen challengeSneezing: Post-allergen challenge
Allegra-D0.11.2
PF-03654746 1 mg0.10.6
PF-03654746 10 mg0.00.7
Placebo0.13.6

[back to top]

AUC0-inf = Area Under the Concentration-time Curve From Time Zero to Infinity.

Bioequivalence based on AUC0-inf. (NCT00835276)
Timeframe: Blood samples collected over a 48 hour period.

Interventionng*h/mL (Mean)
Fexofenadine Hydrochloride2814.79
Allegra®3024.53

[back to top]

AUC0-t = Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration (Per Participant)

Bioequivalence based on AUC0-t. (NCT00835276)
Timeframe: Blood samples collected over a 48 hour period.

Interventionng*h/mL (Mean)
Fexofenadine Hydrochloride2711.8
Allegra®2912.63

[back to top]

Cmax = Maximum Observed Concentration.

Bioequivalence based on Cmax. (NCT00835276)
Timeframe: Blood samples collected over a 48 hour period.

Interventionng/mL (Mean)
Fexofenadine Hydrochloride449.6
Allegra®498.95

[back to top]

AUC0-t = Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration (Per Participant)

Bioequivalence based on AUC0-t. (NCT00835640)
Timeframe: Blood samples collected over a 48 hour period.

Interventionng*h/mL (Mean)
Fexofenadine Hydrochloride1894.48
Allegra®2159.85

[back to top]

Cmax = Maximum Observed Concentration.

Bioequivalence based on Cmax. (NCT00835640)
Timeframe: Blood samples collected over a 48 hour period.

Interventionng/mL (Mean)
Fexofenadine Hydrochloride311.45
Allegra®382.48

[back to top]

AUC0-inf = Area Under the Concentration-time Curve From Time Zero to Infinity.

Bioequivalence based on AUC0-inf. (NCT00835640)
Timeframe: Blood samples collected over a 48 hour period.

Interventionng*h/mL (Mean)
Fexofenadine Hydrochloride2061.26
Allegra®2324.97

[back to top]

Number of Participants Who Showed Improvement in Under Eye Swelling and Dark Circles Relative to Baseline Per Intervention

Efficacy was measured per intervention by assessing number of participants with improvement in under eye dark circles and swelling. Criteria used to assess under eye improvement and swelling was by a 5 point scale comparing each week's photographic appearance to the appearance at baseline: 1) fexofenadine right and placebo left, and 2) fexofenadine left and placebo right. The split face comparison was noted in efficacy measured changes in under eye swelling and dark circles relative to baseline. Participants were graded by 2 blinded dermatologists who reviewed photographs of all participants at entry and weekly until end of study plus one week, day 37. Total number of participants: 30. Placebo right and fexofenadine left 15 participants. Placebo left and fexofenadine right 15 participants. (NCT01172522)
Timeframe: Baseline, weekly, and end of study +7 days

Interventionparticipants (Number)
Fexofenadine0
Placebo0

[back to top]

Mean Individual Symptom Score for Itchy Nose by Post-Treatment Evaluation Time Point

"The individual symptom score for Itchy Nose was rated on a 5-point~scale of severity using the following scale: 0 = None (No symptoms), 1 = MILD (Symptom is present, but easily tolerated), 2 = MODERATE (Awareness of symptoms, bothersome, but tolerable), 3 = SEVERE (Definite awareness of symptoms, difficult to tolerate but does not interfere with activities), 4 = VERY SEVERE (Difficult to tolerate and interferes with the activities of daily living). The Itchy Nose symptom score ranges from 0 - 5. Increasing scores are associated with increasing severity." (NCT01469234)
Timeframe: From time of sensitization (time 0) to end of visit (~8 hours)

,,
Interventionunits on a scale (Mean)
0 minutes15 minutes30 minutes45 minutes60 minutes75 minutes90 minutes105 minutes120 minutes135 minutes150 minutes165 minutes180 minutes195 minutes210 minutes225 minutes240 minutes255 minutes270 minutes285 minutes300 minutes315 minutes330 minutes345 minutes360 minutes
Fexofenadine3.33.22.82.62.42.32.12.11.81.81.81.71.81.71.71.71.71.71.71.81.81.81.71.71.8
Loratadine3.33.12.82.72.62.42.32.21.92.02.12.02.01.92.01.91.91.81.91.91.81.81.81.91.8
Placebo3.43.12.82.82.62.52.42.42.12.22.22.22.22.22.22.22.22.22.12.22.12.22.12.22.2

[back to top]

Mean Individual Symptom Score for Runny Nose by Post-Treatment Evaluation Time Point

"The individual symptom score for Runny Nose was rated on a 5-point~scale of severity using the following scale: 0 = None (No symptoms), 1 = MILD (Symptom is present, but easily tolerated), 2 = MODERATE (Awareness of symptoms, bothersome, but tolerable), 3 = SEVERE (Definite awareness of symptoms, difficult to tolerate but does not interfere with activities), 4 = VERY SEVERE (Difficult to tolerate and interferes with the activities of daily living). The Runny Nose symptom score ranges from 0 - 5. Increasing scores are associated with increasing severity." (NCT01469234)
Timeframe: From time of sensitization (time 0) to end of visit (~8 hours)

,,
Interventionunits on a scale (Mean)
0 minutes15 minutes30 minutes45 minutes60 minutes75 minutes90 minutes105 minutes120 minutes135 minutes150 minutes165 minutes180 minutes195 minutes210 minutes225 minutes240 minutes255 minutes270 minutes285 minutes300 minutes315 minutes330 minutes345 minutes360 minutes
Fexofenadine3.23.02.92.62.32.22.12.12.02.02.01.81.91.91.81.81.81.71.81.91.81.81.81.81.9
Loratadine3.43.13.02.82.72.62.42.42.12.22.32.22.12.12.02.12.02.01.92.12.02.12.22.12.1
Placebo3.33.02.92.82.72.62.42.52.32.42.42.32.32.42.32.32.22.32.32.32.32.42.32.42.3

[back to top]

Mean Individual Symptom Scores for Itchy Eyes by Post-Treatment Evaluation Time Point

"The individual symptom score for Itchy Eyes was rated on a 5-point~scale of severity using the following scale: 0 = None (No symptoms), 1 = MILD (Symptom is present, but easily tolerated), 2 = MODERATE (Awareness of symptoms, bothersome, but tolerable), 3 = SEVERE (Definite awareness of symptoms, difficult to tolerate but does not interfere with activities), 4 = VERY SEVERE (Difficult to tolerate and interferes with the activities of daily living). The Itchy Eyes symptom score ranges from 0 - 5. Increasing scores are associated with increasing severity." (NCT01469234)
Timeframe: From time of sensitization (time 0) to end of visit (~8 hours)

,,
Interventionunits on a scale (Mean)
0 minutes (n=85, n=85, n=85)15 minutes (n=85, n=85, n=84)30 minutes (n=85, n=85, n=85)45 minutes (n=85, n=85, n=85)60 minutes (n=85, n=85, n=85)75 minutes (n=85, n=85, n=85)90 minutes (n=85, n=85, n=85)105 minutes (n=85, n=85, n=85)120 minutes (n=85, n=85, n=85)135 minutes (n=85, n=85, n=85)150 minutes (n=85, n=85, n=85)165 minutes (n=85, n=85, n=85)180 minutes (n=85, n=85, n=85)195 minutes (n=85, n=85, n=85)210 minutes (n=85, n=85, n=85)225 minutes (n=85, n=85, n=85)240 minutes (n=84, n=85, n=85)255 minutes (n=85, n=85, n=85)270 minutes (n=85, n=85, n=85)285 minutes (n=85, n=85, n=85)300 minutes (n=85, n=85, n=85)315 minutes (n=85, n=85, n=85)330 minutes (n=85, n=85, n=85)345 minutes (n=85, n=85, n=85)360 minutes (n=85, n=85, n=85)
Fexofenadine3.23.02.72.32.12.01.81.81.61.51.41.41.41.41.41.41.41.41.41.41.41.41.41.41.4
Loratadine3.02.62.42.21.91.91.81.81.61.51.51.51.41.51.41.51.61.41.41.31.41.41.51.41.5
Placebo3.12.82.42.42.21.91.91.81.71.71.61.71.71.81.71.71.71.61.61.71.71.71.61.81.7

[back to top]

Mean Individual Symptom Scores for Itchy Mouth/Throat/Ears by Post-Treatment Evaluation Time Point

"The individual symptom score for Itchy Mouth/Throat/Ears was rated on a 5-point~scale of severity using the following scale: 0 = None (No symptoms), 1 = MILD (Symptom is present, but easily tolerated), 2 = MODERATE (Awareness of symptoms, bothersome, but tolerable), 3 = SEVERE (Definite awareness of symptoms, difficult to tolerate but does not interfere with activities), 4 = VERY SEVERE (Difficult to tolerate and interferes with the activities of daily living). The Itchy Mouth/Throat/Ears symptom score ranges from 0 - 5. Increasing scores are associated with increasing severity." (NCT01469234)
Timeframe: From time of sensitization (time 0) to end of visit (~8 hours)

,,
Interventionunits on a scale (Mean)
0 minutes (n=85, n=85, n=85)15 minutes (n=85, n=85, n=85)30 minutes (n=85, n=85, n=85)45 minutes (n=85, n=85, n=85)60 minutes (n=85, n=85, n=85)75 minutes (n=85, n=85, n=85)90 minutes (n=85, n=85, n=85)105 minutes (n=85, n=85, n=85)120 minutes (n=85, n=85, n=85)135 minutes (n=85, n=85, n=85)150 minutes (n=85, n=85, n=85)165 minutes (n=85, n=85, n=85)180 minutes (n=85, n=85, n=85)195 minutes (n=85, n=85, n=85)210 minutes (n=85, n=85, n=85)225 minutes (n=85, n=85, n=85)240 minutes (n=85, n=85, n=85)255 minutes (n=85, n=85, n=84)270 minutes (n=85, n=85, n=85)285 minutes (n=85, n=85, n=85)300 minutes (n=85, n=85, n=85)315 minutes (n=85, n=85, n=85)330 minutes (n=85, n=85, n=85)345 minutes (n=85, n=85, n=85)360 minutes (n=85, n=85, n=85)
Fexofenadine3.03.02.82.82.62.62.32.42.02.31.82.21.72.11.72.01.52.01.62.01.42.01.42.01.3
Loratadine3.03.22.63.02.32.82.02.71.92.61.82.51.72.41.62.31.52.31.52.41.52.41.42.31.4
Placebo2.93.02.62.82.42.82.32.62.12.51.92.41.82.41.92.31.72.41.72.41.82.41.72.51.7

[back to top]

Mean Individual Symptom Scores for Nasal Congestion by Post-Treatment Evaluation Time Point

"The individual symptom score for Nasal Congestion was rated on a 5-point~scale of severity using the following scale: 0 = None (No symptoms), 1 = MILD (Symptom is present, but easily tolerated), 2 = MODERATE (Awareness of symptoms, bothersome, but tolerable), 3 = SEVERE (Definite awareness of symptoms, difficult to tolerate but does not interfere with activities), 4 = VERY SEVERE (Difficult to tolerate and interferes with the activities of daily living). The Nasal Congestion symptom score ranges from 0 - 5. Increasing scores are associated with increasing severity." (NCT01469234)
Timeframe: From time of sensitization (time 0) to end of visit (~8 hours)

,,
Interventionunits on a scale (Mean)
0 minutes (n=85, n=85, n=85)15 minutes (n=85, n=85, n=85)30 minutes (n=85, n=85, n=85)45 minutes (n=85, n=85, n=85)60 minutes (n=85, n=85, n=85)75 minutes (n=85, n=85, n=85)90 minutes (n=85, n=85, n=85)105 minutes (n=85, n=85, n=85)120 minutes (n=85, n=85, n=85)135 minutes (n=85, n=85, n=85)150 minutes (n=85, n=85, n=85)165 minutes (n=85, n=85, n=85)180 minutes (n=85, n=85, n=85)195 minutes (n=85, n=85, n=85)210 minutes (n=85, n=85, n=85)225 minutes (n=85, n=85, n=85)240 minutes (n=85, n=85, n=85)255 minutes (n=85, n=85, n=84)270 minutes (n=85, n=85, n=84)285 minutes (n=85, n=85, n=85)300 minutes (n=85, n=85, n=85)315 minutes (n=85, n=85, n=85)330 minutes (n=85, n=85, n=85)345 minutes (n=85, n=85, n=85)360 minutes (n=85, n=85, n=85)
Fexofenadine3.22.21.52.11.42.11.32.11.42.11.32.01.32.01.32.01.42.01.32.11.32.11.32.01.4
Loratadine3.42.51.62.51.62.41.62.41.52.41.52.41.42.51.52.41.52.41.62.41.52.41.52.41.5
Placebo3.42.72.02.61.82.61.82.61.82.61.82.51.82.61.82.61.82.61.82.61.82.51.82.51.9

[back to top]

Mean Individual Symptom Scores for Sneezing by Post-Treatment Evaluation Time Point

"The individual symptom score for Sneezing was rated on a 5-point~scale of severity using the following scale: 0 = None (No symptoms), 1 = MILD (Symptom is present, but easily tolerated), 2 = MODERATE (Awareness of symptoms, bothersome, but tolerable), 3 = SEVERE (Definite awareness of symptoms, difficult to tolerate but does not interfere with activities), 4 = VERY SEVERE (Difficult to tolerate and interferes with the activities of daily living). The Sneezing symptom score ranges from 0 - 5. Increasing scores are associated with increasing severity." (NCT01469234)
Timeframe: From time of sensitization (time 0) to end of visit (~8 hours)

,,
Interventionunits on a scale (Mean)
0 minutes (n=85, n=85, n=85)15 minutes (n=85, n=85, n=85)30 minutes (n=85, n=85, n=85)45 minutes (n=85, n=85, n=85)60 minutes (n=85, n=85, n=85)75 minutes (n=85, n=85, n=85)90 minutes (n=85, n=85, n=85)105 minutes (n=85, n=85, n=85)120 minutes (n=85, n=85, n=85)135 minutes (n=85, n=85, n=85)150 minutes (n=85, n=85, n=85)165 minutes (n=85, n=85, n=85)180 minutes (n=85, n=85, n=85)195 minutes (n=85, n=85, n=85)210 minutes (n=85, n=85, n=85)225 minutes (n=85, n=85, n=85)240 minutes (n=85, n=85, n=85)255 minutes (n=85, n=85, n=85)270 minutes (n=85, n=85, n=85)285 minutes (n=85, n=85, n=85)300 minutes (n=84, n=85, n=85)315 minutes (n=84, n=85, n=85)330 minutes (n=85, n=85, n=85)345 minutes (n=84, n=85, n=85)360 minutes (n=85, n=85, n=85)
Fexofenadine1.21.21.10.90.70.80.60.60.50.70.60.50.60.60.50.60.50.40.50.60.50.40.60.60.6
Loratadine1.31.21.21.01.11.00.70.80.50.80.90.80.70.80.70.70.70.60.60.80.70.70.70.70.6
Placebo1.51.31.21.31.21.11.01.10.91.21.10.90.91.01.00.90.91.01.01.10.91.11.01.01.0

[back to top]

Mean Individual Symptom Scores for Watery Eyes by Post-Treatment Evaluation Time Point

"The individual symptom score for Water Eyes was rated on a 5-point~scale of severity using the following scale: 0 = None (No symptoms), 1 = MILD (Symptom is present, but easily tolerated), 2 = MODERATE (Awareness of symptoms, bothersome, but tolerable), 3 = SEVERE (Definite awareness of symptoms, difficult to tolerate but does not interfere with activities), 4 = VERY SEVERE (Difficult to tolerate and interferes with the activities of daily living). The Watery Eyes symptom score ranges from 0 - 5. Increasing scores are associated with increasing severity." (NCT01469234)
Timeframe: From time of sensitization (time 0) to end of visit (~8 hours)

,,
Interventionunits on a scale (Mean)
0 minutes15 minutes30 minutes45 minutes60 minutes75 minutes90 minutes105 minutes120 minutes135 minutes150 minutes165 minutes180 minutes195 minutes210 minutes225 minutes240 minutes255 minutes270 minutes285 minutes300 minutes315 minutes330 minutes345 minutes360 minutes
Fexofenadine2.82.62.32.01.91.81.61.61.31.31.21.21.11.21.11.11.11.11.11.21.11.21.21.21.3
Loratadine2.72.42.21.91.81.71.51.51.31.21.21.21.21.21.21.21.21.21.21.21.21.21.31.21.2
Placebo2.72.42.12.01.91.61.51.51.41.41.41.41.31.51.41.41.41.41.41.41.31.41.41.41.4

[back to top]

Mean Major Symptom Complex (MSC) Score by Post-Treatment Evaluation Time Point (From 180 Minutes to 300 Minutes)

The MSC Score is calculated as the sum of 5 individual symptom scores for Runny Nose, Itchy Nose, Sneezing, Watery Eyes, and Itchy Eyes. Each individual symptom is rated on a 5-point scale of severity: 0 = None (No symptoms), 1 = MILD (Symptom is present, but easily tolerated), 2 = MODERATE (Awareness of symptoms, bothersome, but tolerable), 3 = SEVERE (Definite awareness of symptoms, difficult to tolerate but does not interfere with activities), 4 = VERY SEVERE (Difficult to tolerate and interferes with the activities of daily living). The total MSC score ranges from 0 - 25. Increasing scores are associated with increasing severity. (NCT01469234)
Timeframe: From time of sensitization (time 0) to end of visit (~8 hours)

,,
Interventionunits on a scale (Mean)
180 minutes (n=85, n=85, n=85)195 minutes (n=85, n=85, n=85)210 minutes (n=85, n=85, n=85)225 minutes (n=85, n=85, n=85)240 minutes (n=84, n=85, n=85)255 minutes (n=85, n=85, n=85)270 minutes (n=85, n=85, n=85)285 minutes (n=85, n=85, n=85)300 minutes (n=84, n=85, n=85)
Fexofenadine6.76.76.56.56.56.36.46.96.5
Loratadine7.47.57.37.47.47.17.07.37.1
Placebo8.58.98.78.58.38.48.48.78.4

[back to top]

Primary Pharmacokinetic Measure: Area Under the Curve (AUC)

(NCT01526213)
Timeframe: 0-72 hours

,,
Interventionmicromolar*hr (Geometric Mean)
WaterGrapefruit juiceModified grapefruit juice
Furanocoumarin-free Grapefruit Juice4.23.23.1
Grapefruit Juice4.23.23.1
Water4.23.23.1

[back to top]

Flaire Diameter (mm)

Flaire diameter was measured with a transparent ruler as the mean of the largest diameter and the diameter at right angles to this. (NCT01586091)
Timeframe: 24 hours per treatment

Interventionmm (Mean)
Placebo69.4
Levocetirizin20.4
Fexofenadine39.9

[back to top]

Pruritus as Assessed by the VAS Score

"We measured drug concentrations and various aspects of skin provocation testing such as itch intensity and wheal size. Measurements made at each time point were as followed: Pruritus was assessed every 30 s for 10 min after SPT using a visual analogue scale (VAS) score with a 0 and 100 at the two ex- tremes of an unmarked 100 mm line with higher values indicating greater puritus. The mean VAS for each 10 min was calculated and used as a primary end Point." (NCT01586091)
Timeframe: up to 10 minutes after skin prick test performed 24 hours after drug administration

Interventionmm (Mean)
Levocetirizin11.5
Fexofenadine25.4
Placebo46.0

[back to top]

Wheal Volume (cm3)

Wheal volume was measured by a non-contact three dimensional measurement system (PRIMOS contact, GFM Messtechnik GmbH, Teltow, Germany). (NCT01586091)
Timeframe: 24 hours per treatment

Interventioncm3 (Mean)
Placebo174.6
Levocetirizin35.2
Fexofenadine106.3

[back to top]

Count of Participants With Side Effects

Patients will write down side effects at the end of each treatment period. If severe patients should seek medical attention immediately and report the side effects to us. (NCT03425097)
Timeframe: Will be assessed at the end of the initial treatment period (2 weeks) and at the end of the crossover period (2 weeks)

InterventionParticipants (Count of Participants)
Fexofenadine1
Placebo0

[back to top]

Mean GERD-HRQL Questionnaire Score

The questionnaire consists of 10 questions with responses of 0-5. The responses of the 10 questions are totaled (range of 0-50) where a higher total indicates more severe disease than a lower total. (NCT03425097)
Timeframe: 2 weeks per treatment

Interventionscore on a scale (Mean)
Run-in Period16.2
Fexofenadine9.8
Placebo12.3

[back to top]

Mean Percent of Days With Reflux

(NCT03425097)
Timeframe: 2 weeks per treatment

Interventionpercentage of days (Mean)
Run-in Period83.4
Fexofenadine52.4
Placebo52.4

[back to top]

Mean Rescue Medications Per Day

Medications such as Tums or Pepcid can be used if reflux symptoms are severe and relief is needed (additional doses of proton pump inhibitors are not allowed beyond the regular dosing) (NCT03425097)
Timeframe: 2 weeks per treatment

Interventionmedications (Mean)
Run-in Period0.29
Fexofenadine0.52
Placebo0.17

[back to top]

Mean Symptom Severity Score

Severity of reflux symptoms on a scale of 0-4 (0=none, 1=mild, 2=moderate, 3=severe, 4=very severe) (NCT03425097)
Timeframe: 2 weeks per treatment

Interventionscore on a scale (Mean)
Run-in Period1.2
Fexofenadine0.8
Placebo0.7

[back to top]

Mean Number of Reflux Episodes Per Day

(NCT03425097)
Timeframe: 2 weeks per treatment

Interventionepisodes (Mean)
Run-in Period1.74
Fexofenadine0.69
Placebo0.67

[back to top]

Mean Change From Baseline HAQ Pain Score at Week 52

The HAQ-Pain score rates the participant's pain over the past week from 0 to 100 with 0 = no pain and 100 = severe pain. A change from baseline value of 0 is imputed at the first post-baseline visit for any participants without post-baseline values. (NCT03994731)
Timeframe: Baseline, Week 52

Interventionscore on a scale (Least Squares Mean)
Pegloticase + MTX-31.02
Pegloticase + Placebo-22.59

[back to top]

Mean Change From Baseline in HAQ Health Score at Week 52

The HAQ health scale is a self-reported measure of overall health. Participants are asked to rate how they are doing, considering all the ways arthritis affects them, on a scale of 0 to 100, where 0 represents very well and 100 represents very poor. A change from baseline value of 0 is imputed at the first post-baseline visit for any participants without post-baseline values. (NCT03994731)
Timeframe: Baseline, Week 52

Interventionscore on a scale (Least Squares Mean)
Pegloticase + MTX-28.85
Pegloticase + Placebo-18.69

[back to top]

Mean Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 52

HAQ-DI is a self-report functional status instrument that is filled out by the participant and measures disability over the past week via 20 questions relating to 8 domains of function: dressing, grooming, arising, eating, walking, hygiene, reach, grip, and usual activities. The HAQ-DI ranges from 0 to 3 with higher values indicating higher disability. A change from baseline value of 0 is imputed at the first post-baseline visit for any participants without post-baseline values. (NCT03994731)
Timeframe: Baseline, Week 52

Interventionscore on a scale (Least Squares Mean)
Pegloticase + MTX-0.35
Pegloticase + Placebo-0.31

[back to top]

Percentage of Participants With Complete Resolution of ≥ 1 Tophi at Week 52

Percentage of participants with complete resolution of ≥ 1 tophi (using digital photography) at Week 52 in participants with tophi at baseline. Participants with resolution of ≥ 1 tophi at a visit are participants with resolution of ≥ 1 tophi at the visit (i.e. have complete response), and no progressive disease for any other tophi. (NCT03994731)
Timeframe: Baseline, Week 52

Interventionpercentage of participants (Number)
Pegloticase + MTX53.8
Pegloticase + Placebo31.0

[back to top]

Percentage of Serum Uric Acid (sUA) Responders (sUA < 6 mg/dL) During Month 6

Responders are defined as participants achieving and maintaining sUA < 6 mg/dL for at least 80% of the time during Month 6. Month 6 includes pre- and post-infusion sUA assessments at Weeks 20 and 22, non-infusion sUA at Weeks 21 and 23, pre-infusion sUA at Week 24 and any unscheduled sUA between Week 20 and Week 24. A participant must have had ≥ 2 sUA observations from different visits in order to be eligible as a responder. Participants meeting the stopping rule (those with a pre-infusion sUA >6 mg/dL at 2 consecutive scheduled trial visits beginning with the Week 2 Visit stopped pegloticase dosing) were counted as non-responders. (NCT03994731)
Timeframe: Month 6 (Weeks 20, 21, 22, 23 and 24)

Interventionpercentage of participants (Number)
Pegloticase + MTX71.0
Pegloticase + Placebo38.5

[back to top]

Percentage of sUA (sUA < 6 mg/dL) Responders During Month 12

Responders are defined as participants achieving and maintaining sUA <6 mg/dL for at least 80% of the time during Month 12 (Weeks 48, 50 and 52). Month 12 includes pre- and post-infusion sUA Weeks 48 and 50, pre-infusion sUA at Week 52, and any unscheduled sUA assessments done at unscheduled visits between Week 48 and 52. A participant must have had ≥ 2 sUA observations from different visits in order to be eligible as a responder. Participants meeting the stopping rule (those with a pre-infusion sUA >6 mg/dL at 2 consecutive scheduled trial visits beginning with the Week 2 Visit stopped pegloticase dosing) were counted as non-responders. (NCT03994731)
Timeframe: Month 12 (Weeks 48, 50 and 52)

Interventionpercentage of participants (Number)
Pegloticase + MTX60.0
Pegloticase + Placebo30.8

[back to top]